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1 INTRODUCTION 
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Parts of this introduction have been published as part of a systematic review and 
meta-analysis (Scott et al., 2018).   
 
In this chapter I will give a brief introduction to the immune system to give some 
context to my PhD. I will then summarise previous trials of immunomodulating 
therapies in PD, briefly reviewing the literature on PD pathology, disease 
heterogeneity and the role of inflammation before giving some examples of how 
B lymphocytes could be involved in disease pathogenesis and progression. I will 
also mention the possible important role of meningeal immunity.  
1.1 Brief introduction to the immune system 
The immune system has evolved to protect organisms, including human beings, 
from microbes,  damage, toxins and cancer.  Inflammatory or auto-immune 
disorders occur when there is a loss of tolerance: the immune system becomes 
misdirected to a self-antigen (for example the neuro-muscular junction in 
Myasthenia Gravis). Mammalian immune systems can be simplistically divided 
into “innate” and “adaptive” immune systems. The innate immune system 
provides an immediate response to molecular structures expressed on microbes 
or viruses. This response is largely the same each time and is provided by 
phagocytes, dendritic cells, neutrophils, NK cells, innate lymphoid cells and the 
complement system (Chaplin, 2010). This is a cascade of proteins triggered by 
early infection that leads to increased phagocytic activity and activation of cell-
killing ‘membrane attack complex’ (as well as playing a regulatory role)(Ricklin, 
Reis, & Lambris, 2016).  The adaptive immune response (consisting of B 
lymphocytes and T lymphocytes) is specific to particular pathogens (and their 
antigens) and is increased by repeated exposure.  The two systems are linked: 
immunoglobulins (antibodies) secreted by B lymphocytes can activate 
complement to increase phagocytosis and innate immune cells such as dendritic 
cells can present fragments of ingested antigen via receptors on their surface 
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(major histocompatibility complex MHC) receptors to T cells to activate them 
(Chaplin, 2010).  B lymphocytes provide ‘humoral’ immunity by secreting 
antibodies specific to particular antigens. These can facilitate phagocytosis by 
opsonising the antigen (making it more attractive to a phagocyte) or by antibody 
mediated cytotoxicity (NK cells) (see later discussion on the roles of B 
lymphocyte). T lymphocytes (CD4 +or CD8+) provide cell mediated immunity 
whereby they are able to kill phagocytes that have ingested or become infected 
by intracellular pathogens (that can’t be accessed by circulating 
antibodies)(Chaplin, 2010).  
 
Many of the functions of the immune system are regulated by cytokines, a 
diverse range of proteins that are able to support immune cell survival, facilitate 
proliferation, activate effector lymphocytes, regulate the immune response by 
inhibiting activation and many others (Abbas et al., 2014). Chemokines are a 
subset of cytokines that regulate cell migration and movement (for example 
movement of immune cells into and out of secondary lymphoid tissue such as 
lymph nodes and the spleen). There are specific groups of cytokines associated 
with particular responses, for example a T helper 1 response (Th1) is associated 
with the cytokine interferon g (activates macrophages to ingest pathogens), a T 
helper 2 response (Th2) is associated with the cytokines interleukin-4 (IL-4), IL-5 
and IL6 (mainly in response to helminths) and T helper 17 response is associated 
IL-17 and IL-22 which recruit other immune cells and drive further inflammation 
(Abbas et al., 2014).  
 
Circulating immune cells (in the blood) are a tiny fraction of the immune 
system: many immune cells are concentrated in lymph nodes or the spleen 
(where, for example a T lymphocyte with a specific antigen receptor is more 
likely to encounter a dendritic cell presenting its cognate antigen)(Ruddle & 
Akirav, 2009). There are also tissue resident immune cells. In the brain these 
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include microglia (long lived innate immune cells capable of adopting a 
phagocytic phenotype that are self-renewing and derived from the yolk sac) and 
macrophages (that are probably derived from the circulating pool)(Li & Barres, 
2018). There are also tissue resident immune cells in the meninges that 
contribute to homeostasis (Derecki et al., 2010). Although the brain used to be 
regarded as ‘immune privileged’ we now also know that circulating lymphocytes 
‘patrol’ the brain for pathogens (Engelhardt, 2010).  
 
Over the last few decades the response of the immune system to the damaged 
central nervous system (CNS) has received increasing attention (Chitnis & 
Weiner, 2017). The focus of my PhD has been on B lymphocytes in Parkinson’s 
disease because i) B lymphocytes are an important part of the immune response 
ii) the immune response is likely to be involved in PD  iii) they offer an attractive 
therapeutic target with one of the many existing therapies that modulate the B 
lymphocyte response and iv) there were very few studies on B cells in PD or its 
models when I started.  
1.2 Parkinson’s disease 
Parkinson’s disease (PD) is a common neurodegenerative disorder, affecting 2-
3% of people over the age of 65 (Pringsheim et al., 2014). Current therapies are 
symptomatic, mainly addressing the  motor features of the disease (tremor, 
rigidity and bradykinesia) by replacing the dopamine that is lost as a result of 
cell death in the substantia nigra pars compacta. Dopamine replacement does 
not address the multitude of non-motor features of the disease such as 
hyposmia, postural instability, dementia, gut dysfunction, sleep disturbance or 
mood symptoms (Schapira, Chaudhuri, & Jenner, 2017). It also does not stop the 
disease from progressing. There are currently no disease modifying therapies 
available. There is therefore an urgent need to better understand disease 
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pathogenesis and to develop therapies that prevent these complications and stop 
disease progression.  
 
In recent years, targeting the immune system has been suggested as  a 
therapeutic strategy not only in PD (Gendelman et al., 2017) but also in other 
neurodegenerative diseases including Alzheimer’s disease (AD) (Butchart et al., 
2015; McGeer, Rogers, & McGeer, 2016) and Amyotrophic Lateral Sclerosis 
(ALS)(Khalid et al., 2017). A number of clinical trials of immune modulating 
therapies  have been completed in PD.  
 
Minocycline, a tetracycline analogue (usually used as an antibiotic) showed good 
results in pre-clinical models preventing loss of dopaminergic neurons and 
associated microglial activation (reviewed in (Cankaya et al., 2019). It is thought 
to reduce microglial activation and T cell transmigration with fewer effects on 
the peripheral immune system(Stirling et al., 2005). A phase II trial in early 
disease (less than five years from diagnosis in medication naïve patients) showed 
that although it was well tolerated there was no evidence of efficacy either at the 
12 month or 18 month end points (NINDS NET-PD Investigators, 2006, 2008). 
The trial was originally designed as a futility trial with the conclusion being that 
the results did not reach the futility threshold and that therefore large phase III 
trials should build on these results but these trials have not been done. It is 
possible that the lack of efficacy was because the treatment was only targeting 
microglia whilst ignoring the peripheral immune response. It is also possible that 
the reason the trail failed was because the follow up time was inadequate and the 
primary end point (change in Unified Parkinson’s Disease Rating Scale, UPDRS, 
a common measure of function in PD) was not sufficiently sensitive to detect 
changes over such a small period of time. 
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 In a similar vein, pioglitazone, used for the treatment of type 2 diabetes, had 
also been shown to have good outcomes in pre-clinical animal models (mainly in 
rodents)(Bonato et al., 2018). It also reduces microglial and astrocytic activation 
and was therefore considered a good candidate (NINDS NET-PD Investigators, 
2015). In a randomised, double blind placebo controlled trial, participants were 
either given 15mg or 45mg of pioglitazone or placebo (in addition to a baseline 
monoamine oxidase inhibitor which they were on prior to the trial). At 44 weeks 
there was no difference in UPDRS scores between the groups. Again, this may be 
because targeting microglia is not enough to slow disease progression. The 
follow up period may also not have been long enough to detect the relevant 
differences.  
 
Only one trial in PD so far has targeted the peripheral immune response, aiming 
to increase regulatory T cells using sargramostim (also known as granulocyte 
macrophage colony stimulating factor (GM-CSF) building on evidence from 
cross-sectional studies that these played a protective role (Gendelman et al., 
2017). This trial showed proof of mechanism in that all subjects showed an 
increase in the number and proportion of T regulatory cells and there were some 
positive trends in the clinical outcomes (magnetoencephalography recorded 
cortical motor activities). However the trial was very small (N=17 in the 
treatment group and N=20 in the placebo) and there were a number of 
concerning adverse events (including vasculitis, urticaria and a stroke in one 
patient)(Gendelman et al., 2017).  GM-CSF has many other effects on immune 
cells apart from expanding regulatory T cells which may have been responsible 
for these adverse effects. Additional trials using large numbers are required, 
potentially using a safer drug to boost the regulatory T cells.  
 
In Alzheimer’s disease (AD), the field has spent the last two decades focused on 
therapies aiming to remove the amyloid pathology associated with disease 
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(Panza et al., 2019). There has been a recent high profile failure of monoclonal 
antibodies to amyloid and indeed all therapies attempting to clear it (Mullard, 
2019) although there are still some trials in prodromal cohorts which have more 
promise (Panza et al., 2019). As a result, the field has started to look at 
downstream pathways for potential targets for disease modification, including 
the immune response.  There has been one phase 1 trial of etanercept (targeting 
tumour necrosis factor alpha, TNFa) in AD, again based on data from clinical 
cohorts showing that higher levels of  TNFa are associated with faster cognitive 
decline, particularly when combined with recurrent infection (Holmes et al., 
2009b). The primary outcomes were safety and tolerability rather than clinical 
efficacy. We therefore await further trials.  
 
Both the clinical presentation and disease progression is very heterogenous in 
PD and this may be an additional reason for a lack of positive trials of potential 
disease modifying therapies (Greenland, Williams-Gray, & Barker, 2019). 
Differences in the immune response to the primary pathology of PD may be one 
of the explanations for the clinical heterogeneity observed. It is important to 
understand the pathways involved (and whether these are protective or harmful) 
in order to identify appropriate drug candidates for repurposing in clinical trials.   
 
1.2.1 Disease heterogeneity 
There is substantial variability in disease course, with around half of patients 
developing dementia and two-thirds developing postural instability over the first 
10 years  from diagnosis. One quarter have a more benign course (Greenland et 
al., 2019; Williams-Gray et al., 2013). Both of these complications impair quality 
of life as well as resulting in increasing health care costs (Aarsland et al.,, 2000).  
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In our lab we have followed a large number of incident PD cases across several 
epidemiological studies. The CamPaIGN study (Cambridgeshire Parkinson’s 
Incidence from GP to Neurologist) consisted of a population based cohort of PD 
patients diagnosed between 2000-2002 with long term (ongoing) follow up 
(Evans et al., 2011; Williams-Gray et al.,, 2007; Williams-Gray et al., 2009, 2013).  
Through this study, we have identified, clinical parameters available at the time 
of diagnosis which allow stratification of patients into ‘high risk’ and ‘low risk’ 
groups for an early dementia (independent of age) using simple bedside 
cognitive tests (semantic fluency and pentagon copying) and tau genotype 
(MAPT H1/H1) genotype. This common inversion polymorphism on 
chromosome 17 is associated with dementia risk in PD as well as susceptibility to 
a number of neurodegenerative tauopathies (Williams-Gray et al., 2009).The 
high dementia risk group has the H1/H1 MAPT genotype, semantic fluency <20 
in 90s and pentagon copying score <2 (this has a positive predictive value for 
dementia of 58% at 5 years and 90% at 10 years)( Williams-Gray et al., 2013). The 
low risk group has the H2 genotype, semantic fluency >20 and pentagon copying 
score > 2 (positive predictive value for dementia 0% at 5 years, 29% at 10 years). 
It is also possible to calculate a patient’s risk of a “poor outcome” five years after 
diagnosis (either postural instability, dementia or death) using age, motor 
UPDRS (axial score) and semantic fluency based on a predictive model 
developed by our group across two independent population based cohorts 
(Velseboer et al., 2016).   
 
Although we have tools to predict prognosis in PD, our understanding of the 
underlying biological factors that determine disease progression and the 
development of dementia is limited.  There is mounting evidence for the role of 
the immune system in disease susceptibility and it is also possible that immune 
factors may contribute to ongoing disease progression in susceptible individuals.  
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1.2.2 Neuropathology of PD 
In common with many other neurodegenerative diseases, PD is characterised 
pathologically by aggregation of misfolded protein (alpha synuclein in the case 
of PD), inflammation (mainly in the form of microglial activation) and synapse 
loss.  
 
Aggregated alpha synuclein is found in the form of Lewy bodies, primarily 
affecting the  substantia nigra which is involved in the control of movement and 
some cognitive functions (Spillantini et al., 1997). Mutations in the SNCA gene 
that codes for alpha synuclein are associated with a range of clinical 
presentations of familial PD, confirming the pathological relevance of this 
protein (Goedert et al, 2013; Kara et al., 2014; Polymeropoulos et al., 1997; 
Singleton et al., 2003; Vekrellis et al., 2011).  Other abnormal proteins including 
tau and neurofibrillary tangles are also found in the PD brain as well as amyloid 
pathology more typical of Alzheimer’s disease (Irwin, Lee, & Trojanowski, 2013).  
The pathology and the clinical manifestations of PD, however, extend beyond 
the substantia nigra and include other brainstem sites, the cerebral cortex and 
also the autonomic and enteric nervous systems (e.g. the gut). There is evidence 
from post-mortem studies to suggest that the pathology may  start in the gut or 
the olfactory epithelium and then spread to and through the brain via the vagal 
or olfactory nerves, initially into the brain stem and then beyond into the 
midbrain and out to the cortex (Braak et al., 2006). Inoculating mice with alpha 
synuclein pre-formed fibrils in the gastric wall results in aggregates in the 
brainstem (vagal nucleus) which supports this hypothesis (Uemura et al., 2018). 
Such findings have led to the prion hypothesis of neurodegenerative disease, 
with alpha synuclein acting in a prion like fashion, as it passes from one cell to 
another (Goedert, 2015) although this remains strongly disputed as PD is not 
‘contagious’ in the same way as true prion disease. However, it is possible that 
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immune cells in the periphery and the CNS are involved with the transfer or 
clearance of alpha synuclein species.  
 
The extent to which activated microglia or other immune cells contribute to cell 
death associated with this pathology and to the propagation and spread of alpha 
synuclein pathology is not known. It is also not clear how signals received from 
the peripheral immune system affect this relationship. 
1.3 Parkinson’s disease and inflammation 
Over three decades ago, ‘activated’ microglia, the resident innate immune cells 
of the central nervous system (CNS), were described in post mortem PD brains 
(McGeer et al. 1988). They were defined as ‘activated’ based on their morphology 
(amoeboid, in preparation for adopting a more phagocytic phenotype) and 
expression of HLA-DR (from group II of the major histocompatibility complex 
(MHC)). MHC Class II molecules on the cell surface are involved in antigen 
presentation to CD4 T cells. The microglia were also noted to have melanin 
debris intracellularly suggesting that they had phagocytosed the pigmented 
neurons in the substantia nigra (McGeer et al., 1988). Imaging studies using the 
PET ligand PK11195 subsequently showed increased uptake in PD patients 
compared to controls, suggesting increased microglial activation (Gerhard et al., 
2006). It has been difficult to disentangle whether this is just a secondary 
phenomenon or whether these activated microglia contribute to ongoing cell 
death, driving further disease progression.  
 
With the advent of large scale genomics, genetic evidence suggests that the 
MHC locus is indeed involved in disease susceptibility and this is not just a 
bystander effect.  There are now a number of genetic studies including large 
meta-analyses of  genome wide association studies (GWAS) data from 13,708 
cases and 95,282 controls demonstrating an association between SNPs in HLA-
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DR and PD risk (Nalls et al., 2014). Data-driven pathway analyses of two 
independent GWAS showed an increase in pathways involved in 
‘leucocyte/lymphocyte activity’ and also ‘cytokine mediated signalling’ 
conferring increased susceptibility to PD even after the known associations with 
the MHC Class II locus were removed (Holmans et al., 2013). Variants in the 
LRRK2 locus on chromosome 12 are also associated with PD: common variants 
modulating disease risk with a small effect size while dominant mutations are 
the commonest Mendelian genetic cause of PD. The same variants are also 
associated with inflammatory bowel disease (Hui et al., 2018). The physiological 
functions of this protein are unclear but it has been linked to the control of 
neurite morphology, vesicle trafficking, dopamine receptor homeostasis, 
regulation of immune pathways, autophagy and insulin signalling (Wallings, 
Manzoni, & Bandopadhyay, 2015). 
 
There is also epidemiological evidence, including a meta-analysis of six large 
studies showing that non-aspirin NSAIDs have a protective effect on the 
incidence of PD with the effect particularly enhanced in regular users ((RR 0.71, 
95% CI 0.58-0.89) (Gagne & Power, 2010) and one large prospective study in 
136,137 people showing that ibuprofen (but not other NSAIDs) has a protective 
effect on susceptibility to PD (Gao et al. 2011). However, the most recent meta-
analysis involving 17 studies and 2,498,258 participants (14,713 PD patients) 
showed no overall effect of NSAID use suggesting that the effect may only be 
true in certain sub-populations (depending on disease stage) or confounded by 
the indications for medication use (Poly et al., 2019). In an insurance-based US 
case-control study (48,295 incident PD cases and 52,324 controls), inosine 
monophosphate dehydrogenase inhibitors (including azathioprine) and 
corticosteroids were found to have a protective effect on PD incidence (Racette 
et al., 2018). The same authors found decreased incidence in a population who 
had received organ transplantation compared to controls (89,790 incident cases 
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of PD and 118,095 population based controls), speculating that this was due to 
the associated immunosuppression (Fan et al., 2019).  
 
In PD, midbrain neurons are particularly vulnerable to pro-inflammatory 
cytokines (presumably mostly produced by neighbouring microglia) such as 
TNF-a and IFNg (Kannarkat, Boss, & Tansey, 2013; Mount et al., 2007). Increased 
pro-inflammatory cytokines have been found in post mortem brain and CSF 
(including IL-6, IL1b, TGF-b and IFNg) (reviewed in (Kannarkat et al., 2013)). In 
animals it is possible to model some aspects of PD (mainly midbrain 
dopaminergic cell loss) solely with the injection of LPS either into the brain or 
the periphery (Kannarkat et al., 2013). T cells  from PD patients cause death of 
autologous induced pluripotent stem cell derived dopaminergic midbrain 
neurons in in-vitro cultures suggesting that this may be one relevant mechanism 
of neurodegeneration (Sommer et al., 2018).  
 
An increase in central pro-inflammatory cytokines may be mirrored or driven by 
changes in the serum with evidence that there is elevation of peripheral 
cytokines in PD patients compared to controls. In a cross-sectional cohort, 
patients had significantly higher cytokine levels at baseline and in response to 
lipopolysaccharide (LPS) stimulation in vitro (MCP-1, RANTES, IL-8, IFNg, IL1b,, 
TNFa)(Reale et al., 2009). We have now shown that this also has prognostic 
implications. In a cohort study based in Cambridge and Newcastle, our group 
found that a more pro-inflammatory serum cytokine profile was associated with 
more rapid motor and more impaired cognitive function over a three year period 
(Williams-Gray et al., 2016). We identified the ‘pro-inflammatory’ component 
from principal components analysis of the results from a ten cytokine panel.  
 
A number of studies have looked at changes in the peripheral T cell 
compartment with some evidence to suggest chronic immune activation in the 
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periphery in PD patients compared with controls (e.g. (Baba et al., 
2005)(Saunders et al., 2012)). More recently, alpha synuclein specific T cells have 
been described that are more frequent in PD patients compared to controls 
(Sulzer et al., 2017).  Epitopes from one specific region of alpha synuclein (Y39) 
were displayed by HLA DRB5*01 and DRB1*15:01 (which are both associated with 
PD) suggesting an mechanistic link for the genetic association (Sulzer et al., 
2017). During my PhD, our group described aberrant replicative senescence in T 
cells, in particular in CD8 cells which fail to develop the CD28loCD57hi 
phenotype, even in the context of prior CMV infection which typically drives 
this. Hence, altered T cell senescence in PD may affect the response to 
neurodegeneration (Williams-Gray et al., 2018). There is also a growing literature 
on monocytes in PD, with some evidence to suggest that there is ongoing 
peripheral activation (via a switch to ‘classical’ from ‘non-classical’ 
monocytes)(Grozdanov et al., 2014)(Kannarkat et al., 2013), again suggesting that 
activation of the immune response is associated with PD.  
 
Modulating the immune response in animal models of PD improves disease 
outcomes. For example, in toxin induced animal models of PD, animals lacking 
mature lymphocytes (e.g. RAG1-/- mice), CD4 cells or T-Cell receptors show an 
attenuated disease course (Brochard et al., 2009) (Lira, Kulczycki, Slack, 
Anisman, & Park, 2011)). Targeting toll-like receptor4 (a receptor involved in 
recognising polysaccharide motifs, TLR4)(Noelker et al., 2013) and Fcg receptors 
(He, Le, & Appel, 2002) also improves disease outcomes. Other therapies that 
have been successful in animal models (mainly rodent based models) include 
fingolimod, tanshinoine, dimethyl fumarate and thalidomide (reviewed in 
Martinez & Peplow, 2018).  
 
Taken together, this suggests that the immune system may be playing a critical 
role in PD that is more than just a bystander effect or epiphenomenon. B 
Chapter 1: Introduction 
Kirsten Scott  November 2019    14
lymphocytes are an important part of the immune response.  A decrease in 
circulating B lymphocytes or their transcripts  in PD has been described (Gruden 
et al., 2012; Kedmi et al., 2011; Stevens et al., 2012). However, no studies to date 
have attempted to look at B lymphocyte subsets or function in PD or to 
interrogate the mechanism behind this observation. In addition, alpha 
synuclein-specific IgG antibodies have been described in PD, but their role is 
unclear with many conflicting studies (see later section on antibodies in PD and 
the systematic review and meta-analysis in chapter 3).  
 
1.4 B lymphocytes 
1.4.1 B lymphocyte development 
B lymphocytes are part of the adaptive immune system although there are some 
B cells that have a more ‘innate’ role (B1 cells in the peritoneum and marginal 
zone B cells in the spleen) (reviewed in Abbas, AK, Lichtman, AH, Pillai, 2014), 
pg2).  
 
At the simplest level, B lymphocytes are defined by their expression of clonally 
diverse cell surface immunoglobulin receptors that can recognise particular 
antigens. They begin their development in the fetal liver and then bone marrow 
with further development in secondary lymphoid tissue (lymph nodes and the 
spleen)(LeBien & Tedder, 2008). The main function of B cells has classically been 
viewed as antibody production following their terminal differentiation to plasma 
cells, but we now know that B lymphocytes have a number of other roles. 
 
 Early B cell development in the bone marrow involves the re-arrangement of 
immunoglobulin gene segments  encoding immunoglobulin heavy chains (VH, 
DH and JH) and light chains (VLJL) (Pieper, Grimbacher, & Eibel, 2013).  This 
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incredible process is capable of producing a B cell repertoire that can recognise 
millions of antigens. At the pre-B cell stage the nascent IgM molecule is only 
found in the cytoplasm, moving to the cell surface in the immature B cell which 
then leaves the bone marrow to circulate in the blood to secondary lymphoid 
tissues (the spleen and lymph nodes mainly but also mucosal tissues, Peyer’s 
patches and possibly the meninges) where they differentiate into naïve, follicular 
or marginal zone B cells (Pieper et al., 2013).  Chemokine and cytokine gradients 
drive subsequent movement of B cells back into circulation (e.g. sphingosine-1-
phosphate) or back into lymph nodes or germinal centres (e.g. CXCL13). Figure 
1-1 gives a broad overview of this process, showing the major developmental 
points, from an immature B cell to a transitional B cell (which is also one of the B 
cell subsets that produces the regulatory cytokine IL10). Subsequently, the B cell 
may become a follicular B cell where upon encountering antigen and co-
stimulatory signals from follicular T helper cells (including CD40L/CD40, ICOS-
ICOSL and CD28/CD86) it can enter the germinal centre reaction where, via a 
process of clonal selection and somatic hypermutation, more specific antibodies 
are generated to the antigen (with subsequent class switching from IgM to IgG, 
IgA or IgG). The B cells then either differentiate into long lived plasma cells 
(homing back to bone marrow) or to memory B cells which retain the capacity to 
recognise antigen and proliferate in response to re-challenge for decades (at least 
in humans)(see Figure 1-1) (Clatworthy, 2014).  
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Figure 1-1 
B cell maturation and development 
 
 
Figure 1-1 B1 cells are found in the peritoneum and in the pleura where they have 
been described in mice, producing low affinity ‘natural’ antibodies to T-
independent antigens (such as polysaccharides). The remainder of B cells are 
considered “B2” cells. Immature B cells will move from the bone marrow into the 
circulation, becoming transitional B cells (shown here as CD24HICD38HI cells) 
(some of which are capable of producing IL10).  They then go to lymphoid tissue 
becoming naïve (characterised by surface expression of IgD), follicular or 
marginal zone B cells. After encountering antigen follicular B cells will move to 
the T-B border in lymph nodes or the spleen and present antigen to T cells (pre-
T follicular helper cells pTfh). The B cell will then either become a short lived 
plasma cell or enter a germinal centre reaction helped by T follicular helper cells 
(Tfh), going through somatic hypermutation leading to class switching (from 
Chapter 1: Introduction 
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IgM to IgG, IgA or IgE) to form a long lived memory B cell (identified by surface 
expression of CD27 in humans)  or a plasma cell (identified by CD138 and CD38). 
Regulatory B cells may be derived from transitional B cells or can be induced by 
cytokine stimulation and are defined by different markers in humans and mice 
(CD38HICD24HI in humans and CD5+CD1d+ or CD9 positive cells in mice).  
 
1.4.2 Potential mechanisms underlying antibody generation in PD 
B lymphocytes can produce antibodies via T cell-independent (TI) and T cell-
dependent pathways (TD) (see Figure 1-2) . TI pathways involve the recognition 
of multimeric carbohydrate and lipid antigens by the B cell receptor (BCR) or by 
toll-like receptors (TLR) on the cell surface of “B1” cells (or marginal zone B cells 
in the spleen). This leads to the production of polyreactive IgM that binds with 
low affinity and can facilitate the removal of blood borne encapsulated 
organisms (LeBien & Tedder, 2008).  Antibodies produced in this context are 
called ‘natural antibodies’. Most of the literature on alpha synuclein antibodies 
suggests that these are natural antibodies (Besong-Agbo et al., 2013; Brudek et 
al., 2017; Heinzel et al., 2014; Kronimus et al., 2016). Natural antibodies are part of 
innate immune surveillance against pathogens or cell damage and are present 
from an early point in development (Panda & Ding, 2015). They are 
predominantly IgM but IgG and IgA natural antibodies have also been described 
(Panda & Ding, 2015). Antibodies to alpha synuclein epitopes could be generated 
via this process.  
 
The recent description of alpha synuclein specific T cells in patients with PD 
(Sulzer et al., 2017) supports the thesis that alpha synuclein antibodies may also 
be generated by a TD response. These antibodies recognise protein antigens and 
their production requires a cognate interaction between “B2” cells and CD4 T 
Chapter 1: Introduction 
Kirsten Scott  November 2019    18
cells. This facilitates iterative rounds of somatic hypermutation and clonal 
selection within a germinal centre reaction to generate class-switched, long lived 
plasma cells or memory B cells capable of initiating a secondary response upon 
further encounter of the antigen (Panda & Ding, 2015). The plasma cells that 
arise from this process are able to produce large quantities of specific, high 
affinity class-switched antibodies (LeBien & Tedder, 2008). Humoral responses 
to self-antigen are limited by negative selection of self-reactive clones during B 
cell development. 
 
However, if the self-antigen is modified sufficiently, as in the case of alpha 
synuclein toxic species, and is present in an immunogenic context, such as cell 
death, some B cell clones may be activated to produce alpha synuclein 
antibodies. Such an antibody response might change over time; firstly IgM may 
dominate, but with progression of the germinal centre reaction, there is class 
switching to IgG or IgE. Secondly, with persistent exposure to neo-antigen, 
clones with higher levels of somatic hypermutation and higher affinity 
antibodies would be selected.  Thirdly, the overall level of alpha synuclein 
antibody might change with age, as older age is associated with decreasing 
antibody response to antigens (e.g. vaccines) and immunosenescence of the B 
cell compartment (Aw, Silva, & Palmer, 2007).  
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Figure 1-2 
Possible mechanisms of antibody generation in PD 
 
Figure 1-2 A modified version of this figure has been published in (Scott et al., 
2018). It illustrates TI and TD dependent mechanisms of antibody generation 
and subsequent neuronal cell death after Fc gamma receptor medication 
phagocytosis, Fc gamma receptor mediation microglial activation and 
subsequent cytokine release (IL6/TNFalpha are neuro-toxic) and antibody 
mediated cytotoxicity towards neurons opsonised by antibody.  
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B cell activation to generate plasma cell-producing antibodies generally occurs 
within secondary lymphoid organs (lymph nodes and spleen) but may also occur 
in tertiary lymphoid follicles that develop in inflamed tissues. The site of B cell 
activation to generate alpha synuclein-specific responses is unclear and may be 
peripheral or within the CNS.  Follicles have been described in the meninges of 
patients with multiple sclerosis (Magliozzi et al., 2006), with the potential to 
generate CNS localised antibodies, but whether such structures exist in PD is 
unknown. 
 
The most common circulating antibody isotype is IgG, that can readily initiate 
and propagate inflammation by activating complement and engaging cell surface 
antibody receptors (Fcg receptors (FcgR)) that are expressed by most innate 
immune cells.  Antibodies bind non-specifically to Fcg receptors on other 
immune cells (e.g.phagocytes, monocytes, dendritic cells) or via engagement of 
their Fc region with complement components (Willcocks, Smith, & Clatworthy, 
2009).  Different subclasses of IgG (IgG1, IgG2, IgG3 and IgG4) have different 
affinities for the FcgR on cells which can be either activating or inhibitory (see 
(Willcocks et al., 2009). There is evidence that FcgRI and FcgRIIB/C are required 
for uptake of alpha synuclein by CNS derived cells (human neuroglioma) in 
culture and that this is mediated by the presence of alpha synuclein specific 
antibodies (Gustafsson et al., 2017). One recent paper suggested that FcgRIIB (a 
low affinity inhibitory Fc receptor) is not only responsible for the inhibition of 
phagocytosis of alpha synuclein fibrils (via low affinity binding with the fibrils 
themselves) but also mediates cell to cell transmission of alpha synuclein (Choi 
et al., 2018). In addition, the glycosylation status of immunoglobulin also affects 
downstream binding and effector function (Jennewein & Alter, 2017). A study 
investigating the IgG glycome in PD showed significant differences between 
patients and controls, with the authors concluding that the changes observed in 
PD may result in enhanced Fcg RIIIa-mediated antibody-dependent cellular 
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cytotoxity (with the potential to contribute to chronic inflammation) (Russell et 
al., 2017).  Our group found recently that autologous serum significantly 
increased monocyte phagocytosis (which was increased in early moderate PD 
compared to controls)(Wijeyekoon et al., 2018). It is possible that this was due to 
the presence of antibodies in the serum but this requires further confirmation.  
 
The presence of alpha synuclein specific antibodies in early PD could potentially 
contribute to pathology by exacerbating local inflammation in the brain, 
promoting neuronal damage and causing disease progression. Consistent with 
this hypothesis, IgG isolated from PD patients and injected into the rat 
substantia nigra causes selective dopaminergic cell death that was absent in 
animals receiving control IgG (Chen et al., 1998).  There is also attenuation of 
disease in Fcg receptor knockout mice receiving PD IgG, confirming that 
activation of microglia by PD IgG is pathogenic (He et al., 2002). Approximately 
30% of dopaminergic cells in the substantia nigra of post mortem human PD 
brains were bound by IgG highlighting that immunoglobulins do cross the blood 
brain barrier in PD and may play a role in disease (Orr et al., 2005). Alternatively, 
alpha synuclein auto-antibodies may play a protective role, facilitating the 
clearance of toxic protein species by opsonizing alpha-synuclein for FcgR-
mediated uptake by phagocytes. Consistent with this hypothesis, the passive 
peripheral transfer of alpha-synuclein specific antibodies in some mouse models 
of PD improved disease outcomes (Masliah et al., 2005). Trials of both passive 
and active immunization therapies targeting alpha synuclein are underway 
(Takamatsu et al. 2017). 
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1.4.3 B lymphocytes: antibody independent functions 
Regulatory B cells 
Like other arms of the immune system, B lymphocytes can be divided into 
immune effectors and  immune inhibitors . The inhibitors, or “regulatory” B cells 
provide a brake on immune activation. Unlike their well described counterparts, 
T regulatory cells they are not defined by a single transcription factor (FoxP3 in 
the case of Tregs) and work via several different pathways to inhibit either T cell 
or innate immune activation.  Several subsets of B cells are able to act as 
immunoregulatory cells (Blair et al., 2010; DiLillo, Matsushita, & Tedder, 2010; 
Iwata et al., 2011; Mauri & Bosma, 2012).  They primarily exert their effect via the 
production of IL-10 and are therefore called sometimes referred to as “B10” cells 
or more generally as regulatory B cells. IL10 produced by B cells is able to induce 
T regulatory cells, to attenuate monocyte and macrophage activity and to 
decrease CD4 cell activation in co-culture assays and in disease model mice (e.g. 
in particular TH1 type responses in collagen induced  arthritis and in 
experimental autoimmune encephalitis EAE)(Mauri & Menon, 2015).  There are 
an increasing number of B cell subsets and markers that have been described as 
regulatory B cells (which act via several pathways in additional to IL10). In mice, 
the most commonly used surface markers are CD1d and CD5 but studies have 
also described IL10 producing, marginal zone B cells, TIM-1+ B cells, 
plasmablasts, plasma cells (also acting via IL-35) PDL1hi cells (acting via PDL1). In 
humans, the IL10 producing subset is usually identified by an immature 
transitional subset (CD27-) CD24hi CD38hi  (acting via PDL1 or IL10), or as B10 
cells CD24hi, CD27+ (IL10) but also as being CD25hi, CD71hiCD73lo (acting via both 
IL10 and IgG4) (markers in both humans and mice are reviewed in (Mauri & 
Menon, 2015). As one might expect, deficiencies of regulatory B cells in mouse 
models and human disease are associated with increased severity of auto-
immune or inflammatory diseases (e.g. systemic lupus erythematosus and 
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rheumatoid arthritis) whilst offering some protection from infection (Mauri & 
Bosma, 2012; Mauri & Menon, 2015).  
 
Apart from their role in regulation, B lymphocytes are also able to produce pro-
inflammatory cytokines such as IL6 (Barr et al., 2012), stimulate the innate 
immune system (via the production of granulocyte macrophage colony 
stimulating factor GM-CSF (Rauch et al., 2012) and are required for the 
maintenance of sub-capsular sinus macrophages (Moseman et al., 2012). B1 B 
cells respond to pathogen associated molecular motifs (PAMPs), acting like 
innate immune cells (mainly in the peritoneum in mice).   
 
There is also evidence that there are changes in the B lymphocytes that 
accumulate with age including impaired vaccine responses, a decrease in B cell 
diversity and an increase in memory B cells reflecting increase antigen exposure 
over a life time (Frasca, 2018). This is also reflected in an increase in a group of B 
cells  that are terminally differentiated and adopt a ‘senescence associated 
secretory profile’ (SASP) (increased secretion of IL-6, IL-8 and TNFa) and 
identified by a ‘double negative’ phenotype (CD27-IgD- B lymphocytes)(Frasca, 
2018). In mouse and humans, a separate subset, age associated B cells (ABC’s) 
have been identified by their expression of the transcription factor T-bet and 
surface markers CD11c, CD80 and CD86. (Karnell et al., 2017; Rubtsov et al., 2011; 
Rubtsova, Rubtsov, Cancro, & Marrack, 2015). These are associated with auto-
immune disease, infection and increasing age (Karnell et al., 2017) but have not 
been described in neurodegenerative disease or PD.  
 
B lymphocytes are therefore an important branch of the immune system, 
performing multiple roles in interaction with T cells and the innate immune 
system and that may change during the aging process. Differences in B cell 
subsets and function have not been described in Parkinson’s disease.  
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1.4.1 Examples of the involvement of B lymphocytes in other diseases 
In the past autoimmune and inflammatory disorders were categorised as either 
antibody mediated (mainly involving B cells) such as Graves’ disease or systemic 
lupus erythematosus (SLE) or T cell mediated (Multiple Sclerosis, type I diabetes 
or  rheumatoid arthritis). More recently, it has emerged that this dichotomy is an 
oversimplification as there is in fact a complex interplay not only between B 
lymphocytes and T lymphocytes but also between the adaptive and innate 
branches of the immune system. All of the B cell functions described above can 
contribute to auto-immunity or inflammation not just antibody production.  
 
Systemic lupus erythematosus has been traditionally thought of as a classic B cell 
antibody mediated disease (Hampe, 2012). B cells play a role in disease primarily 
by the production of antibodies to nuclear components including double 
stranded DNA, RNP particles (anti-Ro, anti-La and anti-Sm) and histones. There 
are several alterations in B cell subsets in addition to this: increased memory B 
cells (with a lower activation threshold) and exaggerated b-cell receptor (BCR) 
responses (Karrar & Cunninghame Graham, 2018). Immune complexes become 
deposited in tissues such as the kidney where they bind to Fc receptors and 
activate complement, recruiting neutrophils and NK cells and leading to further 
inflammation and ultimately organ damage. Serum transfer from affected 
animals in mouse models of lupus causes disease to previously unaffected 
animals (nephritis)(Cheng et al., 2013) providing direct evidence for the 
pathogenicity of the antibody. However, another study used mice expressing a 
transgene allowing surface expression of immunoglobulins but not circulating 
immunoglobulins (ie.no antibody production). The mice still developed disease 
(again, nephritis) suggesting that other aspects of the B cell response were 
involved (possibly antigen presentation to T cells or local cytokine 
secretion)(Chan et al., 1999). B cell depletion in SLE was less effective than 
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expected with depletion occasionally worsening symptoms and two trials of 
rituximab (an anti-CD20 monoclonal antibody) failed to meet their primary 
endpoints (although belimumab, a humanised monoclonal antibody to BAFF is 
now licensed as a treatment in refractory SLE)(Hampe, 2012; Thaunat, Morelon, 
& Defrance, 2010). This may be to do with the selection of patients, timing and 
how the balance between regulatory and effector arms of the B cell response is 
affected.  
 
 In Parkinson’s disease, the involvement of B cells is likely to be a secondary 
phenomenon that then contributes to ongoing disease progression rather than 
being a primary auto-immune disorder like SLE. As described previously, PD  
may share some mechanisms with SLE, such as non-specific Fc receptor 
activation and subsequent local inflammation due to immunoglobulins bound to 
neurons or alpha synuclein in the brain (see previous section).  
 
Type I diabetes (T1DM) on the other hand was viewed until recently as a 
primarily T cell mediated disorder. However, it has now been shown that B cells 
present beta cell antigens to T cells. Mouse models deficient in B cells do not 
develop diabetes and mice with MHC Class II deficient B cells are also protected, 
reviewed in (Hampe, 2012). It has now also been shown that B cell depletion is an 
effective treatment in T1DM (Pescovitz et al., 2009). The current model for 
disease pathogenesis is that pancreatic beta cell antigens are recognised and 
taken up by the BCR on B cells and then presented to CD4+ T cells via MHC 
Class II. These activated T cells then provide further T cell help to the B cells 
facilitating the differentiation into plasma cells and secretion of autoantibodies. 
These then bind to Fcg receptors on other immune effector cells causing further 
inflammation and tissue destruction.  
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These examples highlight the fact that B lymphocytes play very different roles in 
different inflammatory diseases (and even different roles at different time points 
in the same disease). One common criticism of my work from other neurologists 
is that PD does not look like MS (clinically, demographically,  pathologically or 
in the expression profile of post mortem brains (Filiou et al., 2014) and therefore 
‘inflammation’ cannot be involved in its pathogenesis. I have argued that we are 
seeing a different inflammatory response in PD (compared to MS) which is still 
harmful and important to address. Given that the immune response is different 
even within canonical inflammatory or auto-immune conditions, it is not 
unreasonable to look for an inflammatory response unique to or more typical of 
neurodegenerative disorders.  
 
1.5 Meningeal immunity 
During my PhD, meningeal lymphatics were re-discovered having been 
originally described by an 18th century Italian neuroscientist who was then 
forgotten (Aspelund et al., 2015; Da Mesquita, Fu, & Kipnis, 2018; Louveau et al., 
2018). Mass cytometry using CyTOF has shown that B lymphocytes form a 
significant proportion of meningeal immune cells (Korin et al., 2017). Meningeal 
lymphatics have now also been described in human imaging studies using MRI 
(Kuo et al., 2018). In addition, there is evidence that the skull bone marrow niche 
harbours a subset of cells that are responsive to immune signals from the brain 
and can communicate with the brain parenchyma and meninges via tiny 
channels in the bone (Herisson et al., 2018). Ablating the meningeal lymphatics, 
presumed to be draining the CNS results in worsening disease in amyloid, tau 
and alpha synuclein mouse models of neurodegenerative disease (Da Mesquita, 
Louveau, et al., 2018; Louveau et al., 2018; Patel et al., 2019; Zou et al., 2019). 
Improving lymphatic drainage with vascular endothelial growth factor rescued 
these deficits in a model of AD (Da Mesquita et al., 2018). This compartment is 
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likely to be relevant to all diseases affecting the CNS. Given the substantial 
representation of B cells within the meningeal immune compartment, they are 
likely to play a key role. 
1.6 Overall hypothesis 
 
B lymphocytes play a critical role in driving disease progression in PD by 
contributing to a pro-inflammatory milieu in the periphery which in turn alters 
microglial and neuronal homeostasis (via signals received from the meningeal B 
cell population) resulting in increased destruction of dopaminergic and other 
neurons in the brain, contributing to ongoing disease progression.  This B 
lymphocyte response is likely to be, at least in part, antigen specific given that 
there is pathological aggregated alpha synuclein present in the periphery (the 
gut) and the CNS. Some subsets of B cells may also play a regulatory role via IL10 
production. 
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Figure 1-3 
Simplified schema showing the hypothesised relationships between 
peripheral and central inflammation 
 
Figure 1-3 shows an overview of my overall hypothesis linking peripheral 
immune activation (shown here as increased levels of pro-inflammatory 
cytokines) in association with alpha synuclein pathology (e.g. in the gut). This is 
associated with (and possibly drives) microglial activation in the brain which 
contributes to ongoing neuronal cell death (again associated with alpha 
synuclein pathology). B cells specifically are likely to contribute to the peripheral 
immune activation via the production of cytokines and antibodies which cross 
the blood-brain barrier, contributing to a pro-inflammatory milieu in the brain 
that drives disease progression. 
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Figure 2-1 
Clinical studies summary diagram 
 
 
 Figure 2-1: Overview of clinical studies by cohort. Cohort one patients and 
controls were  specifically matched for age, gender and genotype and all assays 
were carried out in control/patient pairs to minimise the effect of inter-assay 
variability on group differences. The other cohorts were matched overall.  The 
bottom panel shows the cell surface markers used in each study. CD19 is a 
surface marker identifying B cells, CD27 and IgD are used together to identify 
naïve B cells (characterised by surface expression of IgD, negative for CD27) and 
memory B cells (CD27 positive, IgD negative). IgM is also a surface 
immunoglobulin on mature naïve B cells.  CD38 and CD24 are used to identify 
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transitional B cells (which are thought to be one of the IL10 producing subsets) 
(CD27-CD24HICD38HI). CD1d and CD5 were chosen as these mark an additional 
subset of regulatory B cells in mice (but this is not consistently the case in 
clinical samples). CD138 was chosen along with CD38 to identify plasma cells 
(which are infrequent in circulating blood).  In cohort 2, additional markers were 
used to identify age associated B cells (Tbet, CD11c, CD86). Cohort 3 was a pilot 
study to look at whether it is possible to identify B lymphocytes in the 
cerebrospinal fluid (CSF) of patients and controls.  
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2.2 Methods 
2.2.1 Participants (Cohort 1, Immune study in PD)  
The study was approved by the Cambridgeshire Research Ethics Committee 
(03/303). Written, informed  consent was obtained from  all participants  in 
accordance with the Declaration of Helsinki.  
 
Inclusion criteria were fulfilment of the UK PD Brain Bank Criteria for a 
diagnosis of definite PD (made by neurologist), age 55-80 years and early stage 
disease (Hoehn and Yahr stage ≤ 2). Exclusion criteria included the presence of 
other neurodegenerative disorders, chronic inflammatory of autoimmune 
disorders, current clinically significant infection, surgery in the last month, 
vaccinations in the previous 3 weeks or recent use of anti-inflammatory or 
immunomodulating medication (steroids in the previous three months, high 
dose aspirin >75mg in the previous 2 weeks, ibuprofen and other non-steroidal 
anti-inflammatory drugs in the previous 2 weeks or any long term 
immunosuppressant drugs such as azathioprine, mycophenolate, methotrexate, 
rituximab or other biological therapies in the last year).  
 
An interim power calculation was performed based on pilot results from 5 
patients and 5 controls with the results suggesting that 23 partipants were 
required in each group to obtain 80% power.  Given likely variability and the 
possibility of assay failure we aimed to recruit 40 in each group to ensure that 
the study was adequately powered.  
 
The patients were stratified into groups at high, intermediate and low risk of 
dementia using predictive factors identified in a longitudinal cohort study 
(Williams-Gray et al., 2009). The stratification was done on the basis of their 
MAPT (tau) genotype, pentagon copying ability and semantic fluency score (the 
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high risk group was defined as MAPT H1/H1 genotype and any one of either 
semantic fluency <20 in 90s or pentagon copying score <2, the intermediate 
group had any one of these factors and the low risk group had none)(as in 
(Williams-Gray et al., 2018). Their overall probability of a ‘poor outcome’ (either 
dementia, postural instability or death) was also calculated using a combination 
of age, UPDRS axial score and semantic fluency score (Velseboer et al., 
2016).Dementia in this context is used as a proxy to measure disease progression 
(as it suggests involvement of brain regions outside the substantia nigra and 
impairments involving other neuronal populations beyond dopaminergic cells 
where the pathology is thought to start).  
 
Age, gender and MAPT-genotype matched controls were recruited from the 
NIHR Cambridge Bioresource (http://www.cambridgebioresource.org.uk/). 
Controls had no history of neurological disease, memory problems or 
depression. Exclusion criteria were the same as for the PD patients. Samples 
from matched patient and control pairs were processed on the same day with 
collection occurring in the morning (between 9 and 11am).  
All patients went through a full clinical assessment including medical history 
and co-morbidities, the Movement Disorder Society Unified Parkinson’s Disease 
Rating Scale (MDS-UPDRS), the Addenbrooke’s Cognitive Examination (ACE-R), 
assessment of semantic fluency (animal naming in 90s), pentagon copying and 
the Beck Depression Inventory (BDI). The overall probability of a bad outcome 
(either postural instability or dementia) was calculated using a validated tool 
which uses axial components of the UPDRS, age and animal fluency (Velseboer 
et al., 2016). 
 
Up to 50mL of venous blood was collected from each patient or control using a 
combination of lithium heparin tubes for peripheral blood mononuclear cell 
(PBMC) isolation, clotted tubes for serum collection and 
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ethylenediaminetetraacetic acid (EDTA) tubes for full blood counts. Clotted 
samples were left at room temperature for 15 minutes before centrifuging at 
2000RPM for 15 minutes. Serum was collected and stored in 200µl aliquots at -
80°C for subsequent use. Patients attended three times over a 4-5 week period in 
order to obtain repeat serum samples to validate baseline cytokine levels and to 
provide serum for subsequent analysis looking at auto-antibodies. 
2.2.2 PBMC extraction, immunocytochemistry and flow cytometry 
Peripheral blood mononuclear cells (PBMC) were isolated from heparinised 
blood using a Ficoll gradient within 2 hours of phlebotomy. The PBMC layer was 
removed and washed twice with PBS.  Depending on the total number of cells, 
excess cells were frozen in freezing medium (90% foetal calf serum [FCS, Sigma 
Aldrich F7524] and 10% dimethyl sulfoxide [DMSO, Sigma Aldrich D8418]) and 
placed in a cryopreservation chamber at -80°C. 
 
Surface staining was done on both fresh and frozen cells initially as part of the 
optimisation of the protocol.  Frozen cells were placed on ice and allowed to 
warm up after being diluted with foetal calf serum (FCS) and subsequently 
placed in a 15mL Falcon tube.  To reduce variation due to batch effects,  I had 
planned to use frozen cells stained in batches. Due to some variability in staining 
of some of the surface markers and variable yield of live cells from frozen 
aliquots I then continued using only freshly obtained ex vivo cells for the final 
protocol (data not shown). 
  
Cells were resuspended at a concentration of 1 x 106 per 100μl of FACS buffer for 
staining plus 2% mouse serum (0.1% BSA, Probumin. Millipore, cat. no. 82-045-1, 
0.01% sodium azide, Sigma Aldrich, cat. no. S2002 made up in Phosphate 
Buffered Saline [PBS], mouse serum Sigma Aldrich, cat. no. M5905).  Cells were 
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left to block for 10 minutes at 4°C.  In the final protocol, 0.5μL of zombie acqua 
was added after blocking and left to incubate for 15 minutes prior to the addition 
of surface staining antibodies. 
 
Antibodies were added in appropriate concentrations after titration experiments. 
The final surface staining panel is below (see Table 2-1 and Appendix II for 
details). Antibodies were incubated with the cells at 4°C. centigrade in the dark 
for 20 minutes.  The cells were subsequently spun and washed twice in FACS 
buffer before being fixed in 2% paraformaldehyde (PFA) for 20 minutes. Cells 
were then washed twice with FACS buffer prior to being placed in FACS tubes 
for analysis. Flow cytometry was run within 2-4 hours of staining for all samples.  
Isotype controls were used for all panels to asses non-specific binding and to 
confirm gating of cell populations. FCS output files were imported into FlowJo 
software (version 10.5.0) which was used for initial gating of the cell populations 
which was done blinded to group. 
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Table 2-1 









BV786 CD19 3 BV786 CD19 3 
FITC CD5 2 FITC CD19 4 
BV605 CD24 5 BV605 CD19 2 
BUV 395 CD27 3 BUV395 CD27 3 
APC CD38 10 APC CD19 2 
PE IgM  10 PE CD19 2 
V450 CD138 5 V450 CD19 3 
APC H7 IgD 2 APCH7 IgD 2 
PerCp Cy5.5 CD1d 3 PerCp Cy5.5 CD19 3 
Live dead zombie aqua 0.5 Live dead zombie aqua 0.5 
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2.2.3 Alpha synuclein measurement 
Alpha synuclein was measured using Meso Scale Discovery (MSD) human alpha 
synuclein kit (K151TGD-2) following the manufacturer’s instructions. Serum 
samples were defrosted and handled on ice before being used immediately. 
Calibrators were prepared using solutions of known concentration to create a 7 
point calibration curve with four fold serial dilution and a zero calibrator blank. 
All samples and calibrators were run in duplicate. Samples were diluted using 
the manufacturer provided diluent (8 fold dilution). The plate was blocked with 
proprietary diluent (number 35) and incubated with shaking for one hour. The 
plate was then washed three times with 150µl of  PBS-tween 20 (Sigma Aldrich 
P1279) (PBS-T)(0.05%). Detection antibody solution was added at a volume of 
25µl. Sample or calibrator solutions were then added at a volume of 25µl. The 
plate was sealed and incubated at room temperature with shaking for 2 hours.  
After incubation, the plate was washed with PBS-T three times and then 150µl of 
read buffer was added and the plate was read on an MSD plate reader (Sector S 
600). The concentrations were calculated from the standard curve using a least 
squares fitting algorithm generated by  Discovery Workbench Software (MSD).  
 
2.2.4 B cell activating factor (BAFF) ELISA 
Serum samples were collected as described above and stored at -80 degrees 
centigrade. Samples were defrosted on wet ice and the ELISA was run within 24 
hours. BAFF was measured using the Abcam BAFF Human ELISA kit (ab119579) 
as per the manufacturer’s instructions. Briefly, standards were prepared by using 
a 10ng/ml stock solution of recombinant human BAFF which was diluted to a 
final concentration of 4,000pg/mL for standard 1. Subsequent standards were 
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made using serial four fold dilutions. The last standard was blank. Serum 
samples were diluted 1:1 with sample diluent. 100µl of either sample or standards 
were added to the plate and incubated at 37 degrees centigrade for 90 minutes. 
The contents of the well were then discarded and 100 µl of biotinylated anti-
human BAFF antibody was added and incubated for 60 minutes at 37 degrees 
centigrade. The plate was then washed three times with PBS. After washing, 100 
µl of Avidin-Biotin-peroxidase complex solution was added to each well and 
incubated at 37 degrees for 30 minutes. The plate was then washed five times 
with PBS.  TMB colour developing agent was then added (90 µl) per well and the 
plate was incubated at 37 degrees for 20 minutes.  100 µl  od TMB Stop solution 
was added after incubation and the optical density (O.D) absorbance was read at 
450nm using a microplate reader. Serum concentrations were estimated based 
on the standard curve generated for each plate. Serum from one control 
individual was run on all plates for the purposes of normalising the data across 
plates.  
 
2.2.5 B lymphocyte stimulation  
I selected standard reagents used for B lymphocyte stimulation (also described in 
(Wagner et al., 2004)). CpG DNA is a pathogen associated molecular motif 
(PAMP) recognised by toll-like receptor 9 which is predominantly expressed on 
B lymphocytes. CD40 ligand is expressed on a number of cells (T cells, B cells, 
dendritic cells and macrophages) and is known to activate B cells, inducing 
proliferation, class switching and antibody secretion (Wykes, 2003). Phorbol 12-
myristate 13-acetate (PMA)  and ionomycin are non-specific immune activators 
that work by increasing intracellular calcium. Brefeldin inhibits transport of 
protein from the endoplasmic reticulum to the golgi apparatus thereby 
preventing the secretion of cytokines. 
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PBMC’s were obtained as for surface staining. As part of the optimisation of this 
protocol, initially the stimulations were performed on ex vivo cells and 
subsequently on frozen PBMC’s to allow for larger batches to be done at the 
same time.  For the clinical study, PBMC’s were aliquoted into 1 x 107 aliquots 
and resuspended in 1ml of 10% dimethyl-sulfoxide (DMSO) (DMSO, Sigma 
Aldrich D8418]) in fetal calf serum (FCS). They were placed into a Mr. Frosty for 
48 hours and subsequently stored at -80 degrees centigrade. 
 
Alpha synuclein preparation 
Alpha synuclein monomers (from rPeptide, S-1001-2) were suspended in MilliQ 
water. Using the Amicon Ultra 3K, samples were concentrated and resuspended 
to make a solution of 10mM Tris-HCl, pH 7.6, 5µg/µl concentration. Lastly the 
tubes were placed in a 37°C thermomixer and shaken for 7 days at 1,000 RPM. 
Preparation of alpha synuclein fibrils was kindly done by William Kuan, a post 
doc in the Barker lab. Fibrils were stored in aliquots of 20µl at -20°C. Prior to use, 
they were defrosted and sonicated with 60 pulses and 10% power to ensure that 
the aggregates were not too large.  
Final protocol 
PBMCs were removed from the freezer and placed on wet ice with 1mL of 10% 
FCS until thawed enough to be transferred to a 15ml Falcon tube containing 10% 
FCS. The tubes were centrifuged at 400g for 10 minutes and then resuspended in 
5mL of 10% FCS for cell counts. The tubes were then spun again at 350g for 5 
minutes and resuspended in RPMI cell culture media with glutamine (Gibco 
21875-034) with 10% heat inactivated foetal calf serum to a concentration of 0.25 
x 106 cells per 200μl. Cells were cultured in 200 μL in a 96 well round bottom 
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plate. The test wells were stimulated with either CpG DNA (1:10000) 
((Cambridge Bioscience #Hycult HC4039)  and CD40 ligand (1:5000) (R and D 
systems, 6245-CL-050 ) or alpha synuclein fibrils for 48 hours.  
 
Five hours prior to removal from culture,  Phorbol 12-Myristate 13-Acetate 
(PMA)(50ng/ml) (Sigma-Aldrich #P8139), ionomycin (500ng/ml) (Sigma-Aldrich 
#I0634) and brefeldin (5μg/ml) (BioLegend #420601) were added to the 
CD40L/CPG wells and to separate intermediate (PIB) wells (see figure). Brefeldin 
was added to the alpha synuclein and unstimulated (BFA) wells at this time 
point too.  
 
Optimisation of the protocol 
Given variable cell yields post freezing, the initial protocol using 1 x 106 cells per 
well was changed to 0.25 x 106 as this gave similar results. Using less cells 
necessitated a change from a 48-well flat bottomed plate to a 96 U bottomed 
plate (which was then used for staining subsequently, decreasing washes and 
related cell loss). The alpha synuclein culture condition was added part way 
through the experiment following results from another member of the lab. A 
number of cell surface markers were trialled and then dropped from the final 
protocol either because of a lack of expected differences post culture (CD27, 
CD38, IgD) or because there was no difference in readouts after stimulation 
(TIM1, CD71, CD73) despite recent literature suggesting that this might be the 
case (Aravena et al., 2017; van de Veen et al., 2013). An intermediate stimulation 
condition using only PIB was removed to streamline processing and save 
antibody (no differences observed in a subset of the data). 
  
Chapter 2: B lymphocytes in PD 
Kirsten Scott  November 2019    42
 
Figure 2-2 
Schematic showing 96 well plate lay out for each assay.  
 
Figure 2-2 legend: Each run of the assay contained a low risk patient (and 
matched control) and either a high or intermediate risk patient (and matched 
control) to reduce the effect of inter-assay variability on between group 
comparisons. CD40L = CD40 Ligand, CPG = CPG DNA, PIB = Phorbol 12 
myristate 13 acetate, ionomycin and brefeldin A (BFA).  
 
Cells were removed from culture at 48 hours at spun at 350g for 5 minutes. The 
supernatants were removed and placed in cryovials at -80 degrees centigrade.  
Surface staining was done as per the protocol above excluding the fixation step 
(see section 2.2.2).  Cells were fixed and permeabilised prior to intracellular 
staining using the eBiosciences fixation and permeabilisation kit (Fix/Perm 
concentrate (00-5123-43) Fix/Perm Diluent (00-5223-56) and 10X Perm buffer 
(00-8333-56)). Cells were incubated with antibodies for 45 minutes (at room 
temperature) and subsequently washed before being suspended in FACS buffer. 
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Flow cytometry was run within 2-4 hours using a BD LSR Fortessa cell analyser. 
A minimum of 5,000 B cells were collected per tube.  
 
Table 2-2 
Antibody panel for stimulated cells post culture 
 
 
Table 2-2 Vol refers to volume per 100µl of staining buffer. See Appendix II for 
the manufacturer’s details on antibodies
Antibody Vol(μL) Compensation antibody 
Vol 
(μL) 
BV786 CD19 3 BV786 CD19 3 
FITC IL10* 5 FITC CD19 4 
BUV 395 CD25 2 BUV395 CD27 3 
APC CD38 10 APC CD19 2 
PE IL10* 5 PE CD19 2 
AF700 MHC Class II 2 AF700 MHC Class II 2 
V450 CD138 5 V450 CD19 3 
Live dead zombie 
aqua 
0.5 
Live dead zombie 
aqua 
0.5 
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2.2.6 Statistical analysis for the peripheral immune study in PD 
Demographic and clinical data and were collected in an Excel spreadsheet 
(Microsoft Office, version 16.5) and initial graphs were generated using FlowJo  
(version 7 for Mac OS). Population statistics were exported into a separate Excel 
spreadsheet that was then merged with the clinical data. Subsequent data 
analysis was performed using IBM SPSS version 25.  Patient and control 
demographic variables were compared using paired t-tests for continuous 
parametric variables (or non parametric equivalents where appropriate) and chi-
squared tests for categorical variables.  The study was primarily designed to 
facilitate paired comparisons between the risk groups (high, intermediate and 
low) and their matched controls.  An independent samples t-test was considered 
inappropriate in this context as it assumes complete independence of the two 
groups where characteristics in one group should not affect selection in the 
other. The control group was specifically matched to the patient group (for 
genotype, age and gender with assays carried out at the same time) and a paired 
analysis was therefore chosen for this reason. Matching groups in this way and 
using paired statistical tests is described elsewhere(Niven et al., 2012).   
 
The Kolmogorov-Smirnov test was used to compare the data to a normal 
distribution. Clinical variables were compared across the three defined risk 
groups (high risk, intermediate and low risk) using a one way analysis of variance 
(ANOVA). Post hoc t-tests were carried if appropriate. Figures show the mean 
and SD unless stated otherwise. Graph Pad Prism (version 7 for Mac) was used to 
make graphs. Heat maps were generated using the gplot function in R. 
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To make representative images at a single cell level in multidimensional space, 
fcs files from each patient were merged using the concatenate function in 
FlowJo.  File sizes were decreased by using the ‘downsample’ plugin which takes 
a representative sample of the original file at a small file size for downstream 
processing (in this case, the file size was reduced to 6000 cells). The tSNE (T-
distributed stochastic neighbour embedding) algorithm was then run on the 
downsampled files for each group (patients versus controls, individual risk 
groups). This is a visualisation algorithm is designed to make images of 
multidimensional data (e.g. multiple flow cytometry markers) in a two 
dimensional space by showing cells that are similar to each other close together 
and those that are different further apart.  
 
For the stimulation experiment, between group comparisons were made either 
using paired t-tests (or non parametric tests where appropriate) for patient 
versus control comparisons or unpaired t-tests between risk groups. Mixed 
measures ANOVAs were used to explore variation in each stimulation condition 
with IL10, IL6 and CD25 as the repeated measures (three levels: unstimulated, 
stimulated and alpha synuclein) and risk group as the independent variable. A 
correlation matrix was also constructed to explore relationships between 
measured variables and outcome measures (as in the previous study).  
2.2.7 Age associated B lymphocytes pilot study (cohort 2) 
Newly diagnosed participants were recruited from the Parkinson’s disease 
research clinic as for the previous study under the same ethical approval and 
underwent the same clinical assessments,  blood sampling, PBMC extraction and 
immunocytochemistry as the participants in the previous study. Controls were 
recruited opportunistically from the spouses or relatives of patients attending 
the research clinic.   
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B lymphocyte surface staining was done using a modified staining panel shown 
in Table 2-3 with an additional intranuclear staining step in order to stain for the 
transcription factor, T-bet (one of the markers used to identify age associated B 
cells). Intranuclear staining was done following fixation and permeabilization 
using the eBioscience Foxp3 transcription factor staining buffer set (cat number 
00-5523-00).  Subsequent washes were done using the permeablisation buffer 
provided with the kit.  Prior to being run on the flow cytometer, cells were 
resuspended in FACS buffer as with the previous study.  
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Table 2-3 Volume refers to volume of antibody per 100µL of staining buffer. See 










BV786 CD19 3 BV786 CD19 3 
FITC CD11c 1 FITC CD19 4 
BV605 CD24 5 BV605 CD19 2 
BUV 395 CD27 3 BUV395 CD27 3 
APC CD38 10 APC CD19 2 
PE Tbet 1 PE CD19 2 
APC H7 IgD 2 APCH7 IgD 2 
PerCp Cy5.5 CD86 3 PerCp Cy5.5 CD19 3 
    
Chapter 2: B lymphocytes in PD 
Kirsten Scott  November 2019    48
2.2.8 Statistical analysis for age associated B lymphocyte study 
Data were collected and organised as described above. Patient versus control 
comparisons were made using unpaired t-tests or non-parametric equivalent 
(Mann Whitney U).  
 
A correlation matrix was constructed to identify significant bivariate correlations 
between B lymphocyte related parameters, alpha synuclein and clinical 
parameters using data from both cohort 1 and cohort 2. Significant associations 
identified in the correlation matrix were taken forward into multiple regression 
models using either motor UPDRS or the probability of a bad outcome as 
dependent variables. All independent variables were entered into the model 
simultaneously. Prior to inclusion in the model, scatterplots were inspected to 
ensure that the associations were not driven by significant outliers. Scatterplots 
shown in the results section show the linear regression line and 95% confidence  
interval unless specified otherwise.  
 
2.2.9 Pilot study: B lymphocytes in human cerebrospinal fluid (cohort 3) 
CSF samples and PBMCs from PD patients and controls were available from a 
parallel study (NET-PDD) running in the Williams-Gray lab.  
Patients were recruited from the research clinic at the Cambridge Centre for 
Brain Repair.  Recruitment was done entirely by AK and CWG. Separate ethical 
approval for the study was obtained. Controls matched for MAPT genotype were 
recruited from the Cambridge bioresource.  Recruitment was ongoing at the 
time of writing and therefore the results are from a subset of patients recruited 
prior to August 2018. 
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Participants attended the Cambridge Centre for Brain Repair for lumbar 
puncture and venepuncture. Clinical assessments were performed as for cohorts 
1 and 2. CSF was collected in a sterile tube which was spun at 300g for 10 
minutes. The supernatant was removed and frozen in 200µl aliquots. The cell 
pellet was resuspended in 100µl of 2% mouse serum in a 96 well plate and left for 
at least 20 minutes to ensure optimum blocking of non-specific antibody binding 
(as described for the previous cohorts). 50µl of 123 count ebeads (Invitrogen 01-
1234-42) were also added to the well to facilitate the calculation of absolute cell 
counts.  Venepuncture was performed as described for cohorts 1 and 2 including 
sending full blood counts. PBMCs were extracted as described in 2.2.2 and placed 
in three wells (unstained, isotype and test wells). Surface antibodies were then 
added to the CSF well and the test PBMC well as shown in Table 2-4 (see 
Appendix II for manufacturer’s details). Once fixed cells were transferred to 
FACS tubes and run on the flow cytometer within 24 hours.  
2.2.10 Statistical analysis for B lymphocytes in CSF study (cohort 3) 
FCS files were gated in FlowJo (version 10.2) as for the other studies. Population 
parameters were exported to Microsoft Excel (version 16.16.1) and statistical 
analyses were performed using SPSS (IBM, version 25).  
Between group comparisons were made using either one way ANOVAs (controls 
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Table 2-4 









FITC CD16 3 FITC CD19 5 
PerCP Cy5.5 CD57 2 PerCp Cy5.5 CD19 2 
APC TLR4 1 APC CD19 4 
A700 MHC Class II 1 A700 CD3 1 
APC H7 IgD 2 APC H7 IgD 2 
PE IgA 10 PE CD19 5 
PE dazzle CD4 1 PE dazzle CD4 1 
PE Cy7 CD3 1 PE Cy7 CD3 1 
BV450 CD45 2 BV450 CD19  
BV510 CD8 1 BV510 CD8 1 
BV605 CD28 2 BV 605 MHC Class II 1 
BV650 CD14 1 BV650 CD14 1 
BV711 TLR2 1 BV711 TLR2 1 
BV786 CD19 3 BV786 CD19 3 
BUV395 CD27 2 BUV395 CD27 2 
    
 
Table 2-4 See Appendix II for manufacturer’s details.  
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2.3 Results 
2.3.1 Participant characteristics Immune study in PD (cohort 1) 
41 patients and 41 controls were recruited (see Table 2-5). Patients and controls 
were matched for age (Mann Whitney U, Z = 0.33, p = 0.71) and gender (Chi-
square = 0, p = 1 for patients versus controls,  Chi-square = 1.1, p = 0.57 between 
risk groups). Disease duration, defined as time from diagnosis, was similar across 
the risk groups (One way ANOVA, F[2,38] = 0.05, p = 0.99).  Samples were 
collected over an 18 month period.   
 
There was  a significant difference between groups in cognition as measured by 
the ACE-R (One way ANOVA F[2.38] = 20.14, p = 0.00001) with the high risk 
group having lower scores than the other two patient groups (t[21] = -3.9, p = 
0.001 versus intermediate and, t[25] = -5.6, p = 0.000009 versus low risk) (Table 
2-5). There were also significant differences in the levodopa equivalent daily dose 
between groups (One way ANOVA, F[2,38] = 4.5, p = 0.02) with the high risk 
group taking significantly less than the low risk group ( t[25] = -2.9, p = 0.007 
versus low) (see Table 2-5). There was no significant effect of risk group on the 
MDS-UPDRS motor score (One-way ANOVA (F[2,38] 3.01, p = 0.06) although 
there was a trend towards this being worse in the high risk group (Table 2-5).  
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Table 2-5 
Participant demographic and clinical information 
 
 
*show paired comparisons between patients and controls.  
 
Full blood counts 
Full blood counts were available for a subset of participants (n=20 patients and 
20 matched controls). As shown previously in the literature, patients had lower 
lymphocyte counts than controls (PD mean 1.36, SD 0.41 and control mean 1.94, 
SD 0.62; paired t test, t[3] = 2.87, p = 0.01). There were no differences between 
patients and controls in the number of monocytes, neutrophils or eosinophils. 



















Age	 68.1(5.6)	 68.4(6.3)	 69.3(4.8)	 70.4(6.7)	 66.3(6.3)	 0.74*	
Gender	
(%	male)	 68.3	 68.3	 66.7	 78.6	 61.1	 1*	
Disease	





N/A	 35.23(12.3)	 42.9(12.0)	 35.43(12.7)	 31(10.8)	 0.06	





N/A	 591.5(292.9)	 389.2(268.7)	 560.3(257.8)	 717.0(279.3)	 0.017	
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Figure 2-3 
Cell counts in PD patients and matched controls 
 
Figure 2-3 WCC white cell count, Neut neutrophils, Lymph lymphocytes, Mono 
monocytes, Eos eosinophils, Baso basophils.  
2.3.2 Immunocytochemistry and flow cytometry 
Gating of B cell subsets was performed as shown in Figure 2-4. All gating was 
done in batches that were processed at the same time with gates remaining 
consistent within each batch of patients and matched controls. I was blinded to 
group for all parts of the analysis.  
 
Overall B lymphocyte numbers were decreased in patients compared to controls 
(paired t-test t[34]=2.08, p = 0.04).  This appeared to be driven by the high risk 
group (see Figure 2-5). There were no differences in CD4 or CD8 T cell numbers 
between groups suggesting that the decrease in lymphocyte counts was driven 
by the B lymphocytes (data not shown).  
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Figure 2-4 
Gating of B lymphocyte populations 
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Figure 2-4  (see following page): B lymphocyte gating starting with lymphocytes, 
then single cells, then live cells and then CD19+ cells (A). The CD27+ and CD27- 
populations are then identified. From the CD27- population, the transitional 
cells are gated(CD19+CD27-CD38HICD24HI) (B). Other gates shown are for 
memory versus naïve B lymphocytes  (C) and plasma cells (gated on live cells 
rather than CD19+) (D). CD5 and CD1d gates were applied initially using the 
lymphocytes as a whole as for CD27 and IgD (see C and F). CD1d positive cells 
were identified using the isotype control and the lymphocyte population as a 
whole (positive control) (G).  
 
Figure 2-5 
B lymphocytes are reduced in PD 
  
Figure 2-5: The percentage of B lymphocytes is reduced overall in patients 
compared to controls (paired t-test  t[34] = 2.08, p =0.04) Controls mean 5.7, SD 
2.8; PD mean 4.6, SD 2.3; low risk mean 4.9, SD 1.9; intermediate risk mean 4.8, 









































IMM043 removed - outlier
Add CD19% data from IMM003 and IMM004
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*
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controls showed that there was a significant difference between high risk 
patients and their matched controls but not between the other groups and their 
matched controls (t[6] = 3.42, p = 0.01). 
 
In order to determine whether the difference in B lymphocyte counts observed 
in the patient cohort was driven by a decrease in one subset of B lymphocytes or 
if it represented an overall decrease in B lymphocytes I next analysed the 
frequency of B lymphocyte subsets including naïve (CD19+IgD+CD27-), memory 
(CD19+IgD-, CD27+), transitional (CD19+,CD27-, CD24HI, CD38HI), plasma cells 
(CD138+ and CD38+CD138+), plasmablast-like (CD24+CD27+), CD5+ and CD1d+ 
cells.  
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Figure 2-6 
Memory versus naïve B lymphocyte subsets in PD  
 
 
Figure 2-6 There were no paired control versus patient group differences in the 
overall percentage of switched memory, unswitched memory, naïve and double 
negative cells (statistics not shown).  There were also no differences between the 
individual risk groups and their matched controls. 
 
There were no differences between patients and matched controls across 
the naïve and memory subsets shown in   
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Figure 2-6 (see Table 2-9 for means and SD across each group, risk group 
data not shown). 
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Figure 2-7 
Transitional and Plasma cell subsets  
 
Figure 2-7  Transitional and intermediate populations, (A, B) and CD27+CD24+ 
(“regulatory”)  subset (C). Plasma cells are shown in D.   
 
There were no overall  paired control versus patient differences in either 
transitional (CD27- CD24HICD38HI) or intermediate transitional B cell subsets 
(CD27-CD24intCD38int), including paired comparisons between the individual 
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risk groups and their matched controls (data not shown). There were also  no 
differences in plasma cells by two different gating strategies (see Figure 2-7 only 
CD38+ CD138+ shown). Exploratory post hoc analysis showed that there was a 
significant difference in the CD24intCD38int subset between those at low risk 
and those at risk (pooled) although this does not stand up to correction for 
multiple testing and is not validated by changes in the true transitional 
population.  
 
There were no overall or risk group level paired patient versus control 
differences in CD5 positive, CD1d positive, CD5+CD1d+ groups or in the CD1d 
MFI ratio (versus the isotype control) (see Figure 2-8).  
 
 Figure 2-9 shows the t-SNE plots giving an overall representation of cell 
populations across patient and control groups. Figure 2-9 shows a smaller B 
lymphocyte population in the high risk group in particular.  
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Figure 2-8 
CD1d and CD5 positive B lymphocytes 
Figure 2-8  CD1d MFI ratio refers to the ratio between the MFI of the stained 
cells versus the MFI of the isotype control (and is not therefore dependent on 
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Figure 2-9 
t-SNE plot showing decreased B lymphocytes in high risk group  
  
Figure 2-9  t-SNE plot showing representative individual cell data from pooled 
patient and control samples, illustrating the small B cell pool in the high risk 
patients. .  
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The correlation heatmap showed the expected relationships between clinical 
variables (see Figure 2-10). The ACE-R and the MMSE were highly correlated 
(r=0.97, p < 0.00001) with both of these tests being negatively correlated with 
UPDRS motor scores (r= -0.43, p = 0.005 and r = -0.39, p = 0.013  respectively). 
The ACE-R was also positively correlated with levodopa equivalent dose (LEDD) 
(r=0.34, p = 0.03). When two outliers on the ACE were removed this relationship 
remained (r=0.43, p = 0.008). The composite variable ‘probability of a poor 
outcome’ also showed the expected relationships with the related clinical 
variables (age; r = -0.61, p = 0.00003, MMSE; r= -0.56, p = 0.0002, ACE-R; r=-0.53, 
p = 0.001, UPDRS motor; r = -0.67, p = 0.000004).  
 
The only B lymphocyte related parameter that correlated with the composite 
variable ‘unfavourable outcome’ was the percentage of CD1d+CD5+ cells (r=-
0.40, p = 0.02).  There were several B lymphocyte related variables that were 
negatively correlated with the motor UPDRS. That is, high proportions of these 
subsets were associated with a lower UPDRS score (which is an indicator of less 
severe disease). This included the percentage of CD24HICD38HI B lymphocytes 
(r = -0.34, p = 0.048), the percentage of CD1d+ lymphocytes (r=-0.35, p =0.042), 
the percentage of CD1d+CD5+ B lymphocytes (r=-0.39, p=0.024) and the CD1d 
MFI ratio (r=-0.46, p = 0.012). The scatterplots shown in Figure 2-11 confirm that 
this is not driven by isolated outliers. Other parameters associated with motor 
UPDRS were serum alpha synuclein (r=-0.41, p = 0.01), total white cell count (r = 
0.45, p = 0.04) and neutrophils (r = 0.53, p=0.01)(see correlation heat map in 
Figure 2-10).  These associations were not corrected for multiple testing. In order 
to look at relationships across variables in a more robust manner, a regression 
model was constructed using all of the B lymphocyte subsets that were 
negatively associated with motor UPDRS given that they were correlated with 
each other. All of the variables were entered into the model at the same time. 
Regression assumptions were not violated: scatterplots were examined for 
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linearity, the regression standardised residuals of the outcome (motor UPDRS) 
were normally distributed, there was independence of residuals as assessed by a 
Durbin-Watson statistic of 2.2 and there was homoscedasticity as assessed by  
inspection of the plot of standardized residuals against standardised predicted 
values. The model as a whole explained 37.6% of the variance in motor UPDRS 
(R2 = 0.376, SE 10.6) and was overall a significant predictor of motor UPDRS 
scores (F [4,24] = 3.612, p = 0.019).  The individual items were not significant 
predictors on their own.
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Figure 2-10 
Correlation matrix of both clinical and B lymphocyte related variables 
 
Figure 2-10 Correlation heatmap showing relationship between clinical and 
immune variables. Darker, larger circles indicated a higher correlation (positive 
in blue and negative in red).   
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Figure 2-11 





Figure 2-11  Associations between motor UPRDS score and B lymphocyte subsets; 
Transitional B lymphocytes (r = -0.34, p = 0.048). 
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2.3.3 Serum B cell activating factor (BAFF)  
Serum BAFF was measured to see whether there was a compensatory increase in 
the high risk group (given the lower B lymphocytes in these patients). There was 
no statistically significant difference in paired comparisons between patients and 
no differences in paired comparisons between risk groups and matched controls 
(statistics not shown, see Figure 2-12). There was no correlation between serum 
BAFF and the percentage or absolute counts of CD19+ B lymphocytes (r = -0.0.01, 
r = -0.02, p = 0.9 respectively). There was a significant difference between serum 
BAFF in the high risk group versus the intermediate and low risk groups 
(unpaired t-tests high versus low t[23] = 3.08, p = 0.005; high versus intermediate 
t[20] = 3.86, p = 0.001).  
 
Figure 2-12 
Serum BAFF levels  
 
Figure 2-12  Control mean 489.5 (SD 401.7), PD mean 439.1 (SD 400.2), low risk 
mean 384.6 (SD 252.1), intermediate risk 223.4 (SD 152.7), high risk 841.3 (SD 
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2.3.4 Participant characteristics B cell functional assay 
Given the observed abnormalities in B cell numbers in patients with PD, we next 
sought to interrogate B cell function, specifically their capacity to secrete 
cytokines when stimulated ex vivo. Samples were obtained from participants in 
the same cohort as those included in the peripheral immune phenotyping study 
described above. Adequate numbers of frozen cells for ex vivo stimulation assays 
were only available in a subset of patients. The demographics of these patients 
are shown below and broadly reflect the trends seen in the main cohort (see 
Table 2-5 and Table 2-6). As in the main cohort the high risk patients were 
significantly more cognitively impaired (mean ACE-R 81.6, SD = 12.58 versus 95.6 
(SD = 3.6) and 96.54 (2.0) in the intermediate and low risk groups respectively) 
(one way ANOVA F [2,27] = 13.00, p = 0.0001). Similarly, there were differences in 
levodopa equivalent dose (LEDD) across groups, with doses being lower in the 
high risk group than the low risk group (one way ANOVA F[2,27] = 4.43, p = 
0.022). The trend towards worse motor UPDRS scores was also preserved in the 
high risk patients but this was no longer significant due to the smaller numbers 
involved (see Table 2-6). Importantly, the participants included in this sub-study 
remained matched for disease duration across groups and patients and controls 
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Age	 68.5	(5.9)	 68.23(5.14)	 68.71	(5.47)	 69.30	(7.17)	 67.77(5.57)	 0.85	
Gender	
(%	male)	
18(60)	 18	(60)	 4	(57.1)	 7	(70)	 7	(53.8)	 1.0	
Disease	
duration	
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Table 2-6: The table shows means and standard deviations (SD). P values refer to 
patient versus control comparisons for age and gender and to between group 
comparisons for the other variables.  
2.3.5 Immunocytochemistry and flow cytometry 
Gating of post culture cells was performed as shown Figure 2-13 and Figure 2-14. 
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Figure 2-13 
Gating of post culture B lymphocytes showing activation markers 
 
 Figure 2-13 Post culture cells were gated using a wide lymphocyte gate followed 
by viability staining, single cell selection and CD19+ lymphocytes (A). Activation 
was assessed using intracellular stains for IL10 and IL6 with gates being set on 
unstimulated (brefeldin only) cells. An additional surface marker, CD25 was also 
used to assess activation with the gates set in a similar manner.  
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Figure 2-14 
Gating of post culture B lymphocytes showing plasma cells 
 
Figure 2-14  Plasma cells were gated from live, single lymphocytes using CD138 
(A) and also CD38+ and CD138+ populations.  
 
There were no significant differences overall in the percentage of either IL10+ or 
IL6+ cells between patients and controls (see Figure 2-15).  There was a 
significant difference in the percentage of IL10 + cells between high risk patients 
and those at intermediate or low risk with those at high risk having significantly 
more (mean 6.56 [SD 3.39] in the high risk group versus 1.93 [SD 0.73] in the low 
risk group and 5.73 [SD 4.57] in the intermediate group) (Mann Whitney U high 
risk versus low risk = 12.00, p = 0.01, Mann Whitney U high risk versus 
intermediate = 14, p = 0.04).   There were also no overall differences between the 
percentage of CD25+ cells in patients compared to controls. There was a 
significantly higher number of CD25+ cells in the high risk group compared to 
the low risk group (Mann Whitney U = 14, p = 0.039) (mean high risk group 5.67 
[SD 3.9], mean intermediate group = 2.08 [SD 1.57], low risk group 1.56 [0.96]). A 
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correlation matrix was constructed of the activation markers which were highly 
correlated (apart from the MHC Class II MFI ratio) (see Figure 2-17).  
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Figure 2-15 
Cytokine production in B lymphocytes  in vitro 
Figure 2-15  Differences in the percentage of IL10+ (A and C),  IL6+ (B and D), Nil 
= unstimulated condition (brefeldin only), PIB = PMA, ionomycin and brefeldin 
and ALL = CPG + CD40L + PIB, Asyn = alpha synuclein. ** p=0.01, *p<0.05  
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Figure 2-16 
Activation markers in B lymphocytes post culture 
 
Figure 2-16 CD25 + (A and D) B lymphocytes are shown as well as the MHC Class 
II MFI ratios (stimulated:unstimulated) (B and C). Nil = unstimulated condition 
(brefeldin only), PIB = PMA, ionomycin and brefeldin and ALL = CPG + CD40L + 
PIB, Asyn = alpha synuclein. ** p=0.01, *p<0.05.
Chapter 2: B lymphocytes in PD 
Kirsten Scott  November 2019    76
Figure 2-17 




Figure 2-17 IL10, IL6 and CD25 refer to the proportion of cells that were positive 
for the respective marker. MHC Class II is the MHC Class II MFI ratio.  
 
As the activation markers were so highly correlated they were converted into  Z 
scores (standardised) and an overall activation score was calculated from the 
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Figure 2-18 
Standardised activation score across groups 
 
 Figure 2-18  Figures shows mean standardised B cell activation scores across risk 
groups. The high risk group had a significantly higher mean standardised score 
in the CPG/CD40L and PIB condition than the low and intermediate groups 
(Mann Whitney U = 26, p = 0.02).  There was also a trend towards a higher score 
in the alpha synuclein condition but this was not significant (Mann Whitney U = 
30.5, p = 0.07).  There were no differences in  IL6:IL10 ratio between patients and 
controls or within patient groups (data not shown).  
 
There were no differences between controls and patients (or between risk 
groups) in the number of CD138+ plasma cells. There were also no differences in 








































CPG+ CD40L + PIB Alpha synuclein
*
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Figure 2-19 
CD138+ plasma cells  
 
Figure 2-19 CD138+ plasma cells in (A) unstimulated (B) stimulated (CPG+CD40L 
+ PIB) and (C) alpha synuclein conditions. There were no significant between 
group differences.  
 
Three mixed measures ANOVAs were performed to confirm the between group 
differences within patients noted above (with IL10, IL6 or CD25 as the repeated 
measures variable with three levels, unstimulated, stimulated or alpha synuclein) 
and risk group (high, intermediate and low) as the independent variable. As 
expected there was a main effect of stimulation condition for all three outcomes 
(F [1.4, 37.3] = 9.48, p = 0.001; F [1.2, 30.6] = 10.36, p = 0.002, F [1.04, 24.9] = 25.41, 
p = 0.00003 for IL10, IL6 and CD25 respectively indicating that an appropriate 
change was seen with stimulation) (see Figure 2-20).  As the assumption of 
sphericity was violated (according to Mauchly’s test of sphericity) the 
Greenhouse-Geisser correction was applied to the degrees of freedom reported 
above with the p values adjusted appropriately. There was a main effect of risk 
group for IL10 (F[2,25] = 3.6, p = 0.041) and for IL6 (F[2,25] = 3.49, p = 0.046) but 
not for CD25 (F [2,24] = 3.36, p = 0.052) (see Figure 2-20). The interaction term 
(risk group x stimulation condition) was not significant for IL10, IL6 or CD25.  
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Figure 2-20 
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2.3.6 Age associated B lymphocytes pilot study (cohort 2) 
We recruited 20 patients and 20 controls (see details for cohort 2 in Table 2-7, 
cohort 1 details are repeated for reference). There was no difference in age 
between PD and controls within cohort 2 (Mann Whitney U = 1.92, z=0.22, p = 
0.82) or in the proportion of males (c2( 1) = 2.51, p = 0.11). Cohort 2 was 
significantly younger than cohort 1 (Two way ANOVA with cohort and status 
[PD versus control] as independent variables, cohort: F [1,119] = 8.26, p = 0.005; 
status F[1,119] = 0.002, p = 0.97).  Disease duration was also significantly less in 
cohort 2 than in cohort 1 (Mann Whitney U = 0.5, z = -6.3, p = <0.0001),  motor 
scores were lower (MDS-UPRS t [58] = 2.15, p = 0.04) and levodopa equivalent 
dose was also lower (Mann Whitney U = 141.0, z = -4.15, p = 0.00003). There were 
no differences in cognition (ACE-R, t[59] = 0.03, p = 0.98) or the probability of a 
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Table 2-7 
Participant demographic and clinical details 
Variable Cohort 2 P value 
 Control PD  
Age 65.0(5.42) 64.7(7.6) 0.82 
Gender 
(%male) 
40 65 0.11 
Disease 
duration 
NA 0.78(0.52)  
MDS-UPDRS NA 28.25(10.76)  
ACE-R NA 92.90(4.52)  
LEDD (mg) NA 302.9(152.56)  
Probability of 
a bad outcome 
NA 0.52(0.21)  
Table 2-7  MDS-UPDRS = Unified Parkinson’s Disease Ratiing Scale, LEDD = 
Levodopa equivalent daily dose, ACE-R = Addenbrooke’s Cognitive Examination 
revised.  
2.3.7 Full blood counts 
As with the previous cohort absolute lymphocyte counts were lower in patients 
versus controls (t[31.27] = -2.98, p = 0.006). There were no between group 
differences in other full blood count parameters. The absolute B lymphocyte 
count was also reduced (Mann Whitney U = 121.0, z = -2.14, p = 0.03) (see Table 
2-8 and Figure 2-22). 
 
Chapter 2: B lymphocytes in PD 
Kirsten Scott  November 2019    82
2.3.8 Immunocytochemistry and flow cytometry 
Gating of cell populations was performed as shown in Figure 2-21. The major 
populations were identified as in the previous study. In addition, age associated 
B cells were identified using Tbet and CD11c.  CD86 had been used as a third 
marker but there were so few cells that were triple positive that this was 
abandoned.  There were no significant differences between patients and controls  
in the percentages of any of the B lymphocyte subsets including the age 
associated B cell subset (see Table 2-9). There was no correlation with age (due 
to the limited age range chosen).  
 
Bivariate correlations were run using combined data from cohort 1 and 2 to see 
whether the associations with motor UPDRS in the initial cohort remained (see 
Figure 2-23). The significant negative correlation between the percentage of  
transitional B lymphocytes and UPDRS remained (r=-0.35, p = 0.009) and also 
between the intermediate transitional subset and UPDRS (r = -0.326, p=0.015). 
This would be consistent with the hypothesis that these regulatory subsets are 
protective.  There was also a significant negative correlation between the motor 
UPDRS and the percentage of naïve B lymphocytes (r=-0.279, p = 0.039).  
Disease duration was negatively correlated with the percentage of transitional B 
lymphocytes (r=-0.405, p = 0.002) and positively correlated with the percentage 
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Table 2-9 
Summary of B lymphocyte subsets across both cohorts 















(x109 per L) 




0.07(0.06)* 0.07(0.07)* 0.39 0.12(0.07) 0.09(0.06) 0.03 
B lymphocyte 
percentage 
5.7(2.8) 4.6(2.3) 0.04 7.5(2.7) 7.4(2.9) 0.86 
Transitional B 
lymphocytes 








53.8(16.2) 53.25(18.5) 0.87 56.72(10.9) 61.06(13.9) 0.35 
Double 
negative 
15.38(14.3) 16.14(15.11) 0.67 6.2(2.9) 6.64(4.2) 0.7 
Age associated 
B cells (ABC) 
   2.9(2.4) 3.32(6.8) 0.47 
*Full blood counts only available on a subset of patients and controls for cohort 1 
excluding the high risk group (N=20 in each group).  P values for cohort 1 reflect 
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paired t tests between patients and matched controls. P values for cohort 2 
reflect independent t tests between patients and controls. 
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Figure 2-21 
Gating strategy for cohort 2 
 
Figure 2-21  Representative plots showing the gating strategy used which was 
similar to that employed for cohort 1.  Age associated B cells were identified 
using a two step strategy, first gating on Tbet positive B cells (G) then on CD11c 
positive cells.  A PE isotype control was used for the Tbet gating.  
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Figure 2-22 
Absolute lymphocyte counts and B lymphocyte counts 
 
 
Figure 2-22  Comparison of absolute lymphocyte and B lymphocyte counts in 
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Figure 2-23 
Correlation matrix showing relationships between B lymphocyte 
parameters and clinical outcomes using combined cohort 1 and 2 data (N = 
55 patients)  (*<0.05, **<0.01)  
 
 
Figure 2-23  Boxes show relevant correlations with the UPDRS motor score. 
“Prob bad” probability of a bad outcome is correlated with the UPDRS score as it 
is derived from it. The other associations in the boxes are between the UPDRS 
and B lymphocyte subsets.  
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Figure 2-24 
Scatterplots showing significant relationships between B lymphocyte 
subsets and motor UPDRS
 
 
Figure 2-24: Motor UPDRS scores are  on the y axis and B lymphocyte subset on 
the x axis, transitional (A), intermediate (B) and double negative (C).  
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I ran a multiple linear regression model using motor UPDRS as the dependent 
variable and CD27-IgD-, CD24HICD38HI and CD24intCD38int as the predictor 
variables. The first analysis was done using the enter method. Regression 
assumptions were met : the dependent variable was continuously distributed;, 
there were two or more independent variables; there was independence of 
residuals (Durbin-Watson statistic = 2.12), the relationships between variables 
were linear according to inspected scatterplots, there was homoscedasticity of 
residual error, there were no significant outliers and the residuals were normally 
distributed. There was some multicollinearity in that the predictors were 
correlated with each other. 
 
The overall model was a significant predictor of motor UPDRS scores (F[3,51] = 
3.12, p = 0.027) explaining 16.3% of the variance in motor UPDRS scores. 
Regression standardised coefficients for the individual predictor variables were 
not significant.  
 
Due to the presence of multicollinearity in the data I ran a further regression 
model, this time using the ‘stepwise’ method which enters each variable in turn, 
keeping those that result in p values of F <0.05 and removing those that have p 
values >0.1. The resulting model was highly significant, (F[1.53]=7.32, p =0.009) 
explaining 12.1% of the variation in UPDRS scores. It included only the 
CD24HICD38HI subset as adding the other variables did not significantly 
increase the percentage of the variance explained (Standardised beta = -0.348, t = 
-2.7, p = 0.009) and they were therefore removed from the model.  
2.3.9 Participants B lymphocytes in CSF in PD and controls  (Pilot study) 
18 patients and 4 controls were recruited (see Table 2-10).  There was no 
significant difference in age between the patients and controls (one way ANOVA 
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F[16,20] = 0.29, p = 0.97).  At the time of writing, only male controls had been 
recruited ( further recruitment is ongoing) (as shown in Table 2-10).  
 
Table 2-10 








Age 68.0 65.61(7.61) 0.977 
Gender (%male) 100 71.4 0.466 
Disease duration NA 1.23(0.73)  
MDS-UPDRS motor score NA 24.17(9.93)  
ACE-R NA 92.0(4.69)  
Levodopa equivalent dose (mg) NA 290.39(153.57)  
 
2.3.10 Full blood counts 
Full blood counts were available for all participants.  There were no significant 
differences in the numbers of lymphocytes, neutrophils, monocytes, eosinophils 
or basophils between patients or controls (at the point of analysis the study was 
underpowered to detect such differences, these are only included to fully 
describe the cohort, see Table 2-11). 
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Table 2-11 
Full blood counts CSF study 
 Controls PD (All) 
Neutrophils 3.49(1.63) 3.8(1.51) 
Lymphocytes 1.3(0.38) 1.36(0.30) 
Monocytes 0.44(0.09) 0.39(0.1) 
Eosinophils 0.15(0.01) 0.15(0.11) 
Basophils 0.02(0.01) 0.04(0.02) 
 
2.3.11 Immunocytochemistry and flow cytometry 
The gating strategy for both peripheral blood mononuclear cells (PBMC) and 
cerebrospinal fluid cells (CSF cells) is shown below (see Figure 2-25). The same 
strategy was applied to both the peripheral and CSF cells in order to make direct 
comparisons.  There were no significant differences in absolute cell counts 
between the controls and PD patients although there is a clear trend towards 
higher cell counts in the patients particularly in the CSF (see Figure 2-27 and 
associated legend, unpaired t-tests, statistics not shown).  
 
There were no significant differences between controls  and PD patients in the B 
cell phenotype (unswitched, memory, naïve versus double negative) (see Figure 
2-28). There was a significant shift between blood and CSF across all participants 
with the majority of B cells being naïve peripherally and the majority being 
memory cells in the CSF (as shown in the radar plot in Figure 2-28, C) (Repeated 
measures ANOVA with 2 factors (tissue blood versus CSF) and phenotype 
(memory versus naïve), the interaction term was significant F [1,16] = 30.19, p = 
0.00005).   
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Figure 2-25  
Gating strategy for peripheral PBMCs and CSF cells (showing PBMCs) 
 
Figure 2-25: Initially CD45+ cells were identified (in order to exclude any non-
immune cells from the CSF population) (A). Lymphocytes and monocytes were 
then identified using FSC and SSC (B). T cell populations and B cell populations 
were identified using CD3 (D), CD4 and CD8 (E) for T cells and CD19, CD27 and 
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IgD for B cells (F and I). Monocytes were identified using MHC Class II, CD14 
and CD16 to ensure that CD16+ NK cells were excluded (G, H).  
 
Figure 2-26 
Gating  strategy showing CSF cells  
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Figure 2-27 
Cell counts in blood and CSF across patients and risk groups 
 
Figure 2-27 shows A) the number of B cells in the CSF B) the number of T cells 
and monocytes and C) the number of cell concentration in the peripheral blood 
of PD patients and controls.  
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Figure 2-28 
B cell phenotypes in peripheral blood and CSF  
 
Figure 2-28 A) Memory and naïve cells as defined by CD27 and IgD in the blood  
and B) the CSF. C) shows a skew towards a memory phenotype in the CSF. 
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2.4 Summary of main findings 
 
I have replicated previous findings of decreased B lymphocytes in PD compared 
to controls with a comparable sample size (N=40 patients and 40 matched 
controls)(Bas et al., 2001 (N=64 PD and 38 controls; Gruden et al 2011 (N=32 PD 
and 26 controls); Stevens et al., 2012 (N=88 PD and 77 controls)) and additionally 
shown that this effect is larger in those at risk of disease progression.  The 
patient sample described in my thesis is unique in being matched to the controls 
for age, gender and MAPT genotype with all assays being run in parallel (patient 
and a matched control). I performed the first study detailing circulating B 
lymphocyte subsets and phenotypes in PD, including age associated B 
lymphocytes. There were no differences in B lymphocyte subsets between 
patients and controls that withstood correction for multiple comparisons 
suggesting that it is not one particular subset driving the observed differences. I 
also showed for the first time,  a robust negative correlation between motor 
UPDRS scores and B lymphocyte subsets that are enriched for regulatory B cells, 
raising the possibility that these cells may play a protective role in disease. There 
is also a negative association with expression of CD1d which is known to present 
lipid or glycolipid antigens to natural killer cells (NK) in particular (Chaudhry & 
Karadimitris, 2014).   
 
I performed ex vivo stimulation assays on peripheral B cells, showing that cells 
from patients at  high risk of progression to dementia are more responsive to 
stimulation in vitro, producing more cytokines than the other PD risk groups. As 
expected, given the decreased number of B lymphocytes, this group also had 
higher baseline levels of BAFF compared to patients at lower risk. I have also 
identified B lymphocytes in the CSF of both patients and controls, with a trend 
towards increased numbers in patient CSF (but the small number of controls 
limits the robustness of this data). I have also described for the first time that 
Chapter 2: B lymphocytes in PD 
Kirsten Scott  November 2019    97
CSF B lymphocytes are skewed towards a memory phenotype, suggesting that 
they are antigen-experienced cells which is likely to be relevant in PD where 
there is a putative antigen in aggregated or misfolded alpha synuclein). 
 
2.5 Chapter discussion 
My initial hypothesis was that there may be an increase in pro-inflammatory B 
cells or memory B cells in patients with PD compared with controls. This 
includes the CD27-IgD- subset which have been reported in other studies 
(summarised in (Frasca, 2018)) which are highly pro-inflammatory (exhibiting a 
senescence associated secretory profile or SASP consisting of TNF-alpha, IL6 and 
IL8, inflammatory microRNAs such as miRs, miR-155/16/93 and a high level of 
expression of  the cell cycle regulator p16INK4) but with a poor ability to 
differentiate or proliferate in response to stimuli. There was no significant 
change in the proportion of these ‘late memory’ (also known as exhausted 
memory or terminally differentiated memory B cells (Frasca, 2018) but the 
functional studies stimulating B lymphocytes in vivo did show that, at least in 
the PD subgroup at high risk of disease progression, there was increased 
production of cytokines and activation markers following stimulation than in the 
lower risk subgroups. This is consistent with previous work by our group in a 
large multicentre longitudinal study of 213 PD patients (and 93 controls) 
(Williams-Gray et al., 2016) which showed that patients with a more pro-
inflammatory circulating cytokine profile had faster motor progression over a 36 
month period and lower MMSE scores. The pro-inflammatory profile was 
derived from a principal components analysis (PCA) and consisted of TNF alpha, 
IFN gamma, IL2 and also IL10 (the latter cytokine does not fit neatly into the 
‘pro-inflammatory’ category).  
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During my PhD I contributed to another study looking at T cell replicative 
senescence (Williams-Gray et al., 2018) where we found that CD8 T cells in PD 
patients did not develop an age associated senescent phenotype in response to 
CMV infection unlike in controls suggesting that there is an aberrant response to 
CMV infection (or aging) in PD patients. .We had hypothesised initially that PD 
patients would show accelerated  (rather than absent) ‘inflammaging’ (or 
immunosenescence),  a process related to aging that involves chronic low grade 
sterile inflammation (Franceschi, Garagnani, Parini, Giuliani, & Santoro, 2018).  
Senescent immune cells have a terminally differentiated phenotype, they do not 
replicate and show increased secretion of pro-inflammatory cytokines such as IL-
6 and TNFalpha (Nikolich-Žugich, 2018). In line with this finding, I also 
hypothesised that I would see less age associated B cells (defined by CD11c+ and 
tbet+ B lymphocytes or by CD27-IgD- B lymphocytes). Neither of these cell 
subsets were different, suggesting that there is not a differential or aberrant 
response to aging that is specific to the B lymphocyte compartment in PD.   
 
A T cell phenotyping study with 113 patients and 96 age and gender matched 
controls noted that there was an increase in T effector memory cells (CD45RO+ 
and FAS+) in PD patients with higher motor UPDRS scores (>31) compared to 
those with lower UPDRS scores (1-20) and controls (Saunders et al., 2012). At the 
same time there was a decrease  in the proportion of CD31+ Treg cells 
(CD4+CD25+CD127-) in the patients with the higher UPDRS scores. Functional T 
cell assays showed impaired Treg suppression of T effector function in PD 
patients versus controls. This finding is not entirely consistent in the literature 
(as reviewed in (Z. Chen, Chen, & Liu, 2018) but in the light of this and other 
studies showing a protective effect of Treg cells in neurodegeneration (F. He & 
Balling, 2013), there has been a phase I trial demonstrating that the recombinant 
granulocyte macrophage colony stimulating factor (GM CSF), sargramostim is 
able to increase the proportion of T regs in  PD patients and this was associated 
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with some improvements in motor outcomes (although the study was not 
powered to identify differences in motor outcomes)(Gendelman et al., 2017).  
Larger trials are awaited. The study did not look specifically at B lymphocytes or 
regulatory subsets.   It is known that B cells themselves are able to produce GM-
CSF(Rauch et al., 2012) and this may also be an avenue for further exploration. It 
is difficult to understand the rationale specifically for the use of GM-CSF when 
there are other drugs that expand this population. GM-CSF has a wide range of 
effects on many immune cells including monocytes and macrophages which 
were not specifically measured or accounted for in this study.  
 
The negative association  between the proportion of regulatory B cells and 
UPDRS motor scores that I have described further expands these findings, 
supporting the view that an imbalance between effector and regulatory functions 
in the lymphoid compartment is associated with worse disease outcomes and 
suggesting that, at least theoretically, attempting to boost regulatory T or B 
lymphocytes is a worthwhile therapeutic strategy to prevent disease progression.  
Ultimately doing a clinical trial of such an agent is the best experimental strategy 
for demonstrating proof of principle as observation studies will only confirm an 
association. For example low dose IL2 is able to induce both T regulatory cells 
(Ye, Brand, & Zheng, 2018) and B regulatory cells (Akimichi Inaba (Clatworthy 
Lab), personal communication based on unpublished data). Fingolimod, a drug 
currently licensed for the treatment of relapsing and remitting multiple sclerosis 
has also been shown to increase the proportion of circulating regulatory B 
lymphocytes (identified by surface markers and by in vitro production of IL10) 
(Blumenfeld, Staun-Ram, & Miller, 2016; Grützke et al., 2015), with the former 
study additionally showing an increase in CSF regulatory B lymphocytes  and 
increased transmigration of the regulatory B cells in an in vitro model of the 
blood brain barrier (Grützke et al., 2015). There is also  some evidence that 
fingolimod is protective in toxin based animal models of PD (Zhao et al., 2017). 
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Another licensed multiple sclerosis drug, glatiramer acetate (Copaxone) is also 
able to induce T reg populations (J. Haas et al., 2009) with an unknown effect on 
regulatory B lymphocyte populations. Belimumab, a monoclonal antibody 
against BAFF has also been shown to expand regulatory B lymphocyte 
populations(Banham et al., 2018) and would be a further potential option.  
 
I also noted a negative association with CD1d positivity and expression on B 
lymphocytes. CD1d has not been studied in the context of Parkinson’s disease 
and was initially included in the phenotyping panel because of its use as a 
marker of regulatory B lymphocytes  in mice along with CD5 (primarily defined 
by their ability to produce IL10)(Mauri & Menon, 2015). In both mice and 
humans it has an additional role in presenting lipid and glycosphingolipid  
antigens to a specific subset of natural killer T cells (NKT)(Chaudhry & 
Karadimitris, 2014; Nair et al., 2015; Oleinika et al., 2018).  
 
Invariant NKT cells can be activated following presentation of antigen and can 
assume a Th1, Th2 or Th17 profile or provide help to the presenting B cells to 
trigger a germinal centre reaction(Chaudhry & Karadimitris, 2014). Perturbations 
of the B cell-iNKT axis can therefore skew the peripheral immune response. In 
SLE patients with active disease there is decreased CD1d expression on B cells 
and also decreased iNKT cells. Once they have reconstituted their B lymphocyte 
population following depletion this disappears in association with a clinical 
response(Oleinika et al., 2018). Human b-glucosylceramide and 
glucosylphingosine specific iNKT cells can activate B cells in vitro and the 
frequency of these cells in mouse models  and  patients is associated with 
treatment response in lupus (Nair et al., 2015)  There is also more recent 
evidence that CD1d expressed on B cells is able to induce a population of 
suppressive iNKT cells capable of suppressing Th1 and Th17 responses and it may 
Chapter 2: B lymphocytes in PD 
Kirsten Scott  November 2019    101 
be this regulatory effect that acts in concert with the other regulatory B cells to 
decrease the deleterious Th1 response (Oleinika et al., 2018).  
 
 
Limitations of this work 
To confirm the abnormalities in B cell subsets and function that I have described 
in patients with PD, one would ideally replicate these findings in a larger cohort 
using a matched design as for cohort 1. Increasing the cohort size was limited by 
the time available to recruit patients to this study and  the practical challenges of 
completing the assessments and assays limit on a large number of patients, 
which would ideally require a large team of investigators and high-throughput, 
automated assays.  The  negative association with the CD1d positive cells could 
be an artefact of the gating which was based on isotype controls but which did 
not give two defined populations. In order to avoid bias introduced by the 
gating, I used the CD1d MFI ratio (ratio of the MFI in the relevant channel to the 
unstained sample run at the same time) which was not affected by gating and 
the effect remained suggesting that it is genuine.  
 
There were also significant batch effects in the B lymphocyte stimulation study 
due to differences in duration of cryopreservation. This problem was offset by 
the fact that I ran the assays with matched high or intermediate risk patient, low 
risk patient and their respective controls in each batch ensuring this 
confounding factor did not affect one group more than others.  
 
When investigating patient peripheral immune cell phenotypes, there are often 
concerns that any observed differences may be mediated by differences in 
medication.  The high risk group in cohort 1 was on the lowest dose of levodopa 
rather than the highest. The levodopa equivalent dose was not directly 
correlated with any of the B lymphocyte subsets suggesting at the very least that 
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there is no dose response effect. Similarly, in Cohorts 2 and 3, LEDD was not 
associated with B lymphocyte subsets or any other parameters measured. In a 
study looking at T cells in 53 treatment naïve patients and 28 healthy controls 
there were differences between patients and controls in response to alpha 
synuclein in vitro suggesting that at least some of the effects observed in 
lymphocytes occur in the absence of drug treatment (Kustrimovic et al., 2016).  
Other studies have found that l-dopa and dopamine agonists can decrease 
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Figure 2-29 Graphical summary of main findings 
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Figure 2-29 I showed that there were less B lymphocytes in the periphery, driven 
mainly by the high risk group and that these B cells produced more cytokine on 
stimulation.  A greater proportion of regulatory B cells was associated with 
better motor outcomes in a cross-sectional study.  
 
2.6 Future directions 
 
There are a number of avenues of research which could be pursued, based on my 
findings: 
 
i) Characterisation of CSF B lymphocytes.  I have identified the presence of 
predominantly memory B cells within the CSF, with potentially higher numbers 
in patients with PD. This observation needs to be validated with the inclusion of 
larger numbers of control CSF samples. In addition, the use of single cell RNA 
sequencing would allow these cells to be transcriptionally characterised and 
would facilitate the identification of specific clones (which may be specific for 
alpha synuclein in PD patients) and allow their comparison to circulating B cells.  
This could potentially include the sequencing of B and T cell receptors building 
on the work by (Sulzer et al., 2017) and is now underway in the 
Barker/Clatworthy Labs. 
 
ii) Extend the assessment of B cells in PD to include the meningeal 
compartment.  There is an increasing appreciation of the complexity of immune 
cell subsets within the meninges, and meningeal B cells are evident in mice.  
Therefore, it would be of interest to investigate B lymphocytes in human dura, 
examining for evidence of B cell follicle formation in association with disease 
and further defining the phenotype and role of these cells. It is possible to obtain 
dural samples in the context of patient’s having brain biopsies for other 
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conditions and in patients with PD who are undergoing the insertion of deep 
brain stimulators. Such experiments rely on opportunistic sampling where it is 
difficult to remove other confounding factors but can nevertheless supply 
relevant in vivo information in humans, and are also a line of investigation being 
pursued in collaboration with Mr Adel Helmy. The decrease in peripheral B 
lymphocytes may be associated with recruitment of B lymphocytes to the 
meninges and this could be shown using mouse models and by looking at 
human dura.  
 
iii) The application and investigation of the effects of different 
immunomodulatory therapies on patients with PD.  To build on these findings 
experimentally in patient cohorts, therapeutic strategies aimed at boosting 
regulatory B lymphocytes may be beneficial and would provide definitive 
experimental proof that the associations I have observed are causal.  Specifically 
taking forward repurposed drugs such as low dose IL2, glatiramer acetate or 
fingolimod in order to show that it is possible to boost regulatory B lymphocytes 
in our patient populations and that this effect is associated with improved 
disease outcomes. Fingolimod is available in an oral once daily preparation that 
is likely to be more acceptable to our patients than the IV or subcutaneous 
administration required from both of these other drugs suggested. 
Demonstrating a change in disease outcome is often difficult in Parkinson’s 
disease trials due to the slow progression of the disease and the heterogeneity of 
clinical outcomes. Choosing an enriched population of patients such as those at 
high risk of disease progression  (identified by the multi-parameter risk score) 
would be one strategy that would potentially allow for the demonstration of a 
proof of principle over an appropriate time period that is within the limits of 
feasibility for a drug trial (for example change in UPDRS motor scores or 
cognition over a 2 year follow up period). The disadvantage of a high risk 
population of patients is that these patients are harder to recruit and will tend to 
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be older and frailer thereby being more vulnerable to infections secondary to the 
drug and also to the cardiovascular side effects which include first dose 
bradycardia (requiring in-patient administration of the first dose). An alternative 
strategy would be to use a high risk prodromal cohort  which represent an earlier 
time point in disease pathogenesis. For example, using a cohort of patients with 
REM sleep behaviour disorder (as described in (Postuma, Gagnon, Bertrand, 
Génier Marchand, & Montplaisir, 2015). One could enrich for participants at a 
high risk of progression to clinically overt Parkinson’s disease and thereby test 
the hypothesis that modulating B lymphocyte function can slow disease 
progression (as measured by a standard clinical trial outcome such as the change 
in motor UPDRS).   
   
iv) Investigate B lymphocytes in Gaucher’s cohorts and in carriers (and monitor 
conversion to PD in a longitudinal cohort) 
There is a well described association between Gaucher’s disease (GD) and 
dysfunction in the B lymphocyte compartment (in the form of an increased risk 
of myeloma and B cell lymphoma) (Mistry, Taddei, vom Dahl, & Rosenbloom, 
2013). One could therefore hypothesise that part of the mechanism underlying 
the association of Gaucher’s disease with PD is related to altered function in the 
B lymphocyte compartment leading to chronic inflammation, but this will 
require further investigation. 
 
There is evidence in both human and mouse cell lines that glucosylsphingosine  
(which accumulates in GD) stimulation is able to induce aggregation of alpha 
synuclein in vitro (Taguchi et al., 2017). There is also a negative association 
between GBA enzyme activity and the levels of plasma alpha synuclein oligomers 
with lower enzymatic activity being associated with higher levels of plasma 
oligomers (Pchelina et al., 2016).  One could therefore hypothesise that part of 
the association between GBA mutations and PD is driven by increased 
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aggregation of alpha synuclein and decreased antigenic presentation (and 
therefore reduced clearance). This may be associated with reduced activation of 
a regulatory subset of invariant NKT cells. This then contributes to a more pro-




There are changes in the B cell compartment associated with Parkinson’s disease 
and its progression. In particular, cells from PD patients at high risk of an early 
dementia produce more cytokines after stimulation.  Higher proportions of 
regulatory B lymphocytes are protective in a cross-sectional cohort. Boosting this 
subset may be a therapeutic strategy.  
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3 ALPHA SYNUCLEIN AUTO -
ANTIBODIES IN PD 
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Figure 3-1 
Alpha synuclein antibody studies overview 
 
Figure 3-1 A shows an overview of antibody studies, highlighting the antigens 
used to identify serum antibodies in a pilot study using cohort 1 described in 
Chapter 2 (controls matched to PD patients for age, gender and genotype). B 
shows the amino acid sequence of alpha synuclein, highlighting the sequence for 
the Y39 peptide (described in (Sulzer et al., 2017) and the peptide including the 
pathologically phosphorylated serine, S129D.    
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3.2  Systematic review and meta-analysis of auto-antibodies to alpha 
synuclein in Parkinson’s disease  
 
It is critical to have a better understanding of how alpha synuclein 
autoantibodies relate to PD and its progression. In particular, there is a need to 
discern whether they constitute a useful diagnostic or prognostic biomarker or 
may have potential therapeutic relevance. In this chapter, I will present a 
systemic review and meta-analysis of antibody studies in PD cohorts, critically 
discuss the value and limitations of existing data and make recommendations for 
future studies. As noted in the acknowledgements section, this work has been 
recently published (Scott et al., 2018). 
3.3 Methods 
3.3.1 Systematic review of alpha synuclein antibody studies in PD 
I searched the literature for studies published prior to 1st June 2018 using 
Pubmed, Medline, Cochrane database, Embase, Google scholar and Keele Web of 
Science.  I used the following search terms: “Antibody and Parkinson’s Disease”, 
“Auto-antibody and Parkinson’s disease”, “Alpha synuclein antibody”, “Alpha 
synuclein auto-antibody”. To ensure complete study capture I also searched 
using “Auto-antibody dementia” “Antibody dementia”. Reference lists of the 
selected papers were also manually searched to identify additional studies. 
Papers were excluded if they did not involve PD patients, if they did not measure 
alpha synuclein antibodies and if there was no control group. Otherwise all 
papers measuring antibodies to alpha synuclein or its epitopes in Parkinson’s 
disease patients were included in the systematic review.  The literature searches 
were done between 1 May 2018 and 6 June 2018. Summary information from each 
study was compiled into a table .  
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In order to assess whether studies were adequately powered, mean alpha 
synuclein antibody titres (or optical density) in each group and standard 
deviations were recorded and used to calculate the required sample size to 
detect a difference of the magnitude reported. The following formula was used to 
calculate sample size (modified from (LLC, 2018).  
!" = $!%	'!(	!% = (1 + 1$	)(-./0ℎ/!
21 − '2	 + 21 − 5
6" − 6% 	)
7 
Where: 
K = nA/nB (matching ratio between groups – nA = PD patients, nB = controls) 
Swithin = pooled standard deviation across groups 
a = Type I error (set at 0.05) 
b = Type II error (1-b = power, set at 0.8) 
The pooled within sample standard deviation was calculated to overcome 
differences in variation between the groups (from (Borenstein, Hedges, Higgins, 
& Rothstein, 2009): 
 
-./0ℎ/! = 	8(!1 − 1)-1
7 + (!2 − 1)-27
!1 + !2 − 2  
 
n1 = sample size (SS) in patients, n2 = SS in controls 
S1 = SD in patients, S2 = SD in controls 
 
3.3.2 Meta-analysis of alpha synuclein antibody studies in PD 
I undertook a meta-analysis, stratified by disease duration given the suggestion 
in the literature that this is a relevant factor (e.g. (Yanamandra et al., 2011). 
Studies with mean disease durations of 5.9 years and less were included in an 
“early disease” meta-analysis and those with disease durations of 7 years or more 
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were included in a “later disease” meta-analysis given the trends noted in the 
review above and in table 1.   
More stringent data quality criteria were adopted for the meta-analysis than for 
the systematic review described above.  
Inclusion criteria: 
i) The study measured antibodies to full length alpha synuclein 
ii) The antibodies were measured using titres (either relative or absolute) 
as a continuous measure   
iii) The study included both idiopathic PD patients and controls  
iv) The study stipulated a measure of disease duration for the cohort 
v) The controls were age and gender matched to the patients 
vi) Antibodies were measured in either serum or plasma 
If a study had not published appropriate statistical tests to determine whether 
the controls were matched appropriately to the patients this was performed 
(independent samples t-test for age; chi-squared test for gender). The study 
estimates were extracted from the included papers according to the protocol 
below. 
Study estimate extraction: 
(i) Means and standard deviations were used as the basis for the study 
estimates, if reported. 
(ii)If these were not reported, then the median and interquartile ranges 
were extracted and converted into means and standard deviations using 
the methodology described in (Wan, Wang, Liu, & Tong, 2014) and an 
online calculator. 
(http://www.comp.hkbu.edu.hk/~xwan/median2mean.html) 
(iii)If the above estimates were not described in the text then they were 
estimated from the boxplots or graphs published in the text.  
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As all studies used different assays and units of measurement, it was not possible 
to do a direct comparison using the raw unstandardised mean difference. The 
study estimates were therefore used to calculate the standardised difference and 
the associated variance (yi and vi respectively) using the metafor package for R 
in R studio (version 1.0.153), and the following formulas: (Borenstein et al., 2009)  
9/ = :1 − :2-./0ℎ/!  
Where yi = standardised mean difference (d) 
:1=  sample mean in PD patients 
:2 = sample mean in controls 
Swithin = within groups standard deviation, pooled across groups (as used above 
for the power calculation) 
 
-./0ℎ/! = 	8(!1 − 1)-1
7 + (!2 − 1)-27
!1 + !2 − 2  
S1 = standard deviation in PD group 
S2 = standard deviation in controls 
A random effects model was used to assess the overall difference between 
patients and controls. Forest plots were generated to show the results 
graphically. Funnel plots were generated to plot standardised mean difference (x 
axis) against standard error (y axis) to assess the impact of publication bias and 
heterogeneity.  
The variance of d (referred to as vi) is given by the following formula (see 
(Borenstein et al., 2009) page 27): 
;/ = 	!1 + !2!1!2 +
(7
2(!1 + !2) 
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3.4 Results 
3.4.1 Systematic review 
A total of 17 papers met the inclusion and exclusion criteria for the systematic 
review (Table 3-1). Eight studies found a statistically significant increase in alpha 
synuclein antibodies in idiopathic PD patients compared to controls (Bryan, Luo, 
Forsgren, Morozova-Roche, & Davis, 2012; Caggiu et al., 2016; Gruden et al., 2011, 
2012; Horvath, Iashchishyn, Forsgren, & Morozova-Roche, 2017a; Shalash et al., 
2017; Q. Xu et al., 2014; Yanamandra et al., 2011). These studies included a total of 
305 patients and 198 controls but two of the papers appear to use overlapping 
patient samples with identical demographic tables and results figures and so the 
second of these was excluded (Gruden et al. 2012; Gruden et al. 2011).  
 
Three papers found raised alpha synuclein antibodies in sub-groups of PD 
patients, either in familial PD (Papachroni, Ninkina, Papapanagiotou, & 
Georgios, 2011), pre-manifest LRRK2 carriers (Alvarez-Castelao, Gorostidi, Ruíz-
Martínez, López de Munain, & Castaño, 2014) or only in CSF and not serum 
(Akhtar et al., 2018). Four studies reported no difference in peripheral anti-alpha 
synuclein antibodies (Smith et al. 2012; Maetzler, Pilotto, et al. 2014; Heinzel et 
al. 2014; Woulfe et al. 2002) and two studies found that alpha synuclein 
antibodies were decreased in patients versus controls (Besong-Agbo et al., 2013; 
Brudek et al., 2017). Importantly the Brudek et al. paper focused on high affinity 
antibodies only which may explain the difference in findings. 
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Table 3-1 
Summary of studies measuring alpha synuclein antibodies in PD 
Table legend: Numbers refer to mean and standard deviation unless otherwise 
specified. The table is ordered according to disease duration. Patient and 
controls groups were considered “matched” if there were no significant between-
group differences in age and gender distributions.  One paper was removed due 
to cohort overlap (Gruden et al., 2012). N/A was recorded in the sample size 
column if there was not sufficient data to do the power calculation. *Range 
**SEM ***author overlap ^^ in each group  DD Disease duration. 
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Three studies investigated antibodies in CSF as well as in plasma or serum 
(Akhtar et al., 2018; Heinzel et al., 2014; Horvath et al., 2017a) with two of these 
finding raised alpha synuclein antibodies in the CSF ((Akhtar et al., 2018; 
Horvath et al., 2017a).  
 
All studies investigated the antibody response to full length alpha synuclein 
apart from the Caggiu et al study that assessed the response to specific epitopes 
deemed to be relevant due to their similarity to EBV (Caggiu et al 2016). 
 
Clinical heterogeneity 
There is wide variation in disease stage and duration across studies (see Table 
3-1). Previous studies have noted an increase in early disease e.g.(Gruden et al., 
2012). Of the five papers reporting a mean disease duration of 5 years or less (see 
table 1), four report an increase in alpha synuclein antibodies in patients 
compared to controls (representing a total of 196 patients and 121 controls 
excluding the first Gruden et al paper as described above)(Xu et al. 2014; 
Horvath, Igor A Iashchishyn, et al. 2017; Smith et al. 2012; Gruden et al. 2012; 
Yanamandra et al. 2011; Shalash et al. 2017). Only the smallest of the studies in 
early PD showed no PD-control difference (N=14 PD patients and 9 
controls)(Smith et al. 2012). Even taking a conservative interpretation of these 
results, the larger studies are consistent in reporting an increase in alpha 
synuclein antibodies in early disease. An additional study for which disease 
duration was unavailable reported an association with HY disease stage with 
increasing titres from HY stage 1 to 2, decreasing at stage 3 (Bryan et al., 2012). 
Alvarez-Castelao et al. found increased alpha synuclein antibodies in LRRK2 
carriers versus controls but not in patients with longer disease durations (>10 
years)(Alvarez-Castelao et al., 2014). Other studies have also reported a similar 
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association with HY staging (Shalash et al., 2017; Y. Xu et al., 2012). Of six studies 
with mean disease durations between 7 and 10 years, two studies report a clear 
increase in patients versus controls(Caggiu et al., 2016; Yanamandra et al., 2011).  
Two further studies show an increase in a subgroup, in familial PD versus 
controls (but not idiopathic PD)(Papachroni et al., 2007) in one study and in CSF 
only and not serum in another (Akhtar et al., 2018). The two studies that showed 
either no difference (Maetzler, Apel, et al., 2014) or a difference in the opposite 
direction (Brudek et al., 2017) did not have age and gender matched control 
groups. In the two studies with disease duration beyond 10 years there was either 
no difference (Alvarez-Castelao et al., 2014) or a decrease in patients compared 
to controls (Besong-Agbo et al., 2013).  
 
Patient age also varies between study cohorts, ranging from a mean of 55.7 
(Yanamandra et al., 2011) to 69.8 (Caggiu et al., 2016)(table 1). Antibody 
responses vary with age and gender (Candore et al., 1997). It is therefore also 
critical to ensure that patient and control groups are well matched. Of the 17 
studies reviewed, 7 either did not report appropriate demographic information 
or the control group was not matched to the patients.  
 
Assay variability 
Most studies have made use of custom ELISAs with one study using a 
commercial ELISA for serum anti-alpha synuclein antibodies (Shalash et al., 
2017).  Two positive studies by the same group in different patient cohorts used 
electroimpedence spectroscopy (Bryan et al., 2012; Q. Xu et al., 2014). Several 
others used immunoblots or western blots (Alvarez-Castelao et al., 2014; 
Papachroni et al., 2011; Yanamandra et al., 2011). ELISAs are limited by many 
factors including the requirement for two independent binding events and 
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problems with non-specific binding (Q. Xu et al., 2014)  There is also variation in 
conditions between studies such as buffers used, protein coating concentration 
and temperature of the assay which are particularly relevant for an intrinsically 
disordered protein such as alpha-synuclein. 
 
Most of the alpha synuclein for the use in ELISAs was generated in E.coli in-
house, and therefore may not include post-translational modifications present in 
mammalian cells (Akhtar et al., 2018; Bryan et al., 2012; Horvath et al., 2017a; 
Maetzler, Pilotto, et al., 2014; Papachroni et al., 2011; Q. Xu et al., 2014; 
Yanamandra et al., 2011)(with other papers obtaining commercially generated 
protein). Alvarez-Castelao et al. attempted to replicate their ELISA findings 
using immunoblots and identified that some of the ELISA positive samples were 
recognising something other than alpha synuclein (Alvarez-Castelao et al., 2014). 
This effect disappeared when they introduced an additional purification step 
suggesting the possibility that at least some of the findings in the literature may 
be due to interfering antibodies to bacterial toxins rather than to alpha synuclein 
itself.  Antibodies present in serum may also be bound to serum protein (either 
specifically or non-specifically) which may interfere with antibody detection 
(Maetzler, Apel, et al., 2014). Most of the papers investigated antibody responses 
to monomeric alpha synuclein (which is not necessarily the disease relevant 
species) with only a minority assessing responses to fibrils, mutated alpha 
synuclein (Alvarez-Castelao et al., 2014; Gruden et al., 2012; Yanamandra et al., 
2011), oligomers or other pathological forms (e.g. phosphorylated alpha synuclein 
(Brudek et al., 2017) or specific peptides (Caggiu et al., 2016). The Brudek et al. 
paper focused on high affinity antibodies and found that these were decreased in 
patients compared to controls which is consistent with them having a role in 
alpha synuclein clearance. As other studies have investigated the overall 
antibody response it is not useful to directly compare these.  
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Lastly, some of the variation between studies may be due to the use of either 
serum or plasma (although only two studies used plasma rather than serum, see 
table 1). It is possible that factors present in plasma but not in serum (e.g. alpha 
synuclein produced by platelets) may affect subsequent results and therefore it 
would be wise to standardise the use of serum across studies.  
 
Power 
Lack of adequate power may be an important factor leading to false negative 
findings in a number of studies. The largest study included 93 PD patients and 
194 controls (Maetzler, Pilotto, et al., 2014) but unfortunately the controls were 
not age and gender matched to the patients (see Table 3-1).  Of the 17 studies, 7 
included appropriate information to calculate power. Of those with incomplete 
information, this was usually because the data were presented as graphs or as 
medians and IQ range. The estimated sample sizes required to detect the 
differences reported ranged from 23 to 382, with a mean of 147 per group (see 
Table 3-1). The only study that was adequately powered was that by Gruden et al. 
that reported much larger differences between controls and patients than other 
studies and is therefore an outlier. Excluding this study, the estimated required 
sample size per group is between 60 and 382. 
 
3.4.2 Meta-analysis 
All of the “early disease” papers shown in Table 3-1 met the inclusion criteria (see 
also flow plot in Figure 3-2).  Means and standard deviations were available from 
two of the studies (Gruden et al. 2011; Xu et al. 2014). The means and standard 
deviations from Horvath et al.  (Horvath, Iashchishyn, Forsgren, & Morozova-
Roche, 2017b) were estimated based on the reported medians and interquartile 
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ranges. The medians and interquartile ranges from the other two papers were 
estimated from boxplots and subsequently converted to means and standard 
deviations as described in the methods (Shalash et al. 2017; Smith et al. 2012). 
Study effect size estimates and model results are shown in Table 3 2. Overall, 
there is a significant increase in antibodies in patients versus controls across 
studies (see forest plot in Figure 3 3) but the effect size is modest (0.88, 95% CI 
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Table 3-2 
Study estimates, standardised effect sizes (yi) and variance (vi) (“early 
disease” <5.9 years disease duration).  
 
 
Year Controls PD yi vi 
  
Mean SD N Mean SD N 
  
Gruden 2011 25.00 50.99 26 310.00 452.55 32 0.83 0.08 
Xu 2012 1.24 1.44 29 1.62 2.04 60 0.20 0.05 
Smith 2012 0.83 1.13 9 1.06 1.81 14 0.14 0.18 
Horvath 2017 5.00 0.67 20 6.50 2.72 20 0.74 0.11 
Shalash 2017 0.49 0.69 20 4.39 1.78 46 2.50 0.12 
Table 3 2 Model results: Estimate = 0.88 (95% CI 0.005-1.17), SE = 0.42, Z = 2.09, p 
= 0.036, I2 = 89.32%, Q(df = 4) = 33.71, p = 0.0001.  
 
Figure 3-3 
Forest plot showing study effect sizes in early disease (<5.9 years) 
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Only two of the “later disease” studies (mean disease duration >7 years) met 
inclusion criteria ((Besong-Agbo et al., 2013; Yanamandra et al., 2011). Means and 
standard deviations were published in the Besong-Agbo study and therefore 
used to calculate study estimates. Medians and interquartile ranges were 
estimated from boxplots in the Yanamandra study which was divided into two 
subgroups (mean disease duration 6.7 years and mean disease duration 9.7 years 
as there was no available data for the patient group overall). Means and standard 
deviations were then derived from this data.  
 
Three studies were excluded due to a lack of reported disease duration (Bryan et 
al., 2012; Heinzel et al., 2014; Woulfe et al., 2002); four studies were excluded due 
to a lack of age and gender matching between patients and controls (Akhtar et 
al., 2018; Alvarez-Castelao et al., 2014; Brudek et al., 2017; Maetzler, Apel, et al., 
2014). The Alvarez-Castelao paper did not include published significance testing 
of the age difference which was therefore done as part of this review. There was a 
significant difference in age between patients and controls according to an 
independent samples t-test (idiopathic PD mean 67.81, SD 9.98 and controls 
mean 61.4, SD 14.7), t [136] = 2.83, p = 0.005). One study was excluded as it only 
measured antibodies to specific epitopes of alpha synuclein rather than the 
entire protein (Caggiu et al., 2016) and one other study was excluded because 
outcomes were recorded as percentage positive on immunoblots (Papachroni et 
al., 2007). 
 
The study estimates are shown in Table 3-3 and the overall random effects model 
is shown in the forest plot in Figure 3-4. There was no overall difference between 
groups in this small sample (estimate = 0.34, 95% CI = -0.57-1.24, p = 0.46) and 
there was also significant heterogeneity (I2 = 87.67%).  
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Given the significant heterogeneity, funnel plots were generated plotting 
standardised mean difference on the x axis against standard error on the y axis 
for studies in the “early disease” group (there were too few in the later disease 
group to make interpretation of these plots meaningful). The plot is symmetrical 
around the effect size of 0.88 (z = 0.20, p = 0.84) but shows that 2 of the studies 
fall outside of the 95% CI of an assumed true effect (see Figure 3-5 ). One of the 
many explanations for the shape of this plot is the presence of true heterogeneity 
between studies (both clinical and assay related factors discussed above). If we 
were able to include more studies in the analysis one would expect, assuming the 
same true effect, that effect estimates from smaller studies would spread widely 
along the bottom with those from larger, more powerful studies appearing at the 
top (see Figure 3-5). One cannot fully discount the role played by publication 
bias in this context as positive findings in this field will be more likely to be 
written up and published than negative results particularly in the context of 
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Table 3-3 
Study estimates, standardised effect sizes (yi) and variance (vi) (“later 
disease”, >7 years disease duration) 
 
Study Year Controls PD yi vi 
  
Mean SD N Mean SD N 
  
Yanamandra 6.7 
years 2011 108.67 126.43 23 696.44 821.82 27 0.95 0.09 
Yanamandra 9.7 
years 2011 108.67 126.43 23 313.11 490.58 12 0.66 0.13 
Besong-Agbo 2013 153.5 103.77 46 105.40 85.83 62 -0.51 0.04 
 
Figure 3-4 
Forest plot showing study effect sizes in later disease (>7 years) 
  
Chapter 3: Alpha synuclein auto -antibodies in PD 
Kirsten Scott  November 2019    127 
Figure 3-5 
Funnel plot showing standard error versus standardised mean difference 
in early disease 
 
3.5 Conclusions and recommendations for future studies 
 
Whilst the available data does not suggest elevation of alpha synuclein 
antibodies universally across all stages of PD, it is consistent with the hypothesis 
that there is an increased antibody response in early disease that wanes during 
disease progression, which is biologically plausible. According to our meta-
analysis the effect size is modest in early disease but the analysis is limited by 
significant study heterogeneity.   
 
There are many caveats to this conclusion based on both the systematic review 
and the meta-analysis, including the limitations of the assays used, the clinical 
heterogeneity of cohorts, the lack of any longitudinal data and poor matching of 
controls to patient groups, meaning that the overall quality of evidence is poor 
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(for example, 7 of 9 studies in later disease did not meet the inclusion criteria for 
the meta-analysis making it difficult to draw any firm conclusions from this 
aspect of the study) .  Hence the value of alpha synuclein auto-antibodies as a 
diagnostic or prognostic biomarker remains uncertain. Further studies are 
needed to demonstrate a consistent, reproducible effect in early PD cases versus 
controls (or indeed between different groups of PD patients), to investigate the 
specificity of raised antibody titres in PD versus other alpha-synucleinopathies, 
and to track longitudinal changes in antibody titres and their relationship to 
disease onset and clinical disease progression. The possible utility of using 
antibody based biomarkers for identifying patients who would potentially 
benefit from either immune modulating or antibody based therapies is also 
unknown.  
There is a clear need for further studies in this field and I therefore have 
developed the following recommendations:  
1. Appropriate sample size with more than 30 in each group (based on 
approximate power calculations from existing studies) 
2. Well characterised clinical cohorts with appropriately matched controls 
using both serum and CSF if possible 
3. Longitudinal assessment to measure changes in antibody levels over the 
course of the disease and relationship with clinical disease progression 
4. Study of prodromal PD cohorts to establish whether the antibody 
response is truly an early feature of the disease 
5. Using a robustly validated method (ideally with validation using a second 
method in the same samples) to measure antibodies including 
standardisation and testing of different coating concentrations, buffers 
and assay temperature.  
6. Study of epitope-specific antibodies and Ig subclasses to allow a fuller 
understanding of the adaptive immune response to PD.  
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3.6 Overview of auto-antibody assays in PD 
In order to investigate alpha-synuclein antibodies in the PD cohorts at the John 
Van Geest Centre for Brain Repair, I developed a set of custom designed Meso-
Scale Discovery (MSD) assays to measure antibodies to a selection of alpha 
synuclein species and tau (as a non alpha synuclein disease relevant antigen). I 
chose this system because there is some evidence that it has increased sensitivity 
and lower background than traditional ELISA based methods (Bastarache, 
Koyama, Wickersham, & Ware, 2014) but also because of the experience in the 
lab with using MSD based systems for measurement of cytokines and alpha 
synuclein (Williams-Gray et al., 2016). Figure 3-6 shows an overview of the assays 
that I used. The initial step involves binding of biotinylated protein to a 
streptavidin coated plate (MSD, L15SA). Serum antibodies then bind to the 
protein after a blocking step. Finally a detection antibody is added that binds to 
the serum antibody and a final read buffer is added.  When the plate is placed in 
the reader an electri-chemiluminescent signal is generated that is in proportion 
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Figure 3-6 




The target antigens were two species of alpha synuclein, alpha synuclein fibrils 
and alpha synuclein monomers. I also used two alpha synuclein peptides; S129D, 
a peptide containing a phosphorylated serine at position 129 known to be 
pathogenic in PD(Anderson et al., 2006) and Y39 which was a custom designed 
peptide based on a recent paper showing that this epitope activated T cells in PD 
(Sulzer et al., 2017). Lastly,  I included tau as an alternative disease relevant 
protein. There is one study showing an association with PD dementia and anti-
tau antibodies (Kronimus et al., 2016) suggesting that an immune response to tau 
may also be relevant to disease progression.  
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3.7 Methods 
3.7.1 Participant recruitment 
For this study, serum samples from the participants recruited for the immune 
study in PD (cohort 1) were used (as described in 2.2.1). Inclusion criteria were 
fulfilment of the UK PD Brain Bank Criteria for a diagnosis of definite PD (made 
by neurologist), age 55-80 years and early stage disease (Hoehn and Yahr stage ≤ 
2). Exclusion criteria included the presence of other neurodegenerative 
disorders, chronic inflammatory of autoimmune disorders, current clinically 
significant infection, surgery in the last month, vaccinations in the previous 3 
weeks or recent use of anti-inflammatory or immunomodulating medication 
(steroids in the previous three months, high dose aspirin >75mg in the previous 2 
weeks, ibuprofen and other non-steroidal anti-inflammatory drugs in the 
previous 2 weeks or any long term immunosuppressant drugs such as 
azathioprine, mycophenolate, methotrexate, rituximab or other biological 
therapies in the last year).  
 
The patients were stratified into groups at high, intermediate and low risk of an 
early dementia using predictive factors identified in a longitudinal cohort study 
(Williams-Gray et al., 2009). The stratification was done on the basis of their 
MAPT (tau) genotype, pentagon copying ability and semantic fluency score (the 
high risk group was defined as MAPT H1/H1 genotype and any one of either 
semantic fluency <20 in 90s or pentagon copying score <2, the intermediate 
group had any one of these factors and the low risk group had none)(as in 
(Williams-Gray et al., 2018).  
 
Age, gender and MAPT-genotype matched controls were recruited from the 
NIHR Cambridge Bioresource (http://www.cambridgebioresource.org.uk/). 
Controls had no history of neurological disease, memory problems or 
Chapter 3: Alpha synuclein auto -antibodies in PD 
Kirsten Scott  November 2019    132 
depression. Exclusion criteria were the same as for the PD patients. Samples 
from matched patient and control pairs were processed on the same day with 
collection occurring in the morning (between 9 and 11am).  
All patients went through a full clinical assessment including medical history 
and co-morbidities, the Movement Disorder Society Unified Parkinson’s Disease 
Rating Scale (MDS-UPDRS), the Addenbrooke’s Cognitive Examination (ACE-R), 
assessment of semantic fluency (animal naming in 90s), pentagon copying and 
the Beck Depression Inventory (BDI). The overall probability of a bad outcome 
(either postural instability or dementia) was calculated using a validated tool 
which uses axial components of the UPDRS, age and animal fluency (Velseboer 
et al., 2016). 
 
Clotted blood samples were left for 20-30 minutes before being spun in a 
centrifuge at 2000RPM for 15 minutes. The serum was aliquoted into cryovials 
and frozen at -80°c.  
 
3.7.2 Antigens 
Alpha synuclein fibrils were produced using the method described in 2.2.1 by 
William Kuan, one of the post docs in the Barker laboratory (using monomeric 
alpha synuclein from rPeptide S-1001-2). The phosphorylated S129D peptide was 
obtained from Abcam (ab188826). The fibrils and S129D peptide were 
biotinylated using the EZ link Sulfo NHS biotin kit as per the manufacturer’s 
instructions (21335). The proteins were dialysed after biotinylation to remove 
excess biotin using Slide-A-Lyzer dialysis cassettes (66205) and associated float 
buoys (Thermofisher 66430) as per manufacturer’s instructions.  Biotinylation 
status was confirmed using the Pierce biotin quantitation kit (28005). The tau 
protein and Y39 were obtained from Creative Biomart as custom biotinylated 
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protein/peptide (tau: MAPT-38H lot 290831, Y39: GKTKEGVLYVGSKTK lot 
100281). Recombinant alpha synuclein was available in a biotinylated form 
commercially (alpha synuclein with biotin Anaspec AS-55581). The 
manufacturers of all the proteins confirm that the products are purified to 
remove endotoxin. The antigens were coated on the plates at a concentration of 
0.15 picomole per well with the exception of tau which was coated at a 
concentration of 0.3 picomole per well. The antigens were diluted in 1% BSA 
(Probumin. Millipore, cat. no. 82-045-1). Prior to finalising the protocol, all 
antigens were tested at two different  coating concentrations (0.15 picomole per 
well and 0.3 picomole per well). 
 
3.7.3 Standard curves 
Seven point standard curves were constructed using known duplicate 
concentrations of commercial mouse or rabbit antibody to the protein or peptide 
in question. All plates included 2 blank wells. For the alpha synuclein fibrils and 
recombinant alpha synuclein, mouse anti-alpha synuclein (Abcam, ab1903) was 
used at a starting concentration of 2000ng/ml with serial 1 in 5 dilutions. For the 
tau protein, mouse anti-tau antibody (Abcam, ab80579) was used at a starting 
concentration of 2000ng/ml with serial 1 in 5 dilutions. For the S129D peptide, a 
rabbit anti S129D antibody was used (Abcam, ab51253) at a starting 
concentration of 2840 ng/ml with serial 1 in 7 dilutions. There was no 
commercial antibody to Y39 and therefore it was not possible to generate a 
standard curve for this antigen. Instead, raw signal intensity scores were 
normalised to a standard serum sample which was the same across assays. The 
concentrations of antibodies for the standard curves were optimised prior to 
running the test assays on patient samples.   
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3.7.4 Assay protocol 
Streptavidin plates were blocked with 150µl of 3% BSA (Probumin. Millipore, cat. 
no. 82-045-1) for 1 hour on a shaker at 4000RPM. They were then washed three 
times with 150µl 0.05% Tween 20(Sigma Aldrich P1279)-PBS. The plates were 
then coated with 25µl of antigen and incubated overnight at 4 degrees 
centigrade. There were 5 plates per lot of samples defrosted (one plate per 
antigen with 40 samples run in duplicate). 
 
Serum samples stored at -80 degrees centigrade were taken out of the freezer the 
following morning and thawed on wet ice. Serum was diluted 1:25 in 1% BSA 
based on experiments with different concentrations. Calibrator antibodies were 
prepared as described above.  
 
The plates were then washed three times with 0.05% Tween 20 PBS. Diluted 
serum or calibrator was added in volumes of 25 µl. Plates were incubated for 1 
hour at room temperature on a shaker at 4000RPM. They were then washed 
again with 0.05% Tween 20 PBS three times.  
 
The detection antibodies were then added. MSD sulfotag anti-human antibody 
was added to the test wells and MSD sulfotag anti-mouse or anti rabbit to the 
calibrator wells at a concentration of 1:500. The plates were then incubated at 
room temperature for an hour on a shaker at 4000 RPM.  
 
After incubation, the plates were then washed three times with 0.05% Tween 20 
PBS and 150µl of 1x read buffer was added . The plates were then read on an MSD 
plate reader (Sector S 600). Absolute concentrations were calculated from the 
standard curve as described above (2.2.3).  
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3.7.5 Human total IgG  
The MSD human total IgG panel (K15203D) was used to measure total IgG in the 
serum samples as per the manufacturer’s instructions. Briefly, samples were 
diluted with the proprietary diluent 100 to a dilution of 1:250000 by performing 
serial dilutions. Calibrators were prepared to produce a 7 point standard curve. 
The plate was washed three times with 0.05% Tween 20 PBS. 25µl of diluted 
serum or calibrator was added,  the plate was sealed and incubated at room 
temperature for 2 hours. The plate was then washed three times with 0.05% 
Tween 20 PBS. 25µl of detection antibody was then added (sulfo-tag anti-human 
IgG) at a concentration of 1:500. The plate was incubated at room temperature 
for a further 2 hours. After incubation, the plate was washed three times with 
0.05% Tween 20 PBS and then 150µl of 2x read buffer was added before reading 
the plate on the MSD plate reader as above. Absolute concentrations were 
calculated using the MSD Discovery workbench software as described above.  
 
3.7.6 Statistics and data handling 
The MSD reader outputs a text file which is then manipulated using the MSD 
Discovery Workbench software in order to generate the standard curve and 
interpolate the calculated titres which were exported into Excel (version 16.16.2).  
Samples with unacceptably high co-efficients of variation (CV) were removed 
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Where s = the standard deviation of the two duplicates and µ is the mean.  
 
The overall plate CVs are reported after removing samples above the cut-off. 
Coefficients of variation (CV) were calculated by dividing the standard deviation 
by the mean. Percentage recovery was calculated using the standards of known 
concentration.Statistical analysis was carried out using SPSS (IBM, version 25) 
and graphs were generated using graphpad prism (version 7 for Mac OS). Paired 
t-tests or non-parametric equivalent were used for PD versus control 
comparisons (given that participants were recruited as age/gender and genotype 
matched pairs with assays  and sample collection run in parallel). Unpaired t-
tests (or non parametric equivalent) were used to compare the risk groups. 
Bivariate correlations were explored using a correlation matrix. A correlation 
heatmap was produced using the corrplot package in R studio (version 1.0.153)..  
3.8 Results 
3.8.1 Participant characteristics 
Participant characteristics for this initial study are described in 2.3.1. For 
optimisation of the assay, sub-groups of samples were used (as described below). 
 
3.8.2 Assay optimisation 
Antigen coating concentration and development of standard curves 
All antigens were tested at concentrations of 0.15 picomole per well and 0.3 
picomole per well (the maximum protein concentration advised by the 
manufacturer). For most of the antigens binding of the control antibodies was 
the same for both concentrations and therefore the lower concentration was 
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chosen for subsequent assays. The concentration of the standards was optimised 
to give readings across the full range of the assay (see Figure 3-7, Figure 3-8, 
Figure 3-9, Figure 3-10). There was no commercially available antibody for the 
custom designed Y39 peptide. The mouse monoclonal antibody (abcam, ab1903) 
used for the alpha synuclein and fibril standards was therefore tested but did not 
show consistent binding (see Figure 3-11).  
Serum dilution 
Initially a serum dilution of 1:500 was tested (in line with the methodology 
employed in a similar study (Brudek et al., 2017). The resulting values were at the 
lower limit of detection of the assay (see Figure 3-13 )and were therefore also 
tested at 1:50. An eventual concentration of 1:25 was used for the final protocol as 
described in the methods. 
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Figure 3-7 
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Figure 3-7 legend: A and B show antigen coating concentrations of 0.15 picomole 
and 0.3 picomole respectively. The highest standard for these curves was 
10,000ng/ml with 5 fold serial dilutions. The curves did not adequately cover the 
lower end of the detection range and therefore the final highest concentration 
used was 2,000 ng/ml shown in C (with 5 fold serial dilutions), covering the 
entirety of the detection range.   
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Figure 3-8 
Optimising standard and antigen coating concentrations (alpha synuclein 
fibril antibody plate) 
 
Figure 3-8 legend: The same standards were used for the alpha synuclein fibrils 
plate as for the alpha synuclein plate (highest concentration 2,000ng/ml with 5 
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Figure 3-9 




Figure 3-9 legend: A and B show standard curves generated using a starting 
standard at 2840ng/ml with subsequent 7 fold serial dilutions at either 0.3 or 1.5 
picomole antigen coating per well as shown. C shows a 5 fold serial dilution 
curve which was similar to A and B.    
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Figure 3-10 




Figure 3-10 legend: Standard curves for tau protein plates showing that the 
standard curves are similar for the two coating concentrations.  
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Figure 3-11 




Figure 3-11 legend: The mouse anti alpha synuclein antibody only bound to the 
Y39 antigen at the highest concentrations and was therefore not useful as a 
standard for the assay.  
 
The alpha synuclein antibody (ab1903) used as a standard for the monomer and 
fibril assays did not bind to the Y39 peptide therefore instead of going forward 
with the standards all samples were normalised to a control sample that was 
included in all plates.  
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Pilot study 1 demographic and clinical details 
A subgroup of patient and matched control samples was selected for a pilot 
study (N=15 in each group). The demographic and clinical details of the sample 
are shown below (see Figure 3-12).  This sub-group was representative of the 
larger cohort and PD patients were well matched to controls for age and gender 
(Age  t[14]=0.29, p=0.77, Gender chi-square[1] = 0.0, p=1). There was no 
difference in disease duration or age between low dementia risk and high 
dementia risk groups (disease duration t[13] = 0.28, p = 0.78, age t[13] = 2.14, 
0.056). There were differences between these groups in their ACE-R scores 
(t[13]=-3.8, p = 0.012) and LEDD (t[13] = -2.6, p = 0.02) as noted for the larger 
cohort (with the high risk group having a lower LEDD and lower ACE-R than the 
low risk group).  
Assay parameters 
The standard curve derived from this experiment is shown in Figure 3-7 C. The 
mean percentage recovery as calculated from the standards was 113% (SD 24.50, 
range 74.4-157.0). The percentage co-efficient of variation was 17.8%. The 
distribution of calculated concentrations is shown in Figure 3-13 with the 
majority of samples falling in the lower end of the standard curve. All samples 
were within the detectable range of the assay.  
 
 Pilot study results 
The antibody titres are shown in Figure 3-14 with associated means and standard 
deviations. Paired comparisons between patients and matched controls were not 
significantly different. There was a significant difference between high risk and 
low risk groups on post hoc analysis (see Figure 3-14 legend).  
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Figure 3-12 
Participant clinical and demographic details for pilot study  
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Figure 3-12 legend: Numbers refer to means and (standard deviation). P values 
refer to paired t tests (PD versus controls), unpaired t-tests (High risk versus low 
risk) or to chi-squared tests (proportion of males). *comparisons between high 
versus low risk.  
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Figure 3-13 
Scatterplot showing standards and samples 
 
 
Figure 3-13 legend: Samples shown in black, duplicate standards shown in red. 
The whole distribution is shown in A, the linear phase is shown in B.  
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Figure 3-14 




Figure 3-14 legend: Mean (SD) – control 168.5 (106.6), PD 160.3(121.1), low risk of 
dementia group 101.4 (78.3), high risk of dementia group 211.8 (132.5). Paired 
comparisons between PD patients and matched controls were not significantly 
different (either as a whole or within the risk groups). ** Mann Whitney U test 
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Pilot study 2  
In order to test the performance of all 5 plates using serum, a further pilot study 
was run using 8 serum samples that were available due to excess storage of 
aliquots from cohort 1 (N=8, 3 PD and 5 controls, 3 males) . Two different serum 
dilutions were tested (1:500 and 1:50).  Diluting samples to a greater extent 
decreases ‘matrix effects’ (the effect of unmeasured factors in the sample on the 
signal e.g. haemoglobin) but this is counterbalanced by the need to reduce 
variability which is greater at higher dilutions.  There were a number of data 
points at the 1:500 dilution that fell below the detectable range of the assay 
(S129D = 4, Y39 = 1, fibrils = 2, alpha synuclein= 2, tau = 4).  There were none 
below the detectable range at the 1:50 dilution which was still on the lower end 
of the standard curve. In addition, Figure 3-15 shows the greater variability using 
the 1:500 dilution but also highlights that it is important to maintain constant 
dilution ratios across assays as more dilute samples give higher estimates.  For 
the final protocol, a dilution of 1:25 was therefore chosen as this was likely to 
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Figure 3-15 
Concentrations of antibodies to each antigen across two different serum 
dilutions 
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3.8.3 Serum antibodies in cohort 1  
Samples were run in two batches (39 per plate in duplicate and one batch control 
serum sample that was run across all plates). PD patients and matched controls 
were run on the same plate. Further analysis using serum samples from our 
other cohorts is still ongoing and therefore not included in this chapter.  
Assay performance 
Samples were removed from subsequent analysis if the co-efficient of variation 
exceeded 20%. Table 3-4 shows the number of samples removed in each batch. 
There were larger numbers in batch 1. It is likely that this improved in batch 2 
with further practice doing the assays. Intra-assay measures of variability are 
shown in Table 3-5 after removal of the samples described in Table 3-4. The 
usually quoted acceptable  maximum for intra-assay variability is up to 15% 
(although some studies use a lower range).  The standard curves all worked as 
expected and resembled example curves shown above (data not shown).  
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Table 3-4 
Table showing the number samples removed due to unacceptable CV 
(>20%) 
 
Plate Samples removed (batch 1) Samples removed (batch 2) 




10 10 1 - 
Fibrils 
antibody 
10 9 - 3 
S129D peptide 
antibody 
4 6 - 1 
Y39 peptide 
antibody 
12 7 1 2 
Tau antibody 6 11 1 2 
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Table 3-5 
Co-efficients of variation (CV) and percentage recovery across both assays 
 
















8.4(5.67) 81.7 (41.3) 5.38(4.2) 97.8(30.1) 
Alpha synuclein 
fibrils 
9.1(5.04) 148(155.2) 5.36(5.3) 112.8(56.7) 
Tau 2.15(4.34) 152.7(102.4) 5.8(5.2) 102(6.9) 
S129D 5.7(6.1) 97.5(64.9) 2.8(2.5) 142.4(66) 
Y39 9.7(5.12)) - 7.1(4.6) - 




Inter-assay co-efficients of variation were deduced using the calculated 
concentrations from the control sample that was run on both plates (alpha 
synuclein = 22.51%, fibrils 43.2%, S129D = 130%, Y39 normalised=16.9%, tau = 
117%,  IgG =16%).  There was an 11 fold difference between the  batch 1 and the 
batch 2 mean for the tau antibody plate. The batch 1 values were more variable 
and were therefore discarded entirely. These samples will be re-run.  
Due to the variability between assays described above, the samples  with 
acceptable CVs were normalised to the control sample run across all plates to 
allow comparisons across assays. 
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Results from cohort 1 samples 
There were no significant differences  between PD patients and age and gender 
matched controls in normalised titres of alpha synuclein antibodies, alpha 
synuclein fibril antibodies, S129D or Y39 peptide antibodies and tau antibodies 
(see Figure 3-16, Figure 3-17,  Figure 3-18 and Table 3-6). There were also no 
differences in total IgG (normalised) between patients and controls (see Figure 
3-18). Participants were stratified by their risk of dementia (low, intermediate 
and high).  The only difference between risk groups and controls was in the 




Table showing normalised antibody titres to five antigens 
 
Antigen Controls PD 
  All Low Int High 
Alpha syn 2.54(1.76) 2.46 (1.88) 2.18(1.18) 2.91 (2.5) 1.71(0.68) 
Fibrils  3.14(1.73) 2.54(1.73) 2.38(1.33) 3.10(2.29) 1.36(0.23) 
S129   2.49(2.37) 2.31(2.10) 1.87(1.30) 2.49(1.85) 3.53(4.4) 
Y39 5.14(5.72) 5.64(6.50) 3.40(1.72) 2.84(1.59) 11.98(10.16)* 
Tau 4.27(2.63) 3.49(3.14) 3.90(1.46) 3.30(3.72) - 
 
Table 3-6 shows mean (SD) for normalised antibody titres (normalised to control 
standard run on each plate). Low = low dementia risk, Int = intermediate 
dementia risk, High = high dementia risk.  *p< 0.02 versus controls.  
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Figure 3-16 
Antibodies to alpha synuclein and alpha synuclein fibrils  
 
Figure 3-16  shows  antibodies to A) alpha synuclein  and B) alpha synuclein 
fibrils (normalised to control sample to allow inter-assay comparisons).  
 
Figure 3-17 
Antibodies to S129D and Y39 peptides 
 
Figure 3-17 shows A) antibodies to the S129D peptide and B) to the Y39 peptide 
(normalised to control sample to allow inter-assay comparisons).  
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Figure 3-18 
Antibodies to tau and total IgG 
 
 
Figure 3-18 shows A) antibodies to tau and B) total IgG (normalised to the 
control sample to allow inter-assay comparisons).  
 
The normalised antibody titres were highly correlated with each other (see 
Figure 3-19) but not with total IgG. There was a negative correlation between 
ACE-R scores  and Y39 antibodies (r = -0.50, p = 0.005) and a positive correlation 
between the motor UPDRS (part III scores)  and Y39 antibodies (r = 0.39, p = 
0.038) (consistent with higher Y39 titres having a worse outcome overall). This 
was largely driven by 5 individuals with high Y39 normalised titres (who had 
worse ACE-R scores and higher motor UPDRS scores putting them in the high 
risk of dementia group as illustrated in Figure 3-17).  A 3D scatterplot confirms 
that the outliers are driving the relationship (see Figure 3-20). Removing them 
removes the significant correlation (Y39 antibodies and ACE-R r = -0.23, p =0.25, 
Y39 antibodies and motor UPDRS r = 0.18, p = 0.36).  
Chapter 3: Alpha synuclein auto -antibodies in PD 
Kirsten Scott  November 2019    156 
Figure 3-19 
Heatmap showing correlations between antibody titres and clinical 
variables 
 
Figure 3-19 The heat map shows values for Pearson’s R. Antibody titres  to 
different antigens are highly correlated with each other * p<0.05, ** p<0.01. 
Addenbrooke’s Cognitive Examination-Revised (ACE-R),  y39 – antibodies to Y39 
peptide,  S129D – antibodies to S129D peptide, Tau – antibodies to tau, Alpha syn 
– Alpha synuclein antibodies, Fibrils – antibodies to alpha synuclein fibrils, CD19 
percentage of total lymphocytes, CD24CD38HI – transitional B lymphocytes 
(“regulatory” B lymphocytes), LEDD levodopa equivalent daily dose.  
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Figure 3-20 
3D Scatterplot showing relationship between Y39 antibody titres 
(normalised) and clinical parameters (ACE-R and motor UPDRS) 
 
Figure 3-20 The red circle shows that the correlations observed in Figure 3-19 are 
largely driven by the 5 outliers with particularly high Y39 antibody levels and bad 
outcomes (lower ACE-R scores and higher motor UPDRS scores).  
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3.9 Summary of main findings 
The systematic review and meta-analysis of studies looking at auto-antibodies to 
alpha synuclein found evidence that there are raised antibodies in early disease 
(less than 5 years). This would be similar to the picture in type 1 diabetes where 
the antibodies to self antigens in the pancreas are higher in the early stages of 
disease (where tissue damage and inflammation are greatest). This response then 
wanes subsequently(Lampasona & Liberati, 2016). It was also clear from 
reviewing the literature and from statistical measures that there is a lot of 
heterogeneity between and within studies that is likely to dilute any apparent 
signal. To move the field forward, I argued that there is a need for larger studies 
using robustly validated methods particularly focusing on the early stages of 
disease but also using longitudinal cohorts.  
 
I subsequently went on to design a set of customised mesoscale discovery (MSD) 
assays to measure antibodies to five disease relevant antigens (monomeric alpha 
synuclein, alpha synuclein fibrils, tau and two disease relevant peptides, S129D 
and Y39). I have reported a number of experiments optimising some of the 
parameters of these assays. In particular, I have optimised the plate coating 
concentration, standards for each plate and the serum dilution. The co-efficients 
of variation (CVs) within batch 1 were unacceptably high for almost a quarter of 
the samples (which had to be removed from subsequent analysis). Batch 2 
showed improved CVs which may have been due to an improvement in lab 
technique and practise with running multiple plates concurrently. There  was 
also significant inter-assay variability. I have now resolved this problem by using 
a control sample run across plates which can then be used to normalise the other 
samples to facilitate comparisons.  
 
I used the custom plates to measure antibodies in a cohort of patients and 
matched controls (the same cohort as cohort 1 in chapter 2). There were no 
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significant patient versus control differences in the normalised titres of alpha 
synuclein, fibril, tau, S129D or Y39 antibodies. When I looked specifically at the 
group at high risk of an early dementia there were significantly higher 
normalised Y39 antibody titres (p = 0.02). This effect was driven by 5 individuals 
in the high risk group. Scatterplots showed that these participants had lower 
cognitive scores (as measured on the Addenbrooke’s cognitive examination 
revised, the ACE-R) and worse motor scores (on the motor Unified Parkinson’s 
Disease Rating Scale).  
3.10 Chapter discussion 
 
The main limitation of the antibody study at the moment is the sample size as it 
is possible that there is a small effect that is masked by other variability, 
including inter-assay variability. The analysis of further samples is ongoing (see 
future directions).  
 
There was marked inter-assay variability despite having previously optimised the 
assay.  The intra-assay CVs improved in batch 2 and in subsequent plate runs in 
the lab suggesting that this was related to laboratory technique. I was assisted by 
two new lab members when I ran batch 1 due to the amount of pipetting 
required to run 6 plates concurrently. I did all the plate preparation and 
pipetting for batch 2 myself and have subsequently closely trained and 
supervised the rest of the team for further assays which has improved the intra-
assay CVs. Other factors such as the age of the samples, time that they were 
defrosted and incubation periods were all similar across batches and I have 
ensured that all buffers are freshly made 24 hours in advance (even the PBS-
tween which shouldn’t alter with age). The use of a standard control across 
batches was useful as this facilitated normalisation of the samples which allowed 
for inter-assay comparisons.  This also highlights the problem in the existing 
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literature around variability across assays measuring antibodies which can only 
really be counterbalanced by greatly increasing sample sizes.  
 
The finding of increased normalised antibody titres to Y39 peptide in the high 
risk group compared to controls is potentially interesting and would support the 
findings from the (Sulzer et al., 2017) paper which found that this peptide 
induced a prominent class II-restricted IL5 and IFN gamma response in T cells. B 
cells may act as major antigen presenting cells, therefore the presence of cognate 
B cells that also recognise this peptide confirms the potential importance of this 
antigen in stimulating adaptive responses.  This Y39-specific response was only 
robust in a few individuals (5 out of 39) and therefore requires further validation. 
These results are consistent with my previous data presented in chapter 2, 
showing that cells obtained from patients in this group produce more cytokine 
when stimulated in vitro, suggesting that patients at risk of progression have a 
more activated peripheral immune milieu and that this may be partly driven by 
an alpha synuclein-specific response, at least in a proportion of individuals. 
Antibodies to the S129D peptide, which was also shown to activate T cells in the 
Sulzer study, were not observed in the sera tested in my study.  
 
The lack of differences between patients and controls in the antibody response 
to the other antigens investigated may reflect the clinical characteristics of the 
patients. The mean disease duration in this group was 4.24 years. Although this 
is still within the “early” side of a disease that can run for over 20 years, my 
hypothesis was that the antibody response would be greatest in early disease and 
therefore expanding the samples to include more recently diagnosed patients 
and those with prodromal PD (for example those with rapid eye movement sleep 
behaviour disorder, RBD) may increase the chance of finding relevant differences 
and identifying this alpha synuclein specific response before it starts to wane.  
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The preliminary finding that there are no other differences in the normalised 
titres of antibodies against the other antigens may reflect a genuine lack of 
difference between the two groups. Some other studies reported null findings (as 
described in the systematic review) and also there is likely to be publication bias. 
Studies reporting negative associations are less likely to be submitted and less 
likely to be accepted compared to ones reporting positive outcomes.  However, it 
is too early to reach this conclusion at this stage as my study is currently 
underpowered.  
 
Most studies to date, including this one, have been designed around identifying 
patient versus control differences rather than looking at whether alpha synuclein 
antibodies are associated with better outcomes cross-sectionally or 
longitudinally.  The real utility of clinical biomarkers in this context is unlikely 
to be in relation to diagnosis (as there is enough published evidence to suggest 
that such tests are neither sensitive nor specific for PD) but potentially in 
identifying patients who have an increased peripheral immune response to alpha 
synuclein which in turn could potentially be driving microglial activation and 
neuronal degeneration in the brain. Such patients would be ideal candidates for 
taking forward into trials of immune modulating therapies. 
 
 A series of recent papers in mice have shown that meningeal lymphatics are 
required for the clearance of amyloid-B (Da Mesquita, Louveau, et al., 2018), tau 
(Patel et al., 2019)  and alpha synuclein (Zou et al., 2019). Appropriate clearance 
of pathological forms of these proteins may be increased by microglial 
phagocytosis (Patel et al., 2019). Antibodies specific for alpha synuclein may be 
involved in this clearance when other mechanisms become saturated and there 
is a build  up of aggregated alpha synuclein in the context of a more pro-
inflammatory environment. 
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3.11 Future directions 
Based on my initial data there are a number of additional directions that could 
be pursued.  
 
i) The first priority for this study is to increase the sample size by 
including PD patients with a more recent diagnosis (and controls) and 
by looking at a prodromal cohort. I have obtained funding from the 
Michael J Fox Foundation to do this and I have obtained the samples 
and started to run the assays for an additional group of PD patients 
(N=20, disease duration <2 years), controls (N=20) and prodromal 
patients at high risk of disease conversion to PD obtained from 
collaborators in Oxford (N=50).  There are a number of large 
Parkinson’s Disease biobanks with stored serum samples from patient 
collected over time (e.g. the ProBAND study which has prospectively 
collected clinical data and serum samples for over 2,500 PD patients 
longitudinally). Assuming there is enough evidence to justify further 
investigation, assessing the predictive effect of the antibody response 
on disease outcome using the large numbers in such a cohort would 
provide a robust demonstration of the effect and its utility as a 
prognostic biomarker.  
 
ii) As suggested in chapter 2, B cell and T cell receptor sequencing of 
both CSF and peripheral lymphocytes will also provide a more 
sophisticated means to identify whether there are specific clones in 
PD patients or in those with worse outcomes.  
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iii) Using animal models it is possible to further investigate the role of 
antibodies in clearance. The therapeutic effect of anti-alpha synuclein 
antibodies is well described in animal models but the relevance of the 
antibody response to clearance by the meningeal lymphatic system is 
not known. Immunological tools such as mice lacking a functioning 
meningeal lymphatic system are available (K14-VEGFR3-Ig mice as 
used in (Patel et al., 2019) and can show the accumulation of e.g. tau 
in a mouse model of Alzheimer’s disease. Using such models to 
investigate the endogenous antibody response in models of alpha 
synucleinopathies and the efficacy of transferred antibodies may help 
to unpick why therapies aiming at removing aggregated protein (with 
antibodies) have so far not worked in human neurodegenerative 
disease (.e.g, crenezumab a monoclonal antibody trialled in 
Alzheimer’s disease has now been withdrawn from trials due to 
futility). In the absence of a functioning lymphatic system it is possible 
that such therapeutic strategies are not likely to work and it is as yet 




A systematic review and meta-analysis of the existing literature suggests that 
there is an early alpha synuclein specific antibody response in PD. I have 
designed and optimised a series of assays to measure antibodies to 4 different 
types of alpha synuclein (monomers, fibrils and 2 peptides S129D and Y39). We 
have started work measuring these in a prodromal cohort.  
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4 MOUSE MODELS 
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4.2 Overview of rationale behind mouse experiments 
 
 
Purple lettering indicates experiments on 6OHDA mice, red lettering indicates 
transgenic experiments. Additional experiments attempting to worsen the 
phenotype in transgenic mice are not included in this overview.  
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4.3 Ethics statement 
All animal experiments were done in accordance with the Animals (Scientific 
Procedures) Act (ASPA), 1986 and the protocols were reviewed by the University 
Animal Welfare and Ethical Review Body under the appropriate project licence 
(either the Clatworthy Lab license or the Barker lab license held by Pam Tyers). 
Each experiment was conducted under an approved study plan that was 
reviewed by the Named Animal Care and Welfare Officer (NACWO) of the 
relevant facility.  
4.4 Introduction to mouse models 
4.4.1 Toxin based mouse models 
It is possible to induce selective dopaminergic cell death in rodents by either 
injecting toxins such as 6 hydroxydopamine (6OHDA) directly into the brain or 
administering them systemically (rotenone, MPTP [1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine] or paraquat). The rationale for using these models related (i) 
to a known loss of dopaminergic neurons in PD and ii) with respect to MPTP, 
related to the discovery of a group of drug addicts in California who attempted 
to make their own heroin (Langston et al., 1999). They ended up injecting MPTP 
which caused a parkinsonian syndrome that responded to standard L-dopa 
treatment. Eventual examination of their post mortem brains showed that there 
was microglial activation as long as sixteen years after the initial insult 
suggesting that there was an ongoing neurodegenerative process (Langston et 
al., 1999).  The 6OHDA model dates from the 1970’s and was a standard model 
prior to MPTP (Bové, Prou, Perier, & Przedborski, 2005). In mice, 6OHDA is 
injected into the striatum or the  medial forebrain bundle where it is transported 
(via the dopamine transporter) into the cytosol of cells causing intracellular 
oxidative stress that replicates some aspects of Parkinson’s disease (Jackson-
Lewis, Blesa, & Przedborski, 2012). Although 6OHDA does not result in 
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aggregates of alpha synuclein or Lewy bodies, there is some evidence that it 
interacts with alpha synuclein (Alves da Costa et al., 2006).  The biggest 
limitation of these models is that the pathology develops rapidly over hours to 
days unlike human disease which progresses slowly over years probably on the 
background of genetic and environmental risk factors that have been present for 
an entire lifetime (Perry, 2012). The MPTP model is less rapid and has some 
element of reversibility over the 6OHDA model but involves the use of a 
neurotoxin that is highly damaging to humans if ingested.  
4.4.2 Transgenic models and those overexpressing alpha synuclein 
Mutations in the  SNCA gene (coding for alpha synuclein) were the first to be 
linked to a rarer autosomal dominant form of PD (Polymeropoulos et al., 1997).  
There are now three known missense mutations in SNCA (A30P, A53T and E46T) 
that are linked to familial PD ((Vekrellis et al., 2011) and duplication or 
triplication of the normal variant also results in familial disease (Singleton et al., 
2003)(Kara et al., 2014). As a result there are several transgenic mouse models 
involving mutated or overexpressed human or mouse alpha synuclein (Blesa & 
Przedborski, 2014). Unlike the toxin mediated models, these models do lead to 
neurodegeneration albeit to a very modest degree. The resultant phenotype and 
pathology is very dependent on the promoter and transgene used as well as the 
amount of alpha synuclein overexpression and the background of the mouse 
strain used (Blesa & Przedborski, 2014).  
 
Transgenic mice expressing mutant alpha synuclein on the mouse or hamster 
prion promotor and PDGF-β (platelet derived growth factor) do not show cell 
loss in the substantia nigra, similarly the tyrosine hydroxylase (TH) promotor 
leads to dopaminergic cell loss in some studies but not others (Blesa & 
Przedborski, 2014)(Marie-Françoise Chesselet & Richter, 2011). Use of the Thy1 
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promotor (either human or mouse) has had slightly more success in that some of 
these models manifest abnormal aggregations of alpha synuclein and have 
behavioural deficits (Marie-Francoise Chesselet et al., 2012). Some of these lines 
have mainly motor neuron pathology which was not considered helpful for 
modelling PD. Unlike the TH promotor, transgenes driven off the Thy1 promotor 
are expressed throughout the brain not just in dopaminergic neurons (Marie-
Francoise Chesselet et al., 2012).  Table 4-1 shows the relative advantages and 
disadvantages of using toxin versus transgenic models.  
 
A number of other transgenic models have been created as further genes causing 
monogenic PD are discovered. Such models include animals with modified or 
knocked out LRRK2, PINK1, PARKIN, DJ-1, MAPT (tau) (Blesa & Przedborski, 
2014; Magen & Chesselet, 2010). Most of these models are limited in their 
recapitulation of only one aspect of disease and none of them develop alpha 
synuclein pathology characteristic of Parkinson’s disease.  
 
Alpha synuclein can also be overexpressed in the brain by injecting it with viral 
vectors (Van der Perren, Van den Haute, & Baekelandt, 2014). Viral vector 
models show better neurodegeneration and dopaminergic cell death than most 
of the transgenic models overexpressing alpha synuclein, possibly due to the 
acute nature of the insult(Blesa & Przedborski, 2014) but have largely been used 
in rats as the stereotaxic surgery is easier in larger rodents.  There are examples 
of successful use of the model in mice (e.g. (Cao, Theodore, & Standaert, 2010). 
There are also multiple ‘hit’ models of PD where, for example, a transgenic 
model undergoes a further insult (e.g. the injection of LPS) that drives the 
pathology (Gao et al., 2011) and viral vector models may be combined with 
transgenic models to exacerbate pathology. More recently, other models have 
used alpha synuclein pre-formed fibrils (that are thought to act as a ‘seed’ to 
trigger alpha synuclein aggregation) either on their own or combined with 
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genetic overexpression of alpha synuclein or viral vector injection to better 
model PD in rodents (Thakur et al., 2017). Combination approaches such as this 
result in more obvious recapitulation of the relevant features of human disease 
including alpha synuclein aggregation, neuroinflammation (microglial and 
astrocyte activation) and cell death (Thakur et al., 2017).  
 
4.4.3 Rationale for choice of animal models 
In my PhD, I planned to use at least two different approaches to model PD. The 
6OHDA model benefits from being well-characterised and being highly 
reproducible.  There was also significant experience within the lab of using this 
model. The other toxin based models including MPTP (and also rotenone and 
paraquat) are also well-characterised but involve the systemic administration of 
the toxin which also is known to have effects on humans if accidentally ingested. 
There are therefore a number of safety concerns and the use is restricted. I 
therefore decided, mainly from a practical point of view, that I would use the 
6OHDA model to explore the effects of B cell modulation on outcomes following 
dopaminergic cell loss. See Table 4-1 for a summary of the benefits and 
disadvantages of the mouse models I considered.  
 
I also used a transgenic model, overexpressing alpha synuclein on the thy1 
promotor. I chose this model as a behavioural phenotype had been described 
previously (with impaired performance on the balance beam and spontaneous 
alternation, tests of motor and non-motor function respectively)(Marie-
Francoise Chesselet et al., 2012) and it appeared to recapitulate some aspects of 
disease (Marie-Francoise Chesselet et al., 2012; Delenclos, Carrascal, Jensen, & 
Romero-Ramos, 2014; Watson et al., 2012). Towards the end of my Phd, I also 
included a further model in mouse that expressed a truncated version of alpha 
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synuclein (that was prone to aggregation) on the TH promotor (Wegrzynowicz 
et al., 2018) . Given the finding that additional inflammatory ‘hits’ worsen alpha 
synuclein pathology e.g. (Gao et al., 2011) and that recurrent infections are 
associated with cognitive decline in AD (Holmes et al., 2009a), I also used a UTI 
model (local infection elsewhere in the body) and the systemic injection of LPS 
to add additional ‘hits’ to the thy1 SNCA model.  
 
At the beginning of my PhD I did also attempt to use an adenovirus associated 
model that involved injecting AAV2-alpha synuclein into the substantia nigra. In 
a mouse it is technically challenging to accurately target the substantia nigra 
accurately and despite involving a research technician with years of experience 
of stereotaxic surgery we were successful at injecting the substantia nigra in less 
than a quarter of the mice. There was minimal spread of alpha synuclein outside 
the injection site and I therefore decided not to continue with this model (data 
not shown in the results section).  
 
I also did not attempt to use pre-formed fibrils as an additional hit. A model 
involving pre-formed fibrils injected peripherally with a CNS trophic viral vector 
was being used in the lab in rats when I started my PhD (William Kuan, 
unpublished work). However, it had not been optimised in mice and the tools 
for looking at the rat immune system (in terms of monoclonal antibodies and 
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Table 4-1 
Summary of the relative advantages and disadvantages of different mouse 
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4.5 Methods 
4.5.1 6-OHDA model 
Mice were anaesthetised to a surgical depth using isofluorane (2L/min) (Baxter, 
Newbury, UK). Their fur was shaved and the underlying skin was cleaned to 
create a sterile field. They were placed in a stereotaxic frame. The needle was 
positioned to target the striatum (antero-posterior [AP] 0.5mm, medio-
lateral[ML} 2mm, ventral [V} 3.0mm from bregma, see Figure 4-1) where 1μl of 6-
hydroxydopamine (5µg/ µL) was injected at a rate of 0.5	μl per minute. Following 
surgery, the needle was withdrawn over 2-3 minutes and the animals were 
allowed to recover in a warmed cage with gel feed. Once recovered, they were 
returned to their home cages and monitored closely for the next seven days, 
including daily weights. They were given mash and Nutella for four days post-
operatively to encourage them to eat as this model is associated with weight loss 
due to the effects on the lateral hypothalamus (and the drive to eat). They were 
given 1ml of sub-cutaneous fluid twice daily for forty eight hours following 
surgery.  
 
4.5.2 Transgenic alpha synuclein models 
Mice overexpressing alpha synuclein on the thy1 promotor (mThy1 -h SNCA, line 
15 mice, see Figure 4-1) were obtained from the Jackson Laboratories 
(https://www.jax.org/strain/017682) (Ouyang Y. 2012. Direct Data Submission 
2012/03/09 MGI Direct Data Submission MGI: J:181092). Mice for experiments 
were bred from a hemizygous carrier and a non carrier.  All mice were genotyped 
using JAX protocols (available at https://www.jax.org/strain/017682). Wild type 
controls and transgenic littermates were co-housed where possible.  Samples 
were also available from an additional transgenic mouse expressing a truncated 
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version of human  alpha synuclein (h1-120) that is prone to aggregation (using 
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Figure 4-1 
Summary of disease models used in experiments 
 
Figure 4-1 A) shows the location of the 6OHDA intra striatal injection. The 
pathology in this model is mainly in the nigro-striatal pathway affecting the 
dopaminergic cells with associated microglial activation and T and B cell 
infiltration B) shows the alpha synuclein transgenic mouse model where the 
transgene is expressed throughout the brain (thy1 SNCA) or in the tyrosine 
hydroxylase positive cells (MI-2 mouse, transgene on the TH promotor) 6OHDA 
6 hydroxydopamine, hSNCA human alpha synuclein. Thy1 mouse Thy1 
promotor. TH Tyrosine hydroxylase 
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4.5.3 Cell transfer experiments 
I obtained spleens from donor mice which were either C57bl/6 or IL10KO mice. 
The spleen was mashed through a 70µm cell strainer with PBS. Red cells were 
lysed using red cell lysis buffer (155mM NH4Cl, 12mM NaHCO3 and 0.1mM 
EDTA) for 1 minute and then spun down for 5 minutes at 1300 RPM. The cells 
were counted using a manual cell counter. B lymphocytes were separated from 
the splenocytes using a magnetic separation pan B cell selection kit (MACS, 
Miltenyi Biotec, 130-104-443) as per the manufacturer’s instructions. Mouse 
serum was obtained from C57bl/6 mice following cardiac puncture. Clotted 
blood was spun down at 2000RPM for 15 minutes and the serum removed and 
stored at -80°c.  
 
4.5.4 µMT cell transfer 
To attempt to rescue the worse outcomes noted in the µMT mice, I transferred 
either B lymphocytes (1 x 107 B lymphocytes per mouse in 200µl, N = 6 mice) or 
200µl normal mouse serum one week prior to 6OHDA surgery (IV via the tail 
vein).   
 
4.5.5 µMT UTI model 
In order to see if the cytokine profile in the meninges was perturbed following 
infection elsewhere I used a model of urinary tract infection (hypothesising that 
B cell in the meninges become activated following systemic infection). This 
involves injecting uropathogenic E.coli (UPEC) directly into the bladder of mice 
aneasthetised to a  surgical depth using isofluorane (2L/min) (Baxter, Newbury, 
UK).   
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The UPEC (UTI89) was a gift from Scott Hultgren (Washington University,  
USA). Bacteria frozen at minus 80°C in 20% glycerol were thawed quickly  
and grown in LB (Lysogeny broth) at 37°C until reaching the end of  
log-phase (OD600 ~ 1.0). Then, they were washed in PBS and passaged  
1:200 into 200 mL of fresh LB. No more than five passages were performed  
before bacteria were used for animal inoculation. Under isoflurane anaesthesia, 
the perineum was cleaned, the urethra catheterized using 0.28 × 0.60 mm 
polyethylene tubing (Instech Laboratories, PA, USA) and 100 μL of UPEC 
(OD600 0.5) instilled. Mice were sacrificed after 48 hrs and organs immediately  
perfused with sterile PBS.  
 
4.5.6 Lipopolysaccaride (LPS) or control IP injections 
I also used LPS to add an additional inflammatory hit to the transgenic thy1 
SNCA model (to recapitulate the effect of intercurrent infections in patients). 
Mice were injected intraperitoneally with either 200µl sterile phosphate buffered 
saline (PBS) or lipopolysaccharide (LPS) at a dose of o.33mg/kg (Sigma Aldrich 
L5293 Ready Made Solution from E. coli 011:B4 1mg/ml). This dose has been 
found to elicit a pro-inflammatory cytokine response in the brain resulting in 
transient, mild sickness behaviour in adult mice (Henry, Huang, Wynne, & 
Godbout, 2009). 
4.5.7 B cell depletion 
Due to problems with survival of the transferred cells in the µMT model (see 
comments in the results section), I decided to deplete B cells using an anti-CD20 
monoclonal antibody in vivo (mIgG2a, kind gift from Biogen).  B cell depletion 
was done 2 weeks prior to surgery.  
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B cell depletion was performed using an anti CD20 monoclonal antibody 
(mIgG2a, kind gift from Biogen, 18B12).  Mice were given a standard dose of anti 
CD20 antibody (10mg/kg) via the tail vein or control antibody at the same 
concentration (anti-human CD20 that has no cross-reactivity with mouse B cells, 
Truxima [Rituximab]).  The Truxima was obtained from vials discarded within 
an hour after patient use in our hospital. For a 30g mouse this was 300µg in 
approximately 150µl of sterile normal saline. Previous studies have shown 
effective depletion at this dose that lasts 5-8 weeks (Bekar et al., 2010a). 
 
4.5.8 Cell transfers following B cell depletion 
Splenocytes were obtained from 10 female C57bl/6 mice (12 weeks old, obtained 
from Charles River/JAX) or from 10 female 12 week old IL10 KO mice (IL10 
knockout B6.129P2-IL10 (tm1cgn)/JAX strain number 002251 obtained from 
Charles River/JAX). Tissue processing was done in a sterile hood  using sterile 
reagents(category 1). The spleens were mashed through a 40µm cell strainer 
using a plunger from a 1ml syringe. The cell strainer was washed with additional 
PBS. They were then spun for 5 minutes at 1300 RPM.  Red cell lysis was 
performed on spleen tissue using red cell lysis buffer for 1 minute (155mM 
NH4Cl, 12mM NaHCO3 and 0.1mM EDTA). The cells were washed with 1mL of 
PBS  and filtered again using a 30µm pre-separation filter. B lymphocytes were 
separated from the splenocytes using negative magnetic separation (MACS, 
Miltenyi Biotec,  Pan B cell separation kit, 130-104-443) as per the instructions 
from the manufacturer. CD20 depleted mice were injected with 1 x 107 B 
lymphocytes in 300µL via the tail vein 2 days prior to 6OHDA surgery in each 
transfer experiment.  
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4.5.1 Culture of IL10 producing B lymphocytes 
A proportion of C57bl/6 B lymphocytes obtained from the Pan B cell separation 
above (20 x 107) were resuspended in cell culture medium  (RPMI with glutamine 
(Gibco 21875-034 and 10% foetal calf serum). They were cultured overnight in 
2mL of media (5 x 106 cells per well) in a 24 well plate with CD40 ligand (murine 
Peprotech Cat 315-15) (0.01µg per 2 ml), CPG (0.6µM, (Cambridge Bioscience 
#Hycult HC4039)  ) and IL2 (100IU/ml, proleukin, Novartis). The cells were 
scraped off the bottom of the plate after 24 hours and washed once in sterile PBS 
and then spun  down(5 minutes, 1300 RPM) and resuspended in sterile PBS with 
1 x 107 cells in 300 µL. Nine CD20 depleted mice were injected as above via the 
tail vein 2 days prior to 6OHDA surgery.  
 
4.5.2 Behavioural testing 
Initial experiments used two motor tests (rotarod and balance beam) in order to 
identify the test that provided the most consistent readout (the rotarod is more 
reproducible but the balance beam, particularly “errors per step” is more 
sensitive to subtle differences). Subsequently only the rotarod protocol was run 
at weekly intervals (and both pre-and post surgery for the experiments using the 
toxin based models). Transgenic animals were tested at regular intervals 
depending on the experiments (see results section).  
 
i)Rotarod – protocol 1 (short test) 
Training was done on day one at two different speeds (16rpm and 24rpm) for a 
total of four trials. If a mouse fell off, it was put on again up to a maximum of 
one minute. Mice were given a break of at least twenty minutes between trials. 
Latency to falling was recording in seconds as well as the speed of rotations (the 
mouse holds on to the rod rather than walking on it).  During training all mice 
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were able to stay on the rotating rod for at least a minute on at least one 
occasion. Training was done over 3 days. Testing was then completed at 30rpm 
with scores recorded across three trials.  The test days were done a week apart 
for 4 weeks post surgery.  
 
ii)Rotarod – protocol 2 (long test) 
The mice were trained over 3 consecutive days using an accelerating protocol. 
They were kept on the rotarod for 5 minutes for each training session with the 
starting speed set at 10RPM (revolutions per minutes) on day 1 (ending at 30 
RPM), 12 RPM on day 2 (ending on 32 RPM) and 16 RPM on day 3 (ending on 36 
RPM). Mice were put back on the rotarod if they fell off within the 5 minute 
period. If a mouse consistently fell off at faster speeds, it was put on at a slower 
speed to ensure it had a full 5 minutes of training. The first fall time was 
recorded. Each training day had 3 separate training sessions with at least a 20 
minute break between each session. On testing days the rotarod was started at 
24RPM (with a  maximum speed of 40 RPM after 5 minutes). The time of the 
first fall was recorded. The performance was recorded as the mean of 4 separate 
tests, at least 20 minutes apart. If there was more than 1 month between testing 
periods, mice were retrained for 2 days prior to re-testing.  
 
ii) Balance beam 
The balance beam consists of a metre long rod with a ‘safe place’ at the end (dark 
box containing bedding) elevated approximately 30cm from the bench. The 
bench is covered in a soft mattress in case of falls. During training mice were 
placed on a 20mm rod approximately 5-10 cm away from the safe box (see Figure 
4-3). They were then encouraged into the box and allowed to explore for 5 
minutes. They were then placed half way along the rod and encouraged to go 
towards the safe box. Lastly they were placed at the beginning of the rod until 
they were able to walk without hesitation to the safe box. A light was focused on 
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the other end of the rod as an aversive stimulus. On testing days, mice were 
placed at the end of a 15mm, 10mm, 8mm and 6mm rod.  No encouragement was 
given on these days to enter the safe box. Their traverse was video recorded to 
facilitate accurate time recording. In the event of a fall, mice were picked up and 
placed back on the rod where they fell. After a fall, if they started off in the 
wrong direction, the trial was terminated and re-started.  
 
Mice were timed from the start to the moment that their noses hit the safe box 
on the video recordings. The number of falls and foot slips were also noted from 
video recordings.  
 
Y maze testing  
Mice were positioned in the middle of a Y shaped maze and their activity was 
recorded over 8 minutes. Spontaneous alternation through each arm was taken 
as a fraction of total activity (with the expectation that the mouse should 
spontaneously explore each arm in turn rather than going back into the arm that 
has just been visited). At the beginning of each recording session the maze was 
cleaned thoroughly with water and then 70% alcohol. Each arm was labelled (A, 
B or C). When scoring the videos, mice were considered to have entered an arm 




Mice were placed in a standard rat cage that had 20cm depth of wood chip 
bedding in which twenty standard marbles had been buried in a grid. They were 
left to explore for 30 minutes (with video monitoring). At the end of the testing 
session, the number of marbles that had been buried were counted. Any marble 
buried more than two-thirds in the wood chip was counted as being “buried”.  
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Figure 4-2 
Y maze set up 
 
Figure 4-2: The mouse is placed in the centre of the maze and then its activity is 
recorded by a camera above the maze for eight minutes. In this example, entry 
into arm “A” would be recorded when the snout and two front paws have crossed 
the line.  
Figure 4-3 
Balance beam set up 
 
Figure 4-3: Balance beam showing a mouse walking on an 8mm wide beam 
towards the safe house (in black)  
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4.5.3 Animal culling and tissue dissection 
Mice were culled using a lethal overdose of intraperitoneal pentobarbitone 
sodium (Merial, UK, 200mg/mol) followed by intracardiac perfusion with ice 
cold phosphate buffered saline (PBS). Lymph nodes, spleens, blood and 
meninges were obtained following saline perfusion if cells were going to be used 
for flow cytometry. After PBS perfusion, the animals were perfused intracardially 
with 4% paraformaldehyde (PFA) (made from paraformaldehyde powder Sigma 
Aldrich 158127). The brains were removed from the skull and placed in 4% 
paraformaldehyde (PFA) overnight for histology. They were then placed in 30% 
sucrose for forty eight hours. Meninges were dissected out using the 
methodology described in (N. Derecki, Louveau, & Kipnis, 2015). For flow 
cytometry they were placed in cold PBS and for whole mount they were placed in 
2% PFA. Meninges used for RNA extraction were placed in RNA later 
immediately after dissection (Sigma Aldrich R0901). Brains for flow cytometry 
were placed in ice cold PBS prior to processing. In order to differentiate between 
intravascular and extravascular cells, animals in some experiments (detailed in 
the methods) were injected IV with CD45 FITC approximately 5 minutes prior to 
being culled.  
 
Brain sectioning 
The brain was serially sectioned at 30μl with every 6th section stored in the same 
well in a 24 well plate using a sledge microtome (Leica SM1400). The sections 
were stored in anti-freeze solution at 4°C for subsequent staining (0.02M 
Na2HPO4, 0.01M NaH2PO4,, 0.3% ethylene glycol [Sigma E9129], 0.3% glycerol 
[Sigma G7893]). 
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4.5.4 Preparation of tissues and blood for flow cytometry 
All processing of tissues was done on ice. Lymph nodes and spleens were placed 
in a cell strainer (70μm) in a small petri dish and minced with scissors. Digestion 
mix  (collagenase D 1mg/ml, DNAse I 0.1mg/ml and 1% foetal calf serum in PBS) 
was added to the lymph nodes (but not spleen). The meninges were mashed 
through a cell strainer (70μm) into a 50mL falcon tube with 40-45mL of RPMI 
culture medium used to wash through the strainer. All tissues were mashed 
through the cell strainer using a plunger from a 1ml syringe. The cell strainer was 
washed with additional digest mix or PBS. The solution was left for 15 minutes at 
room temperature before being mixed with cold PBS and placed on ice. Cells 
were transferred to FACS tubes. The suspension was spun at 1300 RPM for 5 
minutes. Red cell lysis was performed on spleen tissue using red cell lysis buffer 
for 1 minute (155mM NH4Cl, 12mM NaHCO3 and 0.1mM EDTA). The cell pellet 
was then washed twice in PBS. Rat serum was added for blocking (to a 
concentration of 2%)[Normal rat serum Aviva Systems Biology, OORA01679). 
Conjugated cell surface antibodies and a live/dead stain were then added to the 
cell suspension  (listed in the specified for each experiment in the results section 
and listed ) and incubated for an hour. The cells were then washed in 5mL of PBS 
and  re-suspended in FACS fix (1% PFA). They were then run on the flow 
cytometer (BD LSR Fortessa).  
 
4.5.5 Immunohistochemistry 
Primary antibodies were used to stain single forebrain sections and titrated at 
concentrations of 1:100, 1:200, 1:500 and 1:1000 (mouse anti-tyrosine hydroxylase, 
Millipore, MAB31 and sheep anti-tyrosine hydroxylase, Millipore, 1542). 
Biotinylated secondary antibodies were tested at concentrations of 1:1000 or 1:500 
(biotinylated horse antimouse IgG, BA, 2000 and biotinylated rabbit anti sheep 
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IgG BA, 6000). The final protocol used the sheep anti tyrosine hydroxylase 
(Millipore 1542) at a concentration of 1:200 and the biotinylated rabbit anti-sheep 
IgG (BA, 6000).  
 
Wells containing every 6th section were used for staining. Sections were 
quenched with 3% hydrogen peroxide/10% methanol for 10 minutes. They were 
then washed three times before being blocked with 5% rabbit serum in 0.2% 
triton for 1 hour at room temperature.  Sheep anti-mouse tyrosine hydroxylase 
was added (Millipore 1542) at a concentration of 1:1000 over night. Sections were 
then washed and biotinylated rabbit anti-sheep antibody was added and 
incubated at room temperature for an hour. Secondary antibody was washed off 
and the sections were then incubated with ABC avidin/biotin reagent 
(Vectastain ABC Kit, Vector Laboratories) for 45 minutes. Sections were then 
washed again.  Diaminobenzidine solution (Sigma D4293) tablets were added 
until the staining was clear at which point the sections were washed. They were 
then dehydrated using 50%, 75%, 90% ethanol and xylene before being mounted 
in DPX mounting medium (Fluka).  
4.5.6 Stereological estimation of TH+ neuron density 
Sections from each mouse were mounted in anatomical order (caudal-rostral). 
Each animal had 5-6 sections from the substantia nigra (SN). Estimations of the 
number of cells in the SN were performed using a standard methodology 
(Olympus CAST grid system (Guillery & Herrup, 1997)(Stott & Barker, 2014).  
The substantia nigra was defined anatomically as described in previous work in 
the Barker lab ((Stott & Barker, 2014). Briefly, a vertical line was drawn through 
the most medial tip of the cerebral peduncle that then formed the medial border 
(excluding the ventral tegmental area). The dorsal border included all of the 
TH+ cells with the ventral border following the cerebral peduncle until it met 
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the medial vertical line. Between 5 and 6 sections of SN were counted per brain. 
A 4x objective was used to define the region of interest which was then 
visualised under a 40x objective. The number of TH+ cells in each counting 
frame (90 μm x 90 μm) was recorded. Estimated section thickness after 
processing (dehydration, mounting) was 20 μm.  Depth (z section) data was used 
to create a frequency-distribution curve. A final estimation was performed using 
the optical fractionator formula to allow for variable antibody penetration (as in 
(Stott & Barker, 2014)).  
 
4.5.7 Western blots 
Protein extraction from flash frozen PBS perfused brains 
Whole brains were homogenised with homogenisation solution (20% extraction 
buffer Abcam ab 193970, 2% extraction buffer enhancer Abcam ab193971 and 2% 
protease inhibitor Abcam ab65621 made up in ice cold Tris-buffered saline)  
using a 1mL glass homogeniser which had been pre-cooled on ice. The 
homogenate was placed on ice in an eppendorf tube once there were no visible 
solid pieces. The homogeniser was cleaned with de-ionised water between 
samples. Samples were incubated on ice for at least 20 minutes. They were then 
centrifuged at 4°C for 20 minutes at 14000RPM. The supernatant was transferred 
to a pre-cooled Eppendorf and aliquoted into 20µL aliquots. The concentration 
was confirmed using a BCA assay (Pierce BCA protein assay kit, 23225). Samples 
were  frozen at -80°c for subsequent use.  
 
Samples for loading into the gel for Western blotting were made so that there 
was 20µg of protein diluted in LDS sample buffer (made from 4 x LDS sample 
buffer Invitrogen NuPage NP007) and DTT reducing agent (1M Invitrogen 
NuPAGE NP0009 at a final concentration of 0.1M). Samples were then spun for a 
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few seconds. They were then boiled on a hot place for 10 minutes at 70°C. They 
were then centrifuged for 5 minutes on full power (13000 RPM) to remove 
bubbles. Samples were then loaded to a total volume of 20µl. A Biorad ladder 
1610377 was added to one well. Pre-made NuPAGE 10% Bis-Tris gels were used in 
a cassette which was fitted in a tank. MOPS running buffer was then poured in 
to cover the lanes (Novex NuPage MOPS SDS Running buffer 20x NP0001).The 
gel was run for 30 minutes at 100V and then the voltage was increased to 120V 
and run for approximately 1 hour and 30 minutes. The reaction  was stopped 
when the ladder reached the bottom of the gel. The transfer buffer was prepared 
fresh for each run (1 x transfer buffer Novex NuPage 20x NP0006-1, 20 % 
methanol made up in de-ionised water and kept at 4°C. The gel was removed 
from the cassette and soaked in transfer buffer for 20 minutes. Sponges and a 
PVDF membrane were also soaked in transfer buffer. The gel was then placed in 
the apparatus on a PVDF membrane in between filter paper and 3 sponges. The 
tank was then loaded with chilled transfer buffer and run at 30V for 2-3 hours. 
The membrane was then blocked in 5% milk (Sigma-Aldrich ERMBD283) and  
TBS-T (0.1% Tween TBS) for 1 hour at room temperature on a shaker. The 
primary antibody was then applied to the membrane (Abcam ab1903 mouse anti-
human alpha synuclein, 1:2000) overnight at 4°C. The next day the primary 
antibody was washed off with 3 x 10 minute washes with TBS-Tween (0.1%) on a 
shaker. An HRP conjugated secondary antibody was added in 5% milk TBS-
Tween (0.1%) blocking buffer (Thermo-Fisher 62-6520 goat anti-mouse, 1:5000) 
and the membrane was incubated for 1 hour at room temperature on a shaker. It 
was then washed 7 times in TBS-Tween (0.1%) for 10 minutes each on a shaker. A 
SuperSignal West Femto Kit (Thermoscientific 34094) was used  to prepare the 
membrane which was first incubated in the dark for 5 minutes with a mixture of 
peroxidase and enhancer in a 1:1 ratio (as per the kit instructions). The signal was 
developed on the UVI Tech alliance. The membrane was then incubated in 
stripping buffer for 30 minutes(1.5% glycine Fisher Scientific BP381-500, 0.1% SDS 
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Sigma L3771, 1%TWEEN Sigma Aldrich 27434-8, pH adjusted to 2.2 with 
hydrochloric acid). It was then washed x 3 in TBS-Tween (0.1%) and then 
incubated with HRP conjugated anti-B actin antibody for 1 hour at room 
temperature for a loading control. The membrane was prepared and imaged as 
above. The images were analysed using FIJI and normalised to beta actin and 
analysed using Graphpad Prism (version 7.0).   
 
4.5.8 Meningeal wholemounts 
Skull caps were removed prior to extraction of the brain (as described in (N. 
Derecki et al., 2015). They were placed in 2% PFA overnight and then in PBS. The 
meninges were then carefully dissected off the skull cap and washed for 5 
minutes in PBS. The meninges were then incubated for 1 hour at room 
temperature in block/perm solution (0.1M PBS, 1% BSA, 2% serum, 0.1% triton 
X100, 0.05% tween). They were then incubated overnight in antibody dilution 
solution (0.1M PBS, 1% BSA, 0.5% Triton X100) with the antibody. The next day 
they were washed in PBS (x3). The meninges were then gently spread on a glass 
slide using a paintbrush and mounted using mounting media . Antibodies are 
specified in the results section (and Appendix I).  
4.5.9 RNA extraction 
RNA was extracted from mouse striatum and meninges. The tissue was placed in 
RNA lysis buffer (ThermoFisher 4305895) in precellys tubes and then 
homogenised using  a precellys benchtop homogeniser (Precellys 24). The RNA 
was extracted using the Ambion Purelink RNA minikit (cat 12183025) according 
to the instructions of the manufacturer (available at 
https://www.thermofisher.com/document-connect/document-
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4.5.10 qPCR of extracted RNA (meningeal or striatum) 
 The RNA yield was measured using a Nanodrop. RNA was converted to cDNA 
using the ThermoFisher VILO RNA-to-cDNA kit (cat. 11754050). Samples were 
incubated with reverse transcriptase buffer and enzyme mix as per the 
manufacturer’s instructions and placed in a PCR machine (37°C for 60 minutes, 
95°C for 5 minutes and 4°C for hold). The cDNA  obtained was then loaded into 
a PCR plate containing Taqman advanced master mix (ThermoFisher 4444557), 
RNAase free water and primers to a total volume of 10µl. Samples were loaded in 
triplicate and the plate was spun down prior to running on the RT-PCR machine 
(Viia7 system) with 50 PCR cycles. Relative expression (normalised to GAPDH) 







4.5.11 Additional mouse strains used in experiments 
All mice bred in house were genotyped according to standard protocols. C57bl/6 
mice were obtained from Jackson laboratories (JAX) or from in house breeding 
stock. B cell deficient µMT mice were obtained from in house breeding stock.  
They have a mutation affecting the immunoglobulin heavy chain (µ chain) that 
means that they are unable to express membrane bound IgM. The result is that 
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they are unable to produce B cells beyond the pre-B stage. Tissue from MI-2 
mice was kindly given to us by Michal Wegrzynowicz and Maria Grazia 
Spillantini. These mice are a new model of Parkinson’s disease created by 
expressing a truncated version of human alpha synuclein (asyn 1-120) on the 
tyrosine hydroxylase promotor (TH)(Wegrzynowicz et al., 2018) on the 
background of a  C57bl/6J mouse with a spontaneous deletion in SNCA 
(C57BL/6J OlaHsd mice (Snca−/−). These mice were bred in house and the SNCA 
knockout mice and C57bl/6 mice were used as controls.  IL10 knock out mice for 
transfer experiments were obtained from Jackson Laboratories 
(https://www.jax.org/strain/002251).   
 
4.5.12 Statistical analysis 
Behavioural experiments were analysed using two way ANOVAs with motor 
outcome as the dependent variable and genotype as an independent variable. 
Between group differences in B lymphocyte proportions or subsets were tested 
using either unpaired t-tests (for parametric data), Mann Whitney U tests or 
ANOVA depending on the number of comparisons. Further statistical details are 
described in the results section.  
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4.6 Results 
4.6.1 Circulating B lymphocytes in PD transgenic models  
Given that I had found that circulating B lymphocytes were decreased in PD 
patients compared to controls, I looked at circulating B lymphocytes in two 
different transgenic mouse models of PD and wild type control animals, the thy1 
SNCA mouse (overexpression of human alpha synuclein on the thy1 promotor) 
and then the MI-2 mouse (expression of an aggregation prone truncated version 
of human alpha synuclein, h1-120 on the tyrosine hydroxylase promotor). The 
MI-2 mice were compared to two different controls: alpha synuclein null mice 
that carry a spontaneous deletion of a murine alpha synuclein gene (C57BL/6J 
OlaHsd mice (Snca−/−) and C57bl/6 mice. The MI-2 mice are on a C57BL/6J OlaHsd 
background. 
 
 Figure 4-4 and  Figure 4-6 show representative gating for these experiments. 
There was a statistically significant reduction in the proportion of B lymphocytes 
in both alpha synuclein transgenic models versus controls as shown in Figure 4-5 
and  in Figure 4-7 (thy1 SNCA versus control Mann Whitney U = 32, p = 0.0064, 
MI-2 versus c57bl/6 Mann Whitney U = 0, p = 0.008, versus alpha synuclein null 
Mann Whitney U = 1, p = 0.02).  There was also a significant decrease in the 
absolute numbers of B cells in the MI-2 mice versus C57bl/6 mice  (t[8]=2.38, p = 
0.04) but not alpha synuclein null mice. There was no significant difference in 
the absolute counts in the thy1 SNCA mice versus controls (Mann Whitney U = 
21, p = 0.10). In the thy1 SNCA experiments (done over 3 separate experiments), I 
looked at further additional markers including markers of activation (CD69, 
MHC Class II, CD21/35 and plasma cells CD138 as well as looking at neutrophil 
and inflammatory monocyte numbers).  There were no between-group 
differences. 
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Figure 4-4 
Flow cytometry plots showing gating for the analysis of peripheral blood 
(thy1 SNCA study)  
 
 
Figure 4-4 shows initial flow cytometry gating (first row) and then a comparisons 
of representative flow plots showing B cells in the C57bl/6 (middle row) and Thy1 
SNCA mice (bottom row) showing T cells (CD3+), B cells (Cd19+), CD9+ B 
lymphocytes and IgM/IgD staining. The phenotyping was done over 3 separate 
experiments using mouse flow cytometry panels 1,2 and 3 respectively (details in 
Appendix 1). PerCpEF = PerCPefluor 710.  
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Figure 4-5 
B lymphocyte counts and proportions in the peripheral blood of Thy1 
SNCA mice and littermate controls 
 
Figure 4-5 A) shows the differences in the proportion of B lymphocytes  and B) 
shows the differences between the absolute counts between th1 SNCA mice and 
littermate controls. Proportions c57bl/6 mean 36.6% (SD 22.63), thy1 SNCA 
mean 60.4% (SD 13.15). Absolute counts C57bl/6 mean 1.9 x 106 (SD 1.9 x 106), thy1 
SNCA mean 0.5 x 106  (SD 0.43 x 106 ). ** p < 0.01. The data was obtained over 3 
separate experiments, from 13 C57bl/6 mice (N=13, 6 females; mean age 19.1 
months, SD 1.5 months) and 13 Thy1 SNCA mice (N=13, 8 females; mean age 18.7 
months, SD 1.72).  
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Figure 4-6 





Figure 4-6 shows initial flow cytometry gating (first row) and then a comparisons 
of representative flow plots showing B cells and T cells in the C57bl/6 (middle 
row) and MI-2 mice (bottom row). Cells were stained using flow cytometry panel 
2 (see Appendix 1).  
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Figure 4-7 
B lymphocyte proportions and absolute counts in peripheral blood of MI-
2 mice and controls 
 
Figure 4-7 A) B lymphocyte proportions (of total lymphocytes) in MI-2 mice and 
two different control groups (C57bl/6 and C57bl/6J OlaHsd (asyn KO). The MI-2 
mice are on a C57bl/6J OlaHsd (asyn KO) background.  Mean in C57bl/6 76% 
(SD 5.7%), mean in Asyn KO 71.8% (SD 7.3%), mean in MI-2 43.4% (SD 19.9%).  
B) Absolute B lymphocyte counts C57bl/6 mean 1.6 x 106 cells/µl (SD 0.42), Asyn 
KO 1.1 x 106 cells/µl (SD 0.72), MI-2 0.6 x 106 cells/µl (SD 0.9). There were 5 male 
mice in each group, all aged between 17 and 18 months. Asyn KO = alpha 
synuclein null mice. ** p < 0.01 * p<0.05 
 
There were no significant differences between the proportions of CD9+ 
(regulatory B cells) or IgM and IgD positive cells in either  the MI-2 transgenic 
mice or the thy1 SNCA mice versus  controls (see Figure 4-8). There were also no 
differences in the proportion of T cells, inflammatory monocytes or neutrophils 
(data not shown).  
 
There was a significant interaction between genotype and B lymphocyte subset 
in a repeated measures ANOVA with IgM IgD subgroups as the repeated 
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measure and genotype as the between subjects variable (interaction term F [1,24] 
= 5.3, p = 0.03). There was no independent main effect of genotype. Inspection of 
the plot in Figure 4-8  D shows that there is a decrease in the transgenic animals 
away from naïve B cells (IgD+IgM+ mainly) with a slight increase in the IgD-
IgM- population that is driving this interaction effect.  
 
Figure 4-8 
B lymphocyte subsets in transgenic and control mice  
 
Figure 4-8 A) the proportion of CD9+ B lymphocytes in MI-2 mice versus 
controls B) IgD and IgM in B lymphocytes in C57bl/6, Asyn KO (alpha synuclein 
null) and MI-2 mice (N = 5 males in each group, 18 months old). C) the 
proportion of CD9+ B lymphocytes in thy1 SNCA mice versus controls D) Mean 
and SEM IgD and IgM in C57bl/6 mice and Thy1 SNCA (N=13 in each group).   
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4.6.2 µMT 6OHDA experiments 
Once I had established that there were decreased B cells in PD patients and their 
associated models compared to controls, I wanted to find out whether B cell 
deficiency changed the disease outcome.  
 
After surgical lesioning, µMT mice performed significantly worse on the rotarod 
forced walking test than their wild type counterparts (see Figure 4-9). A two way 
ANOVA with genotype and week of testing as independent variables showed 
that there was a significant main effect of genotype overall (F [1, 133] = 26.65, p < 
0.0001) and of time (F[4,133] = 10.33, p < 0.0001) with a significant interaction 
between the two terms (F[4,133] = 3.02, p = 0.02).  
 
I also carried out balance beam testing in a sub-group of these mice in order to 
show that the motor phenotype was robust and to select a behavioural test for 
subsequent experiments. Figure 4-10 shows that the µMT mice also performed 
worse on this test of motor function with a significant main effect of genotype on 
the 15mm (F[1,61] = 15.75, P = 0.0002), 10mm (F[1,61] = 10.19, P=0.002) and 6mm 
rods (F[1,75] =  7.40, P=0.002). There was only a significant overall effect of time 
point in the 15mm (F [3,61] = 2.81, p = 0.04) and the 6mm rods (F[4,75] = 3.06, p = 
0.02). The interaction term was not significant for any of the analyses (data not 
shown).  For subsequent experiments I decided to use the rotarod alone as it 
gave a robust behavioural readout of the surgical lesion that was consistently 
different between the groups. It was also relatively straightforward to perform in 
comparison to the balance beam which required several hours of testing across 
the different beam sizes.   
 
Immunohistochemistry for tyrosine hydroxylase (TH) confirmed that the lesion 
was larger in the µMT mice than in control animals (the optical density of 
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staining in the lesioned striatum as a  percentage of the non-lesioned side was 
less in µMT animals (t[11]= 4.07, p = 0.0006) (see Figure 4-12). There was no 
difference in the nigral TH+ cell counts between the two strains. Microglial 
activation and immune cell infiltration are well described in this model. I had 
not quantified this in the initial experiments due to the unexpectedly early birth 
of my son. Once I had come back from maternity leave it took a while to breed 
enough mice to repeat the experiment. The histology is currently ongoing. 
 
Figure 4-9 
Performance on the rotarod  (short protocol) 
 
 
Figure 4-9 Rotarod performance shown for N = 28 muMT mice (15 male) and N = 
28 C57bl/6 mice (11 male) collected across two experiments (with equal numbers 
in each group for both experiments). All mice were aged between 11 and 14 weeks 
at the time of the experiment. The figure shows mean and standard error of the 
mean (SEM). Lower latencies in this test suggest poorer performance (mice fall 
off sooner). This short protocol test has a ceiling effect (a limit of 60s on the bar) 
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Figure 4-10 
Balance beam performance  
 
Figure 4-10 Balance beam performance in a subgroup of mice from the first 
experiment (10 muMT [5 male] and 10 C57bl/6 mice [4 males]) (the same mice 
were also tested on rotarod). The differences highlighted on the graphs show the 
main effect of genotype which was significant at either a p <0.0001 (***) or 
p<0.001 (**) level.  Longer times in this test suggest poorer performance (the 
mouse takes longer to traverse the beam). The performance on the smaller beam 
sizes was much more variable with many mice falling off so many times that it 
was difficult to calculate total scores  
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Figure 4-11 
Tyrosine hydroxylase staining showing a worse lesion in µMT mice  
 
Figure 4-11 A-D shows  representative slices through the entire brain of  µMT 
mice (A+B injected with 6OHDA and C+D with PBS as a control). E shows 
representative images of the lesion in the striatum, showing that this is more 
extensive in the µMT mouse.   
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Figure 4-12 
Quantification of TH+ staining 
 
Figure 4-12 A Optical density staining in the striatum showing the staining as a 
percentage of the non-lesioned side (N = 8 C57bl/6, N = 5 µMT) from mice culled 
4 weeks after surgery. B Substantia nigra TH+ cell  counts as a percentage of the 
non-lesioned side (N = 8 C57B/6, N = 12 µMT).  
 
4.6.3 µMT cell transfer experiment 
To attempt to rescue the deficits observed in the previous experiments, I 
transferred either B lymphocytes or normal mouse serum into µMT mice one 
week prior to surgery (see Figure 4-13) . The B lymphocyte transfers were not 
successful in the µMT animals (see Figure 4-14) with only one animal having 
measurable B lymphocytes in the peripheral circulation after culling.   There 
were also no B lymphocytes in the secondary lymphoid tissues of the  µMT mice 
that had had cell transfers. In the rotarod test, there was a significant main effect 
of condition in a two way ANOVA (F[3,49]=p = 0.008) with the µMT mice 
performing worse overall as in previous experiments. The differences were 
driven by the µMT versus C57bl/6 difference rather than by treatment group. 
Neither the cell transfer or serum transfer was able to rescue the behavioural 
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phenotype.  As the cell transfer was not successful, further analysis was not done 
on this experiment. Subsequent more detailed review of the literature suggested 
that in the µMT mice, strongly inhibitory T cells block reconstitution of  
transferred B cells (both B1 and B2)(Baumgarth, Jager, Herman, Herzenberg, & 
Herzenberg, 2000). Therefore it is not a useful model for this sort of 
manipulation (or at least would require irradiation prior to reconstitution which 
was not possible within the limits of our animal license). The results do suggest 
that the antibodies are not playing a protective role the serum transfer did not 
rescue the phenotype. 
 
Figure 4-13 
The design of the µMT transfer experiment 
 
 
Figure 4-13 In order to work out which part of the B lymphocyte response was 
responsible for the effect, I attempted to rescue it by transferring B lymphocytes, 
mouse serum (antibodies) or control (PBS) 1 week prior to surgery.  
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Figure 4-14 
B lymphocyte proportions in µMT and control mice following cell or 
serum transfer  
 
 
Figure 4 14  6 µMT (2 males) mice received B lymphocytes derived from 4 
C57bl/6. 7 µMT (3 males) mice received normal mouse serum. Mice were 
between 5 and 6 months of age at the start of the experiment. Cervical and 
inguinal refer to lymph nodes. Cells stained using mouse flow cytometry panel 4 
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4.6.4 µMT meningeal qPCR 
I hypothesised that one of the reasons that the µMT mice perform worse 
following 6OHDA could be that they lack IL10 producing B cells in their 
meninges which would be expected to attenuate the T lymphocyte and 
microglial response to cell death in the striatum, preventing further cell loss.  
 
There was an increase in the expression of meningeal IL10 following UTI 
infection compared to baseline but this was the case across both the µMT mice 
and the controls. There were no differences in IL10 or IL6 following 6OHDA 
surgery (see Figure 4-15) but the data points were variable. 
 
Figure 4-15 
Meningeal cytokines in µMT mice  
 
Figure 4-15 A) shows IL10 expression (relative to GAPDH) in µMT mice and 
controls (N=4 in each group, 12 week old females) at baseline and in the context 
of a urinary tract infection (UTI) (N = 4 in each group, 12 week old females).B) 
shows the IL10 and IL6 expression (relative to GAPDH) following 6OHDA 
surgery (5 C57bl/6 mice and 3 µMT mice, 11-12 weeks old).  
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4.6.5 CD20 6OHDA experiments 
As an alternative to using transgenic B cell depleted animals, I therefore decided 
to deplete B cells using an anti-CD20 monoclonal antibody (mIgG2a, kind gift 




Experimental design for B cell depletion experiment 
 
 
Figure 4-16 12-18 week old female c57bl/6 mice were obtained from in house 
breeding stock 
 
Some mice were culled early due to weight loss following surgery (N=3 control 
group, N=1 in the treatment group). The behavioural testing showed a trend 
towards decreased performance in the B cell depleted animals  (one tailed 
unpaired t-test week 3 showed a significant difference (day 21) t[2] = 3.97, p = 
0.03) but the overall two way ANOVA showed no main effect of treatment (F[1,8] 
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Performance on the rotarod (long protocol) 
 
 
Figure 4-17 12-14 week female mice were used in this experiment. There was a 
trend towards poorer performance in the anti-CD20 animals. There were only 4 
mice in the control group and 6 in the CD20 group that had all time points for 
the repeated measures ANOVA. 
 
The histological examination of brains from this experiment is ongoing.  
The CD20 depletion experiment was repeated with two additional cell transfer 
groups prior to surgery (B lymphocytes or IL10+ B lymphocytes) (see Figure 
4-18.)  
 
In the follow up experiment, B cells (either IL10 producing B cells or just B cells) 
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Figure 4-18). The rotarod data is shown below (Figure 4-19). Three mice in the 
anti-CD20 + B lymphocytes group and 1 in the anti-CD20 and IL10+ B 
lymphocytes group were culled early due to weight loss, There were no overall 
statistically significant differences between the three groups (anti-CD20 and 
IL10+ B cells, anti-CD20 and B cells  and the control group) on a two way 
repeated measures ANOVA(F[1,12]=1.234, p=0.28) (there was a significant 




Experimental design for B lymphocyte depletion and transfer 
 
Figure 4-18  12-14 week old female mice were used for this experiment divided 
into three main groups: CD20 depletion + cell transfer of IL10++ cells, CD20 
depletion + cell transfer of normal B cells and a group only given the control 
antibody.  
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Figure 4-19 
Performance on the rotarod (long protocol) 
 
Figure 4-19 12-14 week old female mice were used in this experiment. There were 
6 mice in the anti-CD20 + B lymphocytes group, 8 mice in the CD20 depletion + 
IL10 group and 9 mice in the control group that had data for all time points 
shown above. Graph shows mean and standard error of the mean.  
   
I then tried a similar experiment using IL10 KO B cells instead of IL10 producing 
B cells to see whether the outcome was worse (see Figure 4-20). The rotarod data 
showed that there was no significant difference between the treatment groups at 
least on the behavioural readout for the experiment (two way ANOVA, F[2,20] = 
0.21, p = 0.8) (see  
Figure 4-21). There were a total of 5 mice culled early in this experiment due to 
weight loss (1 in the B lymphocyte group, 2 in the IL10- group and 2 in the 
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Chapter 4: Mouse models 
Kirsten Scott  November 2019    209 
Figure 4-20 
Experimental design for B lymphocyte depletion and transfer 
 
Figure 4-20 12-14 week old female mice were used in this experiment.  
 
Figure 4-21 
Performance on the rotarod (long protocol) 
 
Figure 4-21 12-14 week old mice were used.  There were 8 mice in the anti-CD20 
and B lymphocytes group, 7 mice in the anti-CD20 and IL10- group and 7 in the 
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To complete the B lymphocyte depletion experiments, I looked at whether the 
timing of B cell depletion made a difference (see Figure 4-22). Analysis of the 
rotarod data from this experiment showed that there was no difference between 
the treatment groups (anti-CD20 or control) (two way repeated measures 




Experimental design showing B cell depletion at a later time point 
 
Figure 4-22 showing B cell depletion occurring after surgery (rather than before 
as in previous experiments).  
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Figure 4-23 
Performance on the rotarod (long protocol) – delayed B cell depletion 
 
Figure 4-23 12-14 week old mice were used in this experiment. N=13 in each group 
had data from all time points.  
4.6.6 Looking for a model with increased numbers of IL10 producing B 
cells in the meninges 
At the same time as doing the experiments described above, I attempted to find 
a mouse model with an increased number of IL10 producing B cells in the 
meninges. Such a model would allow us to interrogate the role of these cells 
without relying on cell transfers.  
 
I was able to look at B cells in the tissue of a knock in mouse expressing a 
mutation in the phosphoinositide-3-kinase d. This mutation causes an 
immunodeficiency syndrome in humans characterised by recurrent 
pneumococcal infections  (P110dE1020K-GL). I was only able to look at the meninges 
in a knock in mouse in which the mutation was expressed in all cells. The same 
group had generated a B cell specific knock in which has been shown to have a 
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2018).Figure 4-24 shows a non-significant trend towards larger numbers of 
CD45+ cells in the meningeal compartment. As described in the methods, IV 
FITC anti-CD45 was injected prior to culling the animals in order to differentiate 
between cells that were resident in the tissues (extravascular, EV, should not be 




Extravascular cells in the meninges in the PI3K knock in model 
 
 
Figure 4-24 A gating of CD45+ extravascular and intravascular cells. EV 
extravascular IV intravascular. B Estimated absolute cell counts in the meninges. 
PI3K TG PI3K transgenic. N = 3 in each group. All mice were 8 week old females. 
Cells were stained using flow cytometry panel 5 (see Appendix I).  
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There was a shift in B lymphocyte phenotype in the PI3K knock in mice, with the 
transgenic mice having more IgD-IgM- B lymphocytes than the controls (see 
Figure 4-25). There was also a trend to a larger number of B1 cells in the 
transgenic mice (Figure 4-26). Unfortunately, I was unable to get more animals 
to increase the sample size or to look at the B cell specific knock in. These 
preliminary results suggest that this would be a useful alternative to using cell 
transfers to increase the meningeal B cells (but further work would be required 
to confirm that these B cells are IL10 producing).  
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Figure 4-25 
PI3K transgenic mice have a shift towards IgM-IgD- B lymphocytes in the 
meninges  
 
Figure 4-25 A) shows gating of CD19+ extravascular B lymphocytes. B) , C) and 
D) show a shift to IgM-IgD- B lymphocytes in the transgenic mice versus 
controls. Statistics shown represent unpaired t-tests. N= 3 in each group. All 
mice were 8 week old females.   
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Figure 4-26 
B1 B lymphocytes in PI3K transgenics and controls 
 
Figure 4-26 shows B1 B cells (as defined by CD5+ Cd23-). N=3 in each group, all 
mice were 8 week old females. 
 
  
Chapter 4: Mouse models 
Kirsten Scott  November 2019    216 
 
4.6.7 Thy1 SNCA behavioural experiments 
I ran multiple behavioural experiments longitudinally in order to see whether I 
could identify an appropriate behavioural readout in aged mice to use to assess 
outcomes after possible manipulation of the B lymphocyte compartment in a 
non-toxin based model.  I was ideally looking for a test that was relatively quick 
to perform that showed a large difference between transgenic (thy1 SNCA) and 
wild type animals (C57bl/6) animals. The initial relatively quick behavioural tests 
showed no significant differences between the transgenic animals and controls 
(see Figure 4-27). Given that other studies (e.g. (Marie-Francoise Chesselet et al., 
2012) had found some subtle motor deficits I looked in detail at possible motor 
phenotypes using the balance beam (see Figure 4-28). There were no between 
group differences in performance on this task, including more subtle deficits that 
may be detected by calculating the number of errors per step. All mice got worse 
at the balance beam as the beam got thinner but this did not differ according to 
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Figure 4-27 
Initial behavioural tests in transgenic Thy1 SNCA mice and littermate 
controls 
 
Figure 4-27 A) Shows the rotarod results recorded as a latency to falling (shorter 
times indicate worse performance). B) shows performance on the Y maze 
(spontaneous alternation) measured as a fraction of overall alternations across a 
6 month period. C) Shows the marble burying scores (total marbles buried over a 
30 minute period). There were 21 thy1 SNCA (mean age 10.6 months, SD 1.85, 14 
females)  and 18 c57bl/6 mice  (mean age 10.3 months, SD 1.11, 8 females) for 
initial behavioural testing.  
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Figure 4-28 
Balance beam results for a cohort of Thy1 SNCA and littermate controls 
 
Figure 4-28 A) shows the total time from start to entry of the ‘safe house’ on the 
balance beam. B) shows ‘test’ time, defined as the time spent moving (excluding 
periods spent grooming/not moving) on the beam. C) Shows the number of falls 
per test and D) shows the number of errors divided by the total number of steps 
taken during the test (giving a measure of errors per step). The results are from a 
total of 36 mice , the same cohort tested previously but several months later (18 
thy1 SNCA, 12 female, mean age 12.8 months SD 1.36; 18 c57bl/6 littermate 
controls, mean age 12.72, SD 1.12, 8 female).   
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4.6.8 Western blots and genotype checking 
I ran western blots on whole homogenised brain tissue from thy1 SNCA animals 
and C57bl/6 controls to confirm that they did overexpress alpha synuclein in 
case there had been an error with breeding (see Figure 4-29). All mice were 
genotyped using ear tags at 5-12 weeks and again after they were culled to ensure 
that genotypes were appropriately assigned (data not shown).  
 
Figure 4-29 
Western blot confirming overexpression of alpha synuclein in thy1 SNCA 
brains 
 
Figure 4-29 shows increased expression of alpha synuclein in the thy1 SNCA mice 
(TG, 2 males, one 8 week old mouse CBS35 and one 77 week old mouse 13A) 
versus C57bl/6 controls (WT, both 8 week old males). A) Western blot with beta 
actin loading control.  
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4.6.9 Additional ‘hits’ to thy1 SNCA model 
In the experiments described in 4.5.2,Figure 4-42 I had hoped to be able to find 
simple behavioural readouts to use in experiments where I depleted or otherwise 
modulated the B lymphocyte compartment. As the behavioural tests over time 
did not show a significant difference between the controls and the transgenic 
mice I added further lesions (or ‘hits’), initially repeated lipopolysaccharide(LPS) 
injections (see Figure 4-30 and Figure 4-31).   
 
As expected all animal weights increased significantly over the 42 weeks of the 
experiment (Figure 4-31 A). I carried out a repeated measures ANOVA with 
genotype, treatment (LPS versus PBS) and gender as independent variables and 
weight as the dependent variable. There was a significant main effect of time (F 
[7,126] = 32.02, p = 2.3 x 10-25) and a significant main effect of genotype with the 
transgenic mice consistently being heavier than their C57bl/6 littermates (F [1,18] 
= 36.5, p = 0.00001). There was a trend towards LPS animals having lower 
weights (F[1,18]=3.07, p = 0.097) and a borderline interaction between genotype 
and treatment (LPS versus PBS) (F[1,18] = 3.74, p = 0.069). When looking at the 
differences within the thy1 SNCA animals there was a significant effect of LPS 
treatment over time, with the LPS animals weighing less (F[1,8] = 0.045).  I had 
therefore planned to use weight as an outcome measure but the finding was not 
replicated in a second cohort (which was housed in a different animal house 
after the closure of the original animal house (N=21 thy1 SNCA, N=18 C57bl/6).  
 
There was no significant effect of either genotype or treatment (LPS versus PBS) 
on marble burying (Figure 4-31 B), spontaneous alternation (Figure 4-31 C) or the 
inspection ratio on the novel object recognition test (done at one time point at 
the end of the experiment) (Figure 4-31 D). At the time I was limited to doing 
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non-regulated behavioural tests due to the restrictions of the Clatworthy animal 








Figure 4-30 LPS lipopolysaccharide, PBS phosphate buffered saline. T refers to 
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Figure 4-31 
Behavioural tests and weight in mice given multiple LPS injections over 
time 
 
Figure 4-31 shows A) mouse weights over time following IP injections B) Marble 
burying C) spontaneous alternation and D) Novel objection recognition (at the 
end of the experiment). Results from 12 C57bl/6 mice (6 female, mean age at the 
start of the study was 13 weeks, SD 5.06), 12 thy1 SNCA mice (6 female, mean age 
at the start of the study was 13 weeks, SD 3.9). 6 mice from each group were 
given LPS injections as shown (with control mice receiving PBS). Females were 
counterbalanced across groups.   
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As I had not managed to clearly obtain a behavioural phenotype using additional 
“hits” with LPS, I then decided to add a further hit (B cell depletion) (see Figure 
4-32).  There was no significant difference between the B cell depleted group and 
the control group on the Y maze and rotarod (see Figure 4-33).  I collected motor 









Figure 4-32 Mice had behavioural testing at baseline (week 1) and at the end of 
the experiment (week 20). All mice were female. Mean age in the depleted group 
was 30.4 weeks (SD 10.5), mean age in the control group was 29.1 (SD 10.74).  
 
After the last time point for behavioural testing, the mice were culled.  Flow 
cytometry was performed on homogenised single cell suspensions of brain and 
splenic tissue looking for evidence of microglial activation. Figure 4-34 shows 
representative gating from the brain cells.  There were no differences in the 
Chapter 4: Mouse models 
Kirsten Scott  November 2019    224 
number or proportion of microglia between CD20 treated animals and controls 
or in the number or proportion of lymphocytes (CD3/CD4/CD8 or CD19) as 
shown in Figure 4-35. Histological examination of this experiment is ongoing.  
 
Figure 4-33 
Difference from baseline on the Y maze and rotarod 
 
Figure 4-33 A) difference in spontaneous alternation (Y maze) from baseline and 
B) difference in rotarod performance from baseline on mice from the experiment 
described in Figure 4-32).  
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Figure 4-34 
Gating of flow cytometry plots for brain tissue (on extravascular live cells) 
 
Figure 4-34 shows the gating on brain tissue with the initially gating of 
infiltrating cells on CD45hi (then on CD19, CD3, CD4 and CD8). The microglia 
were identified by being CD45lo and CD11b/CX3CR1hi. The histogram shows 
MHC Class II MFI on the microglia from a representative control sample and 
CD20 sample (no difference). Cells stained using staining panel 6 (see Appendix 
I) 
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Figure 4-35 
Cell counts in homogenised brain tissue  
 
Figure 4-35 A shows cells counts of MHC Class II positive microglia and CD19 
lymphocytes. B shows microglial cell counts C shows the proportions of 
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4.6.10 B lymphocytes in the meninges,  other lymphoid tissue and the CNS 
Once I had established that B cells were decreased in PD patients and associated 
animal models compared to controls and that this was relevant to disease 
outcomes (at least in a toxin based model of disease). I aimed to see whether 
there was a change in B lymphocyte proportions in other compartments.  
 
I did some initial experiments attempting to optimise the identification of B 
lymphocytes in CNS tissue and the meninges by flow cytometry (data not 
shown). I realised while doing these experiments that it was almost impossible to 
prove that the cells I was seeing were genuinely in the tissue I had homogenised 
and stained. It was always possible to argue that the organs were poorly perfused 
with saline or that the cells were adherent to the vascular endothelium and 
therefore not truly ‘resident’ in the tissues. This was important particularly in the 
case of the meninges as I was surprised by the numbers of cells that I was finding 
as at that stage no one had described B lymphocytes in the meninges. 
 
 I therefore added an additional step for subsequent experiments. I injected an 
IV CD45 FITC antibody (1:200) into the tail vein 5-10 minutes  prior to culling the 
animals in order to gate out the intravenous (IV) cells. Figure 4-36 shows an 
example of the initial gating for these experiments, with the extravascular CD45+ 
cells shown in blue boxes and the intravascular cells shown in red (the cells from 
blood are almost all in this box as one would expect). This also shows the 
population of meningeal B lymphocytes.  
 
Given the observation that there were less circulating B lymphocytes in the 
transgenic models of Parkinson’s disease, I looked in the other tissues, with the 
hypothesis that these B lymphocytes had moved into the CNS compartment in 
response to disease.  Figure 4-39 shows that there was no increase in the number 
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or proportion of CD19+ lymphocytes in the brain or the meninges in transgenic 
versus wild type mice (by flow cytometry) with the spleen and cervical lymph 
nodes also showing no difference. The only statistically significant difference was 
an increase in CD8+ cells in the brains of transgenic mice compared to controls 
(t[3] = 4.4, p = 0.02) which does not remain significant after correcting for 
multiple testing. I also looked at the meningeal wholemounts using confocal 
microscopy to see whether there was an increase in the number of B 
lymphocytes using an alternative method (see Figure 4-40 and Figure 4-41). 
There was no difference in the number of B lymphocytes in the meningeal 
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Figure 4-36  
Representative figures showing initial gating for B lymphocytes from 
multiple organs 
 
Figure 4-36 Axis labels shown at the bottom. EV extravascular, IV intravascular.   
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Figure 4-37 
Representative gating (on splenocytes) for characterisation of peripheral 
lymphoid tissue and meninges 
 
 
Figure 4-37 Representative FACS plots showing gating of lymphocytes and 
myeloid cells (example used is splenocytes). Cells stained using flow cytometry 
staining panel 7 (see Appendix 1) 
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Figure 4-38 




Figure 4-38 A shows initial gating separating the CD45hi (infiltrating cells) and 
CD45lo populations (microglia/macrophages) with subsequent gating for T cells 
(CD4, CD3, CD8), B cells (CD19) and CXCR1+ cells (and a subgroup that is 
CXCR1+ and MHC Class II positive. B) shows the proportion of microglia and C) 
proportion of MHC Class II microglia. Cells were stained using flow cytometry 
panel 9 (see Appendix 1).  
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Figure 4-39 
Distribution of lymphocytes in CNS and lymphoid tissue in thy1 SNCA and 
C57bl/6 mice 
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Figure 4-39 shows the distribution of lymphocytes across A + B) brain tissue C + 
D) meninges E + F) spleen and G + H) cervical lymph nodes. Graphs on the left 
show the proportions (%) of T cells and B cells (of CD45+ lymphocytes) and 
graphs on the right show the estimated absolute cell counts. Data from 2 
separate experiments using 5 thy1 SNCA mice (mean age 75.6 weeks, SD 25; 3 
female) and 4 C57bl/6 littermate controls (mean age 81.75, SD 17.9, 2 females). 
CD8+ staining on brain did not work for the second experiment and is therefore 
not shown.  
 
Figure 4-40 




Figure 4-40 shows the dural lymphatics (schematic shows that this is adjacent to 
bregma) with a cluster of B lymphocytes shown in blue (B220)  (B220-ef450 
1:200, Lyve-1 PE 1:150, FITC IgD 1:200, Phalloidin-AF647 1:25).  
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Figure 4-41 




Figure 4-41 shows meningeal B lymphocyte counts from 4 thy1 SNCA mice 
(female, 38-48 weeks old) and 4 C57bl/6 littermates (female 37-48 weeks old) 
 
It was also difficult to be sure that the meningeal cells that I was finding by flow 
cytometry were truly from the meninges. Dissecting the meninges off the skull is 
a delicate procedure and it is possible that these are contaminated by B 
lymphocytes from the skull bone marrow.  Figure 4-42 shows that there are a 
significant number of cells from the skull (after removal of the dura), including a 
population of B lymphocytes making it difficult to be sure of the original of the 
cells in the meningeal homogenate. Figure 4-42 also shows that in a group of 
thy1 SNCA mice B lymphocytes make up the majority of the lymphoid 
population in the blood (mean 48%, SD 15.73), spleen (mean 61.85%, SD 16.21),  
bone marrow (52.29%, SD 11.29) and skull (mean 63.43%, SD 63.43). Cd19+ B 
lymphocytes make up 22.01% of the meningeal lymphoid population (SD 8.55).  
There were no differences in this distribution between “old” (11-19 month old 
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B lymphocytes in haemopoietic tissue, secondary lymphoid tissue and 
meninges 
 
Figure 4-42 shows the proportion (A) and absolute number (B) (log 
concentration per ml) of B lymphocytes in each organ (that were extravascular) 
 The red dots show blood (intravascular). Data from one experiment with 7 male 
thy1 SNCA mice (3 “old” mice 11-19 months old, 4 “young” mice 3 months old.  
 
There were significant differences in the distribution of IgD+IgM+ (naïve) and 
IgD-IgM- (assumed to be antigen experienced)  B lymphocytes between the 
different tissues (see Figure 4-43 and Figure 4-44). While blood, bone marrow 
and spleen were all dominated by naïve B lymphocytes, the meninges and skull 
were dominated by IgD-IgM- cells. There was no effect of age on this 
distribution (data not shown, Repeated measures ANOVA F[1,29] =0.94, p 
=0.34). There was a significant main effect of organ (F[14,29] = 5.45, p = 0.002) 
and a significant interaction between IgMIgD status (naïve versus IgM-IgD-) and 
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organ (F[4,29])=57.132, p = 2.4 x 10-13).  There were more CD5+ and CD23-CD5+ 
positive cells in older mice (in bone marrow) than in younger mice (see Figure 
4-45) (t[5] = 6.53, p=0.00013 and t[5] = 6.19, p = 0.0016 respectively).   
 
This distribution was similar in C57bl/6 and Thy1 SNCA mice (see  Figure 4-46) 
(with the meninges having less naïve cells and relatively more IgM-IgD- than the 
spleen overall).  There were no other differences in the distribution of 
inflammatory monocytes, neutrophils or T cells between C57bl/6 and Thy1 SNCA 
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Figure 4-43 
Gating of B lymphocyte subsets in extravascular CD19+ B lymphocytes 
 
Figure 4-43 A shows representative gating plots illustrating the distribution of 
naïve B lymphocytes and IgM-IgD- cells across tissues. B shows CD5+ B 
lymphocytes. C B1b cells (CD23-CD5+) and D CD62 ligand (CD62L) positive and 
negative cells from bone marrow and skull. Cells stained using flow cytometry 
staining panel 8 (see Appendix I).  
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Figure 4-44 
B lymphocyte subsets across organs 
 
 
Figure 4-44 shows the distribution of IgM+IgD+ (naïve) B cells and IgM-IgD- 
cells across A) blood B) meninges C) skull D) bone marrow and E) spleen.  Data 
from one experiment with 7 male thy1 SNCA mice (3 “old” mice 11-19 months old, 
4 “young” mice 3 months old). 
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Figure 4-45 
CD5+ lymphocytes and B1b lymphocytes (CD23-CD5+) 
 
Figure 4-45 shows A CD5+ B lymphocytes and B B1b lymphocytes (Cd23-CD5+). 
Data from one experiment with 7 male thy1 SNCA mice (3 “old” mice 11-19 
months old shown in blue, 4 “young” mice 3 months old shown in black).  
 
 Figure 4-46 
B lymphocytes in Thy1 SNCA and C57bl/6 mice  
 
 Figure 4-46 Naïve and IgD-IgM- B lymphocytes in 4 thy1 SNCA mice (mean age 
75.6 weeks, SD 25; 2 female) and 4 C57bl/6 littermate controls (mean age 81.75, 
SD 17.9, 2 females). Cells stained using flow cytometry staining panel 7 (see 
















IgM+IgD+ IgM-IgD- IgM+IgD+ IgM-IgD-
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4.6.11 Depletion of B lymphocytes from meningeal and lymphoid tissue 
I looked at the blood, meninges, cervical lymph nodes and spleens of th1 SNCA 
and C57bl/6 mice who had been given a single dose of either an anti-CD20 
antibody or control antibody (0.33mg/kg). The mice were culled 21 days after B 
cell depletion. Figure 4-47 shows representative flow cytometry plots confirming 
that B cells were reduced in all tissues. I noticed that in the meninges in 
particular, it was mainly a population of CD45 high CD19+ cells that were 
depleted. There still remained cells that were CD45 low CD19+. Figure 4-48 and 
Figure 4-48 show that B cells were depleted across tissues. Comparisons of B cell 
proportions and absolute counts were significant between animals given the 
control and CD20 antibody (see Figure 4-48).  In the meninges in particular, 
naïve B cells were preferentially depleted over the IgM-IgD- population which 
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Figure 4-47 
Representative flow cytometry plots following B cell depletion 
 
 
Figure 4-47 B cell depletion in the CD45hi CD19+ population in A) blood and 
cervical lymph node and B) spleen and meninges. In the meninges there is 
complete depletion of the CD45hi CD19+ B cell population but not the CD45 lo 
population in both the Thy1 SNCA mice and C57bl/6 mice. Cells stained using 
flow cytometry panel 8 (see Appendix 1) 
  
Chapter 4: Mouse models 
Kirsten Scott  November 2019    242 
 
Figure 4-48 
B cell depletion across tissues in both thy1 SNCA and C57bl/6 
 
Figure 4-48 B cell depletion in A) blood showing absolute lymphocyte counts B) 
blood showing percentages and C) in tissues C = cervical lymph nodes M = 
meninges S = spleen. Mann Whitney U tests * p< 0.5, *** p<0.0001. Experiment 
performed in 3 C57bl/6 mice (age 16 months, 1 male and 2 female; 2 given CD20 
antibody and 1 given control antibody ) and  5 thy1 SNCA mice (age 16 months, 3 
female, 2 male; 3 given CD20 antibody and 2 given control antibody).  
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Figure 4-49 
Flow cytometry plots showing that naïve B cells are preferentially 
depleted from the meninges 
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Figure 4-50 
Depletion of naïve and IgM-IgD- B cells from organs 
 
 
Figure 4-50 The grey circles highlight the meningeal B cells showing depletion of 
naïve cell with relative sparing of IgM-IgD- cells. C cervical lymph nodes M 
meninges S spleen.  This is from the same experiment shown in Figure 4-48. 
4.7 Summary of main findings 
The main significant findings from my mouse work were that B cell deficiency 
results in worse outcomes on motor tests and in a larger neurotoxin (6OHDA) 
induced histological lesion affecting dopaminergic projections to the striatum in 
mice with a genetically driven B cell deficiency (µMT mice). A similar trend was 
observed in mice depleted of B cells using an anti-CD20 monoclonal antibody 
(but this requires a larger sample size to confirm). I attempted to rescue this 
phenotype using IL10 producing B lymphocytes, hypothesising that these would 
be protective in this model based on the clinical data from chapter 2. Although 
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these mice had better outcomes than mice given back normal B lymphocytes the 
effect was not statistically significant. I then looked to see whether I could find a 
mouse model with increased numbers of IL10 producing B cells in the meninges. 
I explored using the PI3Kd conditional knock in mouse (P110dE1020K-GL, with the 
E1020K mutation in the Pik3cd gene in all cells). In initial experiments 
phenotyping this mouse, I did confirm that there are increased numbers of B1 
cells in the meninges (of the global knock in mouse) and it would therefore be 
useful exploring the B cell specific knock in (P110dE1020K-B) to use in 6OHDA 
experiments. If it is the IL10 produced by B cells in the meninges that drives the 
phenotype then these mice would be expected to have much better outcomes.  
 
My experiments using two different alpha synuclein transgenic mice showed that 
there was a decrease in circulating B lymphocytes that paralleled the observation 
in PD patients discussed in Chapter 2, suggesting that this is directly related to 
alpha synuclein pathology. The exact mechanism behind this remains unclear.  I 
had hypothesised that this decrease in circulating B lymphocytes was due to a 
shift in B lymphocytes from the periphery to the central nervous system (either 
directly into the brain to into the meninges).  I quantified B lymphocytes in the 
meninges and the brain using flow cytometry and confocal microscopy (in the 
meninges) but did not detect the expected difference. I did observe for the first 
that the phenotype of the B lymphocytes in the meninges and in the skull was 
different to that of circulating B lymphocytes or those found in secondary 
lymphoid tissue. These B cells tended to be IgM-IgD- suggesting a shift to a 
more antigen experienced phenotype which mirrors the shift in human CSF 
towards CD27+IgD- and away from the predominantly naïve (CD27-IgD+) 
phenotype in circulating B lymphocytes.  
 
I did several experiments attempting to worsen the phenotype in transgenic 
models of PD with repeated a repeated inflammatory insult (exposure to LPS) 
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but these were ultimately unsuccessful (at least in producing a reliable 
behavioural readout).  
4.8 Chapter discussion 
Previous studies have looked at the effect of lymphocyte deficiency on motor and 
histological phenotypes in toxin based models of PD, one using athymic rats (J 
Wheeler et al., 2014) and another using RAG-/- mice which lack mature T and B 
lymphocytes (Ip, Beck, & Volkmann, 2015). Both of these studies noted worse 
outcomes in lymphocyte deficient mice but did not identify the mechanism 
behind this observation, noting only that the effect was rescued by bone marrow 
transplantation  (Ip et al., 2015). Given my results it is possible that this effect is 
at least in part mediated by B lymphocytes (particularly in the RAG-/- mice that 
lack B lymphocytes as well as T lymphocytes). When I attempted to rescue the 
effect in µMT mice (in order to demonstrate mechanism), the transferred cells 
did not remain in circulation or in the lymphoid organs. Subsequent more 
detailed review of the literature in these mice suggested that this had been noted 
before. Nicole Baumgarth et al. showed two decades ago that reconstitution of 
µMT mice was blocked by strongly inhibitory CD4+ T cells (Baumgarth et al., 
2000). The transferred cells only fully reconstituted when the mice were 
irradiated. They were able to reconstitute neonatal mice successfully suggesting 
that tolerance is broken in an early developmental window due to a lack of 
exposure to B cell antigens in these mice.  As a result, I switched to using an 
anti-CD20 antibody to deplete the mice of B cells. The resulting difference in 
behavioural testing was not statistically significant although the numbers of 
animals included in this study was relatively small (N=4 and N=6 in the depleted 
and non-depleted groups respectively). 
 
Another limitation of this approach is that although the anti-CD20 antibody is 
able to reliably deplete circulating B lymphocytes but depletion of tissue resident 
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B cells is less effective, particularly after only one dose. As my hypothesis was 
that it was likely to be meningeal B lymphocytes that were responsible for the 
effect observed one would need to ensure complete depletion of ‘tissue resident’ 
subpopulations as well as circulating B lymphocytes and those in secondary 
lymphoid tissue. This requires additional experiments to establish a more effect 
dosing schedule. The dose that I used (0.33mg/kg) was based on a study in a 
murine model of systemic lupus erythematosus (Bekar et al., 2010b). In this 
study they found that one dose was effective at depleting circulating B 
lymphocytes and those in the lymph nodes and spleen with the peak effect 
occurring 1-3 weeks after drug treatment. B lymphocytes in the peritoneum 
(mainly B1 lymphocytes) and the bone marrow were less effectively depleted and 
it is possible that meningeal B lymphocytes are similarly resistant to depletion as 
suggested by the flow cytometry plots shown in my experiments where there 
remains a population of CD19 CD45lo B lymphocytes after anti-CD20 treatment.   
 
It may be that with more robust depletion, for example with repeated or high 
dosing there would be a larger different between the depleted and non-depleted 
groups.. It would then be possible to see more clearly the effect of cell transfers 
on the phenotype. I enriched IL10 producing B lymphocytes after incubation 
with IL2 overnight (as this had been shown to be an effective method of skewing 
the phenotype of these cells by another student in the lab, Akimichi Inaba). 
Other studies have used CD5+CD1d+ cells obtained by FACS sorting. I did 
initially try this strategy but found that the time  and manpower required to sort 
sufficient numbers of cells to allow the transfer of 1 x 107 cell per mouse was too 
great.  
 
The concept for these transfer experiments in the CD20 depleted mice was based 
on a study by Thomas Tedder (Matsushita et al, 2008). In this study in EAE, they 
showed that B cell depletion resulted in different outcomes depending on the 
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timing of depletion: depletion prior to the induction of disease resulted in worse 
EAE scores. They rescued this phenotype by transferring CD20- CD5+ CD1d+ 
‘regulatory’ B lymphocytes. My experiments transferring IL10 producing B cells 
and IL10-/- B cells did not result in a convincing improvement (or worsening) 
respectively. One explanation is that the CD20 depletion was insufficient as 
discussed above. Another explanation is that I did not use CD20 negative B cells 
(as we did not have these available to use at the time of the experiments). Using 
CD20- b cells would mean that any residual antibody would not deplete the 
newly transferred cells. It was also not possible to assess the survival of 
transferred cells as it was impossible to distinguish them from the host cells. A 
further modification in addition to using CD20- cells would be to use eGFP+ cells 
so that host cells could be identified (including trafficking within the tissues 
such as the meninges).  
 
Given my hypothesis that the protective effect of B lymphocytes was mediated 
by IL10 producing B cells in the meninges, I also looked for IL10 RNA by RTPCR 
of meningeal tissue, expecting to find a decrease in µMT mice. I did not find any 
differences between µMT mice and controls at baseline, in a UTI model or after 
6OHDA surgery. The experiment was challenging because of the relatively small 
concentrations of RNA obtained from the meninges and would benefit from 
further optimisation before rejecting the hypothesis.  
 
I had hoped to find a simple behavioural readout in the alpha synuclein 
transgenic mice so that I had an additional (and more chronic) model to use to 
modulate the B lymphocyte compartment.  The published literature suggests 
that alpha synuclein overexpressing transgenic mice  have a stronger behavioural 
phenotype (Marie-Francoise Chesselet et al., 2012)  but the evidence is not 
consistent. One possible explanation is the additional unmeasured effect of the 
local microbiome on alpha synuclein pathology. The only clear phenotype that I 
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did find was a weight difference. When our animal house was shut down and we 
were required to move our mice, subsequent cohorts did not replicate this 
pattern. Assuming the effect was true in the initial cohort, there must be an 
environmental explanation. There is now increasing evidence for the role of the 
microbiome in PD in both humans and mouse models. Several studies have now 
shown that the microbiome is altered in PD patients versus controls (Heintz-
Buschart et al., 2018; Hill-Burns, Factor, Zabetian, Thomson, & Payami, 
2011)(Petrov et al., 2017). It is also possible to induce PD pathology in rodents by 
transplanting faecal material from PD patients(Sampson et al., 2016). It is 
possible to speculate that some of the variation in phenotypes across studies may 
be due to the unmeasured effect of the local microbiome on disease pathology.  
The further additional of other ‘hits’ to the transgenic models (including LPS and 
b cell depletion) was also unsuccessful in providing a behavioural readout. It is 
possible that there was an effect on microglial activation or alpha synuclein 
pathology (this histology is ongoing) but this is often harder to quantify and 
does not lend itself to multiple repeated experiments over time.  
 
I have described a shift in phenotype of the B lymphocytes in the meningeal and 
skull compartments. I had expected the phenotype of the immune cells in the 
skull to mirror that in the bone marrow. This was not the case, with the 
meningeal and skull having a majority of IgM-IgD- B lymphocytes and the blood, 
spleen and secondary lymphoid organs having a greater proportion of naïve 
(IgM+IgD+) B lymphocytes. Vascular channels connecting the skull to the brain 
via the dura have been described in both mice and humans (Herisson et al., 
2018).  After CNS injury (in this case a murine model of stroke), neutrophils and 
monocytes are preferentially recruited from the skull niche to the brain through 
these channels, flowing against the direction of blood flow which was from the 
brain to the skull (Herisson et al., 2018).  Differences in cell populations in the 
skull bone marrow compared to tibial bone marrow could be due to different 
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signals from the brain (including inflammatory signals from microglia such as 
IL1B or damage associated molecular motifs). 
 
4.9 Future directions 
 
(i)Optimise CD20 antibody depletion model. Given that the 6OHDA model gives 
a clear behavioural and histological phenotype, it makes sense to look at the 
effects of modulating B lymphocytes in this model going forward, initially 
beginning by optimising the dose of B cell depletion required and establishing 
the dose required to completely deplete the meningeal and skull compartments. 
In addition, using the 6OHDA model in combination with  other B lymphocyte 
transgenics such as the CD19 deficient mouse (that is lacking in CD19 B cells 
with fewer B1 B cells and CD5+ CD1d+ regulatory B cells in particular) and 
comparing this to CD19 overexpressing mice which have corresponding 
decreased proportions of these subsets) could be used to interrogate the 
mechanism behind the observations made in my PhD (using a similar approach 
to that described in (K. M. Haas et al. 2005).  
 
 (ii)Describe the meningeal B lymphocyte response to injury 
Initial subsequent experiments would include characterising B cells in the 
meninges at an early time point (e.g. 6 hours after surgery) and at later time 
points. I would also aim to use a data driven approach to  look at transcriptome 
of these cells using single cell RNA sequencing at baseline and in response to 
injury (using the 6OHDA model and additional models of sterile injury such as 
murine stroke and sterile meningitis to see whether the response is specific to 
damage of dopaminergic cells).  I would then repeat the experiments attempting 
to rescue the phenotype in the depleted mice by using CD20-/- eGFP+ cells so 
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that I could look at trafficking of cells from the circulation to the meninges and 
the CNS.   
 
(ii)Describe the response of skull B lymphocytes to injury. Given the more recent 
finding of the relevance of the niche in the skull bone marrow, I would 
additionally look in more detail at the phenotype of B cells in the skull at 
baseline and in response to injury, attempting to identify the relevant signals 
from the brain that result in mobilisation or activation of B lymphocytes in bone 
marrow and how this relates to trafficking within the meninges. I would also be 
able to use additional tools such as mouse models with increased numbers tissue 
resident IL10 producing B lymphocytes. (such as the P110dE1020K-B conditional 
knock in mouse which has a population of resident IL10 producing B cells that 
increase susceptibility to streptococcal infection (Stark et al., 2018)).  These mice 
would require further characterisation initially to confirm that the meningeal 
(and skull) B lymphocytes have a similar phenotype to the cells in the lung.  
 
(iv)Use an additional mouse model (MI2) to confirm the effect.  If experiments 
using 6OHDA confirm that B cells in the meninges producing IL10 are able to 
rescue the phenotype, I would then aim to test whether this reversed the 
behavioural and histological phenotype observed in the MI-2 mice (which have 
only recently become available and do show a clear behavioural phenotype with 
decreased dopamine production in the substantia nigra).  
4.10 Conclusions 
The results from the animal studies are consistent with the hypothesis that B 
lymphocytes play a protective role.  I have described the phenotype of meningeal 
B lymphocytes and observed that they are similar to skull B lymphocytes (but 
not tibial bone marrow lymphocytes)  Further studies are required to clarify the 
role of meningeal and skull based B lymphocytes in disease. 
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5.1 Summary of main findings 
Overall, my results show convincingly that changes in B lymphocytes are 
associated with Parkinson’s disease, although exactly how much this contributes 
to the pathogenesis of this condition in humans remains unresolved.  
 
In clinical cohorts, I have shown for the first time that the decrease in B 
lymphocytes is particularly driven by a group at high risk of dementia and that 
cells from these patients produce more cytokine (both IL10 and IL6) after in vitro 
stimulation than controls. I have also shown that having a greater proportion of 
‘regulatory’ B lymphocytes is associated with better UPDRS scores. This 
association is also true of the expression of CD1d+ B lymphocytes which are 
known to present lipid or glycolipid antigens to NK cells and may be involved 
either in clearance or in the attenuation of Th1  T cell responses. I have shown 
that there is a trend towards an increase in B lymphocytes in the cerebrospinal 
fluid (CSF) and described for the first time a shift in phenotype of CSF B 
lymphocytes from naïve (in the circulation) to memory B cells (antigen 
experienced). This may be relevant in PD where there are CNS and peripheral 
antigens associated with pathology (mainly alpha synuclein aggregates).  There 
were no differences between patients and controls (or within groups at low or 
high risk of dementia) in the numbers or proportions of different B cell subsets 
in blood or CSF including age associated B cells in the circulation.  
 
I performed a systematic review and meta-analysis of previous studies looking at 
alpha synuclein antibodies in PD and found that there is evidence that there are 
increased alpha synuclein antibodies in early disease suggesting that this is part 
of an early immune response to alpha synuclein pathology that then wanes as 
the disease progresses. I developed Mesoscale Discovery (MSD) based assays to 
measure antibodies to alpha synuclein species and epitopes and showed in a 
small pilot study that there were no differences between patients and controls.  
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In animal studies, I have shown that there is also a decrease in circulating B 
lymphocytes in two different alpha synuclein transgenic models (thy1 SNCA that 
over expresses human alpha synuclein on the thy1 promotor and MI-2 mice that 
express a truncated version of alpha synuclein prone to aggregation). I did not 
find any differences in the number of meningeal B lymphocytes between 
transgenic and control mice. I did show that the phenotype of the meningeal and 
skull lymphocytes was different to circulating B lymphocytes (and bone marrow 
B cells from the tibia) which is likely to be relevant to disease. These cells are 
skewed away from a naïve phenotype towards a more antigen experienced, tissue 
resident phenotype.   
 
When I looked at the effect of B cell deficiency in a toxin based model of 
Parkinson’s disease (6OHDA) I found that a genetic deficiency of B cells (in µMT 
mice that lack mature B lymphocytes) was associated with worse behavioural 
outcomes and a more extensive histological lesion. I replicated the trend in the 
motor phenotype using an anti-CD20 monoclonal antibody to deplete B cells.  
The histological analysis of this experiment is pending. Based on experiments 
done several years ago in experimental autoimmune encephalitis (EAE), I 
hypothesised that this difference in outcome in depleted mice was due to a loss 
of the protective effect of regulatory B lymphocytes. I therefore tried to rescue 
the phenotype by transferring IL10 producing B lymphocytes. The behavioural 
results suggested a trend towards improved outcomes in the group given IL10+ B 
lymphocytes but this was not statistically significant and the histological analysis 
is ongoing.  
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5.2 Clinical implications 
The main implication of this work is that B cell depletion is unlikely to be 
therapeutically effective in PD as having fewer B lymphocytes appears to be 
associated with disease and with worse outcomes. On the other hand, the 
evidence presented in my thesis suggests that increasing the proportion of 
regulatory B lymphocytes may be a therapeutic strategy. There are a number of 
existing therapies that increase regulatory B lymphocytes (as well as having 
effects on regulatory T cells) including low dose IL2 (currently in trials as a 
disease modifying agent in amyotrophic lateral sclerosis, 
https://clinicaltrials.gov/ct2/show/NCT03039673) and oral agents used in 
multiple sclerosis such as fingolimod and glatiramer acetate.  
 
5.3 Discussion of results and future work 
The main limitation of my PhD as a whole is that although I have demonstrated 
several changes in the B lymphocyte compartment in both mice and humans 
associated with disease and have addressed the original aims of my PhD. This 
has left many unanswered questions about the mechanistic relevance of my 
results which will be discussed below.  
 
My clinical studies were limited in that they were cross sectional in design.  
Longitudinal studies would have been informative to investigate changes in the 
B lymphocyte populations over time that were associated with disease 
progression but this was not practical in the time frame of a PhD. I had also 
considered using a sub-population of patients enriched for B lymphocyte 
abnormalities: as mentioned in chapter 2, patients who are carriers of a mutation 
in the glucocerebrocidase (GBA) gene are more likely to get PD and to progress 
to dementia. These patients are also known to have a number of abnormalities 
affecting B lymphocytes (including an increased risk of myeloma and B cell 
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lymphoma)(Mistry et al., 2013). Although their predisposition to PD and to B 
lymphocyte abnormalities may be coincidence, this would be an interesting 
group to investigate further. The reason that I did not do this was that we had 
relatively few patients with the mutation in our research clinic (approximately 5-
8 at the time I started my PhD) and it would have meant expanding the project 
to involve multiple centres which we did not have the resources to do. Looking 
at how B lymphocytes are involved in clearance, antigen presentation to T cells 
and antibody production in this group would be interesting.  
 
Another potentially interesting group of patients are those with a leucine-rich 
repeat kinase 2 (LRRK2) mutation which is the commonest genetic cause of late 
onset autosomal dominant and sporadic PD (indistinguishable clinically from 
idiopathic PD)(Klein & Westenberger, 2012). LRRK2 is expressed in immune cells 
and is a negative regulator of nuclear factor of activated T cells (NFAT) which is 
involved in regulating the immune response in innate immune cells and T 
lymphocytes (Liu et al., 2011). Changes in LRRK2 expression have been described 
across immune cell subsets including B lymphocytes (in PD unselected PD 
patients versus controls)(Cook et al., 2017) and it carries shared genetic risk with 
Crohn’s disease, an inflammatory disease affecting the bowel (Hui et al., 2018). 
Disruptions in this gene are linked to a number of possible mechanisms in PD 
including perturbations of vesicular trafficking, protein synthesis, immune 
response regulation, inflammation and cytoskeleton homeostasis (Wallings et 
al., 2015).  Further interrogating the role of B lymphocytes in the gut and in the 
circulation in patient and animal models may also add further insights into 
relevant pathways involved in driving a peripheral inflammatory response in the 
gut that is associated with alpha synuclein pathology.  
 
Several epidemiological studies have shown an association between 
inflammatory bowel disease and Parkinson’s disease (Lin et al, 2016; Villumsen et 
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al,  2019) but this has not been replicated in all studies, including (Camacho-Soto 
et al,  2018) who found an association in the opposite direction. This may be 
explained by the confounding effects of immunosuppressive therapies which 
were different across studies. GI dysfunction is associated with PD and 
constipation is known to be a prodromal feature(Fasano et al, 2015).  There is 
also data showing a change in the microbiome of PD patients (Heintz-Buschart 
et al, 2017; Hill-Burns et al., 2017; Sampson et al., 2016; Scheperjans et al., 2014) as 
well as evidence of increased gut leakiness in PD: there is raised LPS binding 
protein in the serum of PD patients versus controls as well as increased intestinal 
mucosa staining for E.coli, nitrotyrosine and alpha synuclein (Forsyth et al., 
2011).  Given this evidence, factors affecting the host response (and in particular 
that by B lymphocytes) may be relevant in driving ongoing systemic 
inflammation related to gut pathology in PD. For example, the Clatworthy lab 
recently described a marked induction of anti-commensal IgG in the colons of 
patients with ulcerative colitis (a form of inflammatory bowel disease). This IgG 
then causes cross-linking of Fcg receptors on mononuclear phagocytes leading to 
IL-1b production and the subsequent activation of type 17 immunity (Castro-
Dopico et al., 2019). Looking at a group of PD patients with the additional 
genetic risk of Crohn’s disease and attempting to identify a B cell based response 
to circulating endotoxin or commensals in the gut (from stool samples) would 
have been a further interesting study. Recruitment of patients with LRKK2 
mutations would have been more complicated and time consuming as it requires 
screening of a large  number of patients and a multi-centre approach to get the 
required number of patients for any study. It may be possible to recruit a 
sufficient cohort of non-affected carriers of the relevant mutations in LRKK2 
using the Cambridge bioresource.  
 
The rationale for looking at alpha synuclein antibodies in PD was to identify 
whether there was some evidence that the B cell response was antigen specific or 
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whether it was the non-antibody producing arm of the B lymphocyte 
compartment that was involved. The alpha synuclein antibody assay that I 
developed as part of my PhD (and piloted in a small sample of early disease 
patients and controls) has now been used by an MPhil student under my 
supervision to show that there is a marked increase in alpha synuclein antibodies 
(to fibrils and unaltered alpha synuclein but not Y39 or S129D peptides) in a 
prodromal cohort using serum from collaborators in Oxford (data not included 
as it forms part of her MPhil thesis). The main limitation of this assay in the data 
I have presented as part of my PhD is that there was substantial variability 
between batches. By including a standard control with all plates and being 
meticulous with laboratory technique across those performing the assay we have 
now reduced this variability substantially (with mean CVs of 10-15%). This assay 
provides an initial result but is limited in that it is not exactly clear what post 
translational modification are present (in the fibrils particularly) and which 
epitopes are bound by the antibody. It also doesn’t answer the question about 
the provenance of the antibodies – whether they are produced by long lived 
plasma cells (having had an initial antigen exposure in the past) or if there are 
ongoing germinal centre reactions driving the response or whether it is primarily 
a poly-specific B1 type response (which is less likely as I did not measure IgM 
antibodies). The evidence from the meta-analysis and data from our MPhil 
student together suggest that there is indeed an early antibody response which 
subsequently wanes (studies looking at antibodies in later disease show no 
difference between patients and controls, as summarised in (Scott et al., 2018).  
Subsequent follow up work could look at specific antibody production by plasma 
cells or plasmablasts in culture following stimulation as well as using alternative 
more accurate assays to look at the binding kinetics between serum antibodies 
and alpha synuclein.  
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I spent a lot of time during my PhD doing behavioural testing in the alpha 
synuclein transgenic mice. The original aim had been to identify a clear 
phenotype that could then be used as a readout following B lymphocyte 
depletion (as this had been considered the main therapeutic option at the 
beginning of my PhD). In retrospect, it would have been better to have spent 
more time interrogating the mechanisms behind the differences observed in the 
B cell depleted mouse (initially the µMT mice and then CD20 depleted mice) 
and controls to confirm that the difference in lesion size was associated with an 
increase in microglial activation and immune cell infiltration (this work is being 
completed at the moment by an MPhil student who I am supervising). The 
transgenic alpha synuclein model (thy1 SNCA) is also limited by having a poor 
histological phenotype (there is known to be minimal neurodegeneration in this 
model). I did not continue to look for more subtle behavioural deficits, reasoning 
that this was unlikely to provide a reliable readout.  The MI-2 mouse tissue only 
became available to us at the end of my PhD. These mice do have a clear 
behavioural deficit on motor testing that has been replicated several times 
(Wegrzynowicz et al., 2018). One of the reasons for this may be that the mice are 
on an alpha synuclein null background as previous studies have shown that 
endogenous mouse alpha synuclein can inhibit the aggregation of human alpha 
synuclein (Wegrzynowicz et al., 2018). This model would have been a better 
model to use although the deficit still takes 18 months to develop (which does 
reflect the time course of PD better despite being inconvenient for experiments). 
The thy1 SNCA mice have endogenous mouse alpha synuclein in addition to the 
human alpha synuclein transgene which may have reduced the associated 
pathology and behavioural phenotype.  
 
The 6OHDA model on the other hand provided a clear behavioural phenotype 
and the experiments could be done over a 4-5 week period. The major 
disadvantage (as discussed in Chapter 4) is that the acute neurotoxic nature of 
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the insult does not reflect PD at all (a complex disease that probably develops 
over decades) and it is therefore difficult to generalise findings from it to human 
PD. However, further defining the association between the meningeal B 
lymphocytes and microglial activation and the relationship with cell death may 
provide some important insights. In my experiments, I did not find a difference 
in the numbers of meningeal B lymphocytes between transgenic animals and 
controls but this was only using small numbers of mice and therefore requires 
further experiments.  I also did not look for differences in function or surface 
markers in this population of cells which is likely to be relevant.  
 
One possible explanation for the decrease in B lymphocytes in patients and 
transgenic models  is that this is as a result of chronic antigen stimulation of the 
BCR with associated B cell anergy (decreased responsiveness) (as a result of 
alpha synuclein in the periphery, repeated infections or apoptosis/cell death). 
Usually, stimulation via the BCR provides a survival signal in B cells expressing 
functional membrane bound immunoglobulins (‘mature’ B cells) (at the 
immature stage in the bone marrow niche, a high affinity interaction with the 
BCR and a strong activating signal induces apoptosis as this is usually the result 
of binding of self antigen in the bone marrow).  Some elegant experiments have 
been done in mice expressing a transgene affecting the immunoglobulin heavy 
and light chains, resulting in B cells that are highly specific for only one antigen 
(hen egg lysozyme, HEL)(Cambier, Gauld, Merrell, & Vilen, 2007).  If one crosses 
this mouse with a mouse expressing soluble HEL (ML5 mice), the mice produce 
transitional B cells in the periphery as expected but the number of mature 
follicular B cells is very much decreased. These B cells also fail to respond or 
proliferate in response to antigen(Goodnow et al., 1988). Loss of B cell anergy is 
associated with auto-immune disease (as the self-reactive B cells are not 
silenced)(Cambier et al., 2007). However, this does not neatly fit as an 
explanation because the cells from patients with a high risk of an early dementia 
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produced the most cytokine (IL6 and IL10) (ie. were less anergic) in vitro while at 
the same time being decreased in number and proportion in the circulation.  
 
The other possibility that I have not looked at in the patient cohorts is the role of 
infection in disease progression. It is possible that having lower B lymphocytes is 
associated with a decreased response to new infections or a slower response to 
those previously encountered, making these patients more vulnerable to 
repeated infections. These infections, or systemic inflammatory events, 
contribute to microglial activation. In Alzheimer’s cohorts, having higher levels 
of TNFa at baseline as well as repeated systemic inflammatory events (SIE) was 
associated with faster disease progression(Holmes et al., 2009a). Following 
patients over a longer time period and recording such events may show a similar 
pattern in PD (with the caveat that it is challenging to define what counts as a 
significant SIE). 
 
B cells are thought to play a deleterious role in the development of post-stroke 
dementia where there is delayed infiltration by B cells into the core of the stroke 
from around 7 weeks after injury (see (Doyle et al., 2015). There is also the 
eventual formation of intraparenchymal (intralesional) B cell clusters 
surrounded by T cells and CD11c positive (dendritic cells) producing IgG. 
Preventing this response with B cell depletion stopped the development of 
delayed onset dementia in mouse models. The authors did not measure 
behavioural outcomes or lesion size immediately after the stroke. Based on my 
work one would hypothesise that they would be worse in the depleted mice 
initially (in terms of motor testing and lesion size as there is no reason to think 
that the 6OHDA driven lesion is different to an ischaemic injury in its effect on 
ensuing inflammation).  In fact, this would fit with similar kinetics of the effects 
of B cell depletion in EAE (Matsushita et al., 2008) where depletion of B cells 
prior to disease induction results in worse outcomes (in terms of EAE scores, 
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which is rescued by transferring CD5+CD1d+ B cells) but if done 14-21 days post 
injury it leads to better outcomes. The effect at the early time point is therefore 
due to the loss of regulatory B cells and the beneficial effect later in disease is 
due to the loss of the effector arm of the B cell response (which is mainly 
inflammatory). Such evidence may raise the question of B lymphocyte depletion 
in later PD. I have argued that I have not found any evidence in my PhD to 
support B cell depletion as a therapeutic strategy. Unlike the stroke model, there 
is not convincing evidence of ongoing B cell effector activity (at least in terms of 
an antibody response in late disease according to my meta-analysis) and 
therefore I argue that this should not be considered. However, my data does not 
definitely address this issue, and it may well be that B cells play a dual role in PD, 
as in many autoimmune disorders with both a disease ameliorating effect of 
regulatory B cells and a disease exacerbating effect of inflammatory B cells or 
antibody.  
5.4 Summary of future work 
 
I have listed possible directions for future work at the end of each data chapter. 
In summary, the main priorities moving forward would be to investigate the role 
of B lymphocytes (in particular) but also other immune cells within the CSF 
compartment and meninges (dura) to see how these impact on disease. Single 
cell RNA-sequencing would allow for these cells to be transcriptionally 
characterised in detail and compared to circulating B cells. The strength of 
having well characterised clinical cohorts of PD patients in Cambridge is that we 
could then ask questions about whether there are particular transcription 
signatures associated with a poor outcomes.  I would also aim to take the 
antibody work further by looking for B cell receptor specificity for alpha 
synuclein or its epitopes and seeing whether B cells are capable of presenting 
these to T cells (looking at cells carrying the HLA alleles associated with PD).  
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Ultimately, I would also aim to design a trial boosting B regulatory cells in very 
early disease stage patients (potentially using a prodromal cohort) in order to 
show that these cells are playing a role in disease progression (and to find a 
treatment that would delay this progression).  
 
In mouse models I aim to further optimise the dosing of the anti- CD-20 
antibody in order to repeat the experiments of transferring IL10++ or IL10-/- cells 
and using other tools such as CD20- eGFP cells so that I can look at trafficking to 
and from the meninges at different time points in disease (being sure that the 
transferred cells aren’t depleted by residual circulating antibody). Given that the 
MI-2 mice have a clearer behavioural phenotype I would also repeat experiments 
using LPS in these mice and attempt to modulate the B cell compartment at 
different time points (using both depletion and the transfer to IL10++ B cells) to 
see whether these have an effect in a more chronic model of PD.  
 
5.5 Conclusion 
I have described a large number of changes in B lymphocytes in PD patients and 
animal models of PD. These changes suggest that pan-B cell depletion is unlikely 
to be a good therapeutic strategy but that boosting regulatory B lymphocytes 
and decreasing peripheral immune activation (e.g. B cell production of 
cytokines) may be a better target for future trials as these are associated with 
better outcomes. It is important to investigate alterations in this compartment 
further as there are many existing therapies that target B lymphocytes in 
different ways.  
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APPENDIX I: MOUSE FLOW CYTOMETRY ANTIBODIES 
Single colour controls were made for each experiment using excess mouse 
splenocytes.  
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Antibodies used in mouse experiments 
Antigen	 Fluorophore	 Manufacturer	 Cat.	no	
CD8	 FITC	 Biolegend	 100706	
IgM	 PerCPefluor-710	 eBioscience	 46-5790-82	
CD62L	 APC	 Biolegend	 104412	
CD43	 APCCy7	 Biolegend	 121220	
MHC	Class	II	 AF700	 eBioscience	 56-5321-82	
CD21/35	 PE	 Biolegend	 123410	
IgD	 PE	dazzle	 Biolegend	 405742	
CD4	 PECy7	 Biolegend	 100528	
CD9	 eFluor450	 eBioscience	 48-0091-82	
CD138	 BV711	 Biolegend	 142519	
CD19	 BV785	 Biolegend	 302240	
Live	dead	zombie	UV	 Biolegend	 423107	
CD9	 FITC	 Invitrogen	 11-0091-82	
CD20	 BV421	 Biolegend	 150405	
CD69	 BV605	 Biolegend	 104529	
CD45	 BV650	 Biolegend	 103151	
Ly6c	 APC	 Biolegend	 128016	
Gr1	 APCCy7	 Biolegend	 108424	
CD19	 eFluor450	 Invitrogen	 48-0193-82	
GL7	 ef660	 eBIoscience	 50-5902-82	
CD3	 BV605	 Biolegend	 100237	
IgD	 FITC	 eBIoscience	 11-5993-85	
CD11b	 APCefluor780	 Invitrogen	 47-0112-82	
CD45	 FITC	 Biolegend	 103108	
F4/80	 APC	 Biolegend	 123116	
CD45	 AF700	 BD	biosciences	 560510	
CXCR5	 PE	dazzle	 Biolegend	 145504	
Gr1	 BV405	 BD	biosciences	 560453	
CD5	 BV510	 Biolegend	 100627	
CD11b	 BV650	 BD	biosciences	 563402	
CD3	 AF700	 Biolegend	 100216	
CD25	 PE	 Biolegend	 102008	
CD23	 PECy7	 Biolegend	 101614	
B220	 efluor450	 eBioscience	 48-0452-82	
Phalloidin	 AF647	 invitrogen	 A22287	
Lyve1	 PE	 R	&	D	 Fab2121p	
IgD	 FITC	 Biolegend	 405704	
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APPENDIX II: HUMAN FLOW CYTOMETRY 
Antigen	 Fluorophore	 Manufacturer	 Category	number	
CD19	 BV786	 BD	bioscience	 563325	
CD25	 BUV395	 BD	bioscience	 564034	
CD138	 V450	 BD	bioscience	 562098	
CD38	 APC	 BD	bioscience	 555462	
MHC	Class	II	 AF700	 BD	bioscience	 560743	
Live	dead	zombie	aqua	 	 Biolegend	
423101	
CD5	 FITC	 BD	bioscience	 555412	
CD24	 BV605	 BD	bioscience	 562788	
CD27	 BUV395	 BD	bioscience	 563816	
CD38	 APC	 BD	bioscience	 555462	
IgM	 PE	 BD	bioscience	 555783	
CD138	 V450	 BD	bioscience	 562098	
IgD	 APCH7	 BD	bioscience	 561305	
CD1d	 PerCp	Cy5.5	 Biolegend	 350312	
CD19	 FITC	 BD	bioscience	 555412	
CD19	 BV605	 BD	bioscience	 562653	
CD19	 APC	 BD	bioscience	 555415	
CD19	 PE	 BD	bioscience	 555413	
CD19	 V450	 BD	bioscience	 560353	
CD19	 PerCp	Cy5.5	 Biolegend	 363016	
CD16	 FITC	 BD	bioscience	 555406	
CD57	 PerCp	Cy5.5	 Biolegend	 359621	
TLR4	 APC	 Biolegend	 312816	
IgA	 PE	 Miltenyi	Biotec	 130-093-128	
CD4	 PE	dazzle	 Biolegend	 300574	
CD3	 PECy7	 BD	bioscience	 563423	
CD45	 BV450	 BD	bioscience	 560397	
CD8	 BV510	 BD	bioscience	 563919	
CD14	 BV650	 BD	bioscience	 301836	
TLR2	 BV711	 BD	bioscience	 742770	
CD11c	 FITC	 BD	bioscience	 561355	
Tbet	 PE	 BD	bioscience	 561265	
CD86	 PerCp	Cy5.5	 BD	bioscience	 561129	
IL10	 PE	 BD	bioscience	 559330	
IL6	 FITC	 BD	bioscience	 340526	
CD25	 BUV395	 BD	bioscience	 564034	
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